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Abstract 
 
 
Glioblastoma (GBM) is a known photon radio-resistant tumour and charged ion 
therapy could be an alternative treatment to improve survival and quality of life. 
This work aims to determine the effects of ion species, 4He, 12C, 20Ne, 28Si and 56Fe 
and photon 200 kVp X-rays - 1.7 keV/µm on three different glioblastoma cell lines, 
T98G, U87 and LN18. Their capacity for potential lethal damage repair (PLDR) was 
also examined. Mono-energetic beams of 4He, 12C, 20Ne, 28Si and 56Fe were 
generated by the Heavy Ion Medical Accelerator at Chiba at the National Institute 
of Radiological Sciences (NIRS) in Chiba, Japan. X-rays experiments were also 
performed at NIRS.   
  
The linear energy transfer (LET) of charged ions used ranges from 2.3 - 200 
keV/µm, covering the entrance (plateau) to clinically relevant and high LETs that 
simulate space radiation. Space radiation biology was an opportunistic study at 
NIRS. Exposure to space radiation is known to be a high risk to the central nervous 
system. It is acknowledged that there are benefits and limitations of using GBM cell 
lines to study space radiation. Using GBM cell line which arises from the brain may 
aid in the understanding of the effects of space radiation to the brain. Moreover, 
some strains of GBM cell lines are low dose hypersensitive and very low doses that 
are used to study space radiation maybe relevant. The limitation is that they are 
not normal cells such as the lymphocytes or fibroblast; hence, restrictions may 
have to be applied when interpreting these results. Clonogenic assay was used to 
determine the efficacy of the radiations. For potential lethal damage repair (PLDR) 
study, the cells were allowed 24 hours to repair before plating out.  
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Results show that LN18 relative biological effectiveness at 10% survival (RBE10) 
increases with LET and peaks 85 at keV/µm; however, both T98G and U87 at 200 
keV/µm. LN18 α (single hit kill) peaks at 200 keV/µm, whereas, U87 and T98G 
peak at 100 keV/µm. The statistical significance between the mean of RBE10; and of 
the mean of α between the three GBM cell lines (p < 0.01) demonstrates that each 
GBM cell line response uniquely to the similar ion and LET. Linear regression line 
shows there is a linear relationship between α and RBE as a function of LET for all 
three cell lines. Additionally, GBM cells have the capability to repair potential lethal 
damage induced by radiations; and are LET and dose dependent.  
 
 
Keywords: Glioblastoma (GBM), ion therapy, carbon ions, neon ions, helium ions, 
silicon ions, iron ions, PLDR, PLDR-ratio, LET, RBE10, RBE2 Gy, RSF2 Gy, α parameter, 
β parameter, α/β ratio, and space radiation. 
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binds. When EGF attaches to EGFR, it activates the enzyme 
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and multiply. EGFR is found at abnormally high levels on the 
surface of many types of cancer cells, which may divide 
excessively in the presence of EGF 
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NIRS National Institute of Radiological Sciences, at Chiba, Japan 
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MDM2 mouse double minute-2-homolog: also known as E3 
ubiquitin-protein ligase Mdm2 is a protein that in humans is 
encoded by the MDM2 genes. Mdm2 is an important 
negative regulator of the p53 tumour suppressor 
20Ne neon ion 
p53 a gene that is thought to play a role in regulating cell death 
or apoptosis, in suppressing tumours, in regulating the cell 
cycle, and in stopping the cell from dividing when the DNA is 
damaged; functions as a tumour suppressor gene, thus, 
preventing cancer. It is also known as the ‘guardian of the 
genome’ because of its role in conserving stability by 
preventing genome mutation 
PDGFR-α platelet-derived growth factor receptors α; are cell surface 
tyrosine kinase receptors for members of the platelet-
derived growth factor (PDGF) family. PDGF subunits -A and -
B are important factors regulating cell proliferation, cellular 
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including cancer 
PDGF platelet-derived growth factor is one of the numerous 
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division 
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gene are a step in the development of many cancers 
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Q quality factors that defined RBE that is unique to the type of 
incident radiation 
RBE relative biological effectiveness, the RBE for a given test 
radiation is defined as the ratio between the absorbed dose 
of a reference radiation and the one of the test radiation, 
required to produce the same biological effect 
RBE10 Relative Biological Effectiveness dose at 10 % survival 
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SF survival fraction 
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Spill “spills” or small packets of protons thus, the dose delivered 
is not continual but discontinuous over a very small time 
scale. 
SPE solar particle event 
SSB single strand break of DNA. 
TIC ‘tumour initiating cells’ (stem cells/origin of GBM) from 
individual GBM patient 
TMZ Temozolomide (brand names Temodar and Temodal and 
Temcad) is an oral chemotherapy drug. It is an alkylating 
agent used as a treatment of some brain cancers; as a 
second-line treatment for astrocytoma and a first-line 
treatment for glioblastoma multiforme 
WHO classification World Health Organization classification of tumours 
initiated in 1956 with the objective to establish a  
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classification and grading of human tumours that is accepted 
and used worldwide. It is also one component of 
combination of criteria used to predict a response to therapy 
and outcome 
X-ray electromagnetic waves of high energy and very short 
wavelength, which are able to pass through many materials 
opaque to light. It has no charges or mass and is produced by 
firing electrons at a metal target 
 
     
  
    
   
 
 
 
 
 
Nomenclature 
 
 
Absorbed dose physical dose quantity of ionizing radiation absorbed 
by a body that is measure in Gray (1 Joule/kg) as the 
energy absorbed per unit mass. 
Astrocyte   star-shaped glial cell of the central nervous system. 
Bragg peak pronounced peak on the Bragg curve which plots the 
energy loss of a charged particle during its traversal 
through matter. For charged ions, the peak occurs 
immediately before the particles come to rest. It is this 
Bragg peak that makes ion therapy advantageous over 
photon treatment for cancer. 
Charged particle therapy an alternative radiotherapy which uses beams of 
energetic charged particles for cancer treatment. 
Commonly used particles are proton, α particle; He-, 
Ne- and C-ion; and others. 
Clonogenic assay a technique used for studying the response of cells to a 
specific agent. Cells are seeded in a dish, treated and 
their capability of producing a colony of a given size 
(more than 50 cells) is tested. 
Cross section probability per unit fluence (usually expressed as μm2). 
Dose    energy absorbed per unit mass (Gray). 
Fluence (1) ICRU definition (Φ): the quotient of dN by da, 
where dN is the number of particles incident on a 
sphere of cross-sectional area da (i.e., Φ = dN/da). The  
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unit for fluence is 1/m2, but cm–2 is frequently used; 
particles per unit area (cm-2). (Fluence may be a 
function of one or more other variables [e.g., Φ (L, t), 
the distribution of fluence as a function of linear 
energy transfer (L) and time (t)]. (2) Planar fluence 
(F): the net number of charged particles traversing a 
given area. Unit: particles/cm2. 
Fluence rate (dF/dt) total number of particles incident from all directions 
on a small sphere divided by the cross-sectional area 
of the sphere and per time interval. SI unit is m-2s-1 
(1/m2s). 
Flux (Φ) term used historically by the nuclear community for 
fluence rate and also used for particle flux density, but 
deprecated by the ICRU convention to eliminate 
confusion between the terms “particle flux density” 
and “radiant flux.” See fluence rate. 
Gamma (γ) radiation gamma rays have the smallest wavelengths and the 
most energy of any other wave in the electromagnetic 
spectrum. These waves are generated by radioactive 
atoms and in nuclear explosions. Gamma-rays can kill 
living cells, a fact which medicine uses to its advantage, 
using gamma-rays to kill cancerous cell. 
Glial cells also called neuroglia (glia means glue), are non-
neuronal cells that maintain homeostasis, form myelin, 
and provide support and protection for neurons in the 
central and peripheral nervous systems. 
Hadron therapy  charged ion/particle radiotherapy. 
Hypoxia a condition where there is insufficient amount of 
oxygen reaches the cells/tissues. 
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Particle Accelerator a machine that used electromagnetic fields to 
accelerate charged particles (electron, proton, ions) to 
almost the speed of light to produce beams or charged 
particles for radio-therapy treatment and research. 
Particle fluence the use of a sphere of cross-sectional area dA 
expresses where an area dA is perpendicular to the 
direction of each particle and is independent of 
incident of angle of the radiation. The unit of particle 
fluence is particles/cm2. 
Particle therapy a form of external beam radiotherapy using beams of 
energetic protons, neutrons, or positive ions for cancer 
treatment: an alternative radiotherapy that is known 
to be more effective in killing cancer cells. 
Photon a particle representing a quantum of light or other 
electromagnetic radiation: a photon carries energy 
proportional to the radiation frequency and has zero 
rest mass. 
Proton therapy a type of radiation treatment that uses protons to treat 
cancer: another name is proton beam therapy. A 
proton is positively charged and at high energy, 
protons beams can destroy cancer cells. 
Radiation emission of energy as electromagnetic waves and or as 
moving subatomic particles, especially high-energy 
particles emission of energy which results in 
ionization. 
Radio-resistance the level of ionizing radiation that organism is able to 
withstand, resisting the effects of radiation, especially 
in reference to the treatment of malignancy. 
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Radio-sensitivity the relative susceptibility of cells, tissues, organs or 
organisms to the harmful effect of ionizing radiation 
which results in severe injury or death. 
Redistribution during radiation, cells exhibit differential radiation 
sensitivity when they are in different phases of the cell 
cycle, for example; cells in mitosis are most sensitive 
to DNA damaging agents; and cells in late S-phase 
most resistant. After multiple doses (fractionation), 
cells progression to a new phase of the cell cycle is 
called redistribution or re-assortment which makes 
them more sensitive (therapeutic gain). 
Repair radiation caused damage to DNA by causing a single 
strand break (SSB) which is sublethal; double strands 
break (DSB) which could be potentially lethal or lethal; 
and chemical change or mutation. SSB and potential 
lethal damage could be repaired by the cell but not 
lethal damage and chemical change or mutation. 
Repopulation in terms of radiation, damages and cell death occur 
during treatment can induce an increased in rate of 
cells population (proliferation) both in normal and 
tumour cells. Accelerated repopulation can occur in 
the later part of fractionation therapy. 
Reoxygenation the presence of oxygen increases radiation sensitivity, 
tumour ≦ 1mm in size is fully oxic, but tumours over 
this size develop regions of hypoxia. When tumour 
shrunk due to treatment, the occluded blood vessels 
can be reopened and blood and oxygen supply are 
available; resorption of dead cells leads to decreased 
distance from capillaries to tumour cells, thus 
improving oxygen supply. 
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Overview of the project 
 
 
 
A. Motivation and aims 
 
This work was supported by the European Community’s Seventh Framework 
Programme under the grant agreement No. 215849-2 - Particle Training Network 
for European Radiotherapy (PARTNER). This PARTNER project was dedicated to 
radiobiological experiments for particle therapy with the aim of revealing the 
underlying biological mechanism and finding the influences [such as hypoxia and 
tumour initiating cells (TIC)] that can modify the response of tumour cells to 
particle radiation. Several ions were used for irradiation to reveal the optimum 
choice of ion for the particular tumour involved. The prospect is that the results 
could be employed in mathematical modelling to improve clinical decision making 
process and patient survival (Annex 1-PARTNERS). 
 
Hypoxic cell experiments were not performed due to two changes in plan. The 
hypoxic chamber at the Surrey Ion Beam Centre (SIBC), University of Surrey was 
under construction and was not ready for use; and at the National Institute of 
Radiological Sciences (NIR) and Heavy Ion Medical Accelerator at Chiba (HIMAC), 
Japan; another group was working on the hypoxic plan. Thus, hypoxic experiments 
were not carried through to conclusion. 
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B. Objectives 
 
The purpose of this study was to determine the effects of different charged ion 
species, 4He, 12C, 20Ne, 28Si and 56Fe made available by NIR/HIMAC on glioblastoma 
(GBM), and ‘tumour initiating cells (TICs). To achieve the aims as mentioned above, 
a set of objectives developed as listed below: 
 
 It has been hypothesized that GBM TICs cells were the cause of recurrence 
of GBM post treatment; and charged ion treatment were deemed to be more 
effective. Moreover TIC with charged ion irradiation has never been done 
before (no data). Preliminary experiments of TICs cells were done at SIBC 
and Royal Surrey County Hospital (St Luke Cancer Centre). As TIC cells 
were not approved to be used at NIRS/HIMAC, it could not be studied.  
 
 Five different GBM cell lines were first used for comparison but due to 
beam time availability, it was reduced to three in carrying out full 
investigation. The three GBM cell lines are T98G, U87 and LN18 with known 
genetic alteration were experimented upon (to detect each GBM unique 
response based on their genetic alteration). T98G has both mutated PTEN 
and p53, U87 has mutated PTEN but wild type p53 and LN18 has wild type 
PTEN and heterozygous functional p53 as shown in Table 3:1. 
 
 The focus is to investigate the influence of each ion species and LET on each 
GBM, verifying the individual relative biological effectiveness (RBE) at 
RBE10, RBE2 Gy and RSF2 Gy; α, β and α/β values of each ion type and LET; and 
also to determine different GBM response to the same energies and charged 
ion, LETs and dose.  
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 As hypoxic experiments were not possible, an alternative cause of GBM’s 
radio-resistance was investigated, namely the capacity of potential lethal 
damage repair (PLDR) on the three GBM. 
 
 
C. Overview of dissertation 
 
To begin with, a brief overview is provided of preliminary work carried out at SIBC, 
University of Surrey, prior to the main investigations proceeding to NIRS/HIMAC, 
Chiba, Japan. A short chronology and description of this is provided in Appendix A, 
detailing the preliminary work. The TICs were not permitted to be experimented at 
NIRS/HIMAC. 
 
Chapter 1 gives a brief overview of GBM and motivations of particle therapy that 
could be suitable for GBM treatment. A short description of space radiation is also 
introduced; 28Si and 56Fe ions are relevant to, and could simulate space radiations. 
Space radiation studied here is not related to the treatment of GBM. It was an 
opportunistic study, albeit using GBM cell lines. Chapter 2 provides the 
background study of GBM including its location, cell types and its Standard of Care 
treatments. The conventional photon radiations are described followed by the 
radiobiology aspects that limit photon radiations. The inadequacies of photon 
radiations lead to a need for an alternative radiotherapy treatment that could be 
charged ion radiation which has a higher LET, RBE and inverse depth-dose profile. 
Limitations and uncertainties of charged ion radiation are also acknowledged 
besides the potential efficacy of charged ion radiations. GBM treated by various 
charged particles are also briefly introduced. The concepts of clonogenic assay and 
cell survival curve are mentioned followed by the linear quadratic model that will 
be used to analyse the results.  
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Materials and methods are presented in Chapter 3. The results are detailed in 
Chapter 4. Chapter 5 discusses the results and compares with results of others 
published in the literature.  Some assumptions and implications are made known.  
 
The dissertation is rounded up with an overall conclusion and a series of 
recommendations for Future Works are found in Chapter 6 and 7 respectively. 
Appendix B details the preliminary work done at SIBC and Appendix C lists the   
scientific output from this project to date, including poster and oral presentations 
and journal submissions.  
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Chapter 1 
 
 
 
Introduction 
 
 
 
1.1 Overview of glioblastoma 
 
Glioblastoma is the commonest primary brain tumour. Local control of the disease 
is of utmost importance as it rarely metastasizes outside the central nervous 
system but frequently relapses near the primary site (Maher et al., 2001, Furnari et 
al., 2007). The tumour location itself in the brain is a challenge for successful 
treatments as it is intertwined with neurons, whose function is critical, and 
extreme care is required so as not to disturb other functioning system in the brain. 
Treating GBM effectively without affecting the healthy brain tissue is a challenge 
with photon radiation. Moreover, it is radio-resistant to radiotherapy. Radio-
resistance is a term used that means a tumour is less susceptibility to damage from 
therapeutic radiation compared to the surrounding host tissues (Windeyer, 1954). 
The ability of the cells to repair radiation induced damaged is also one of the 
causes of resistance. The infiltrative and heterogeneous nature and together with 
hypoxia in GBM (Van Meir et al., 2010, Furnari et al., 2007, Maher et al., 2001) has 
been related to its resistance to treatments. Furthermore, extensive genomic 
instability of GBM also results in treatment failures. There are many other causes  
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of tumour radio-resistance and failures to treatments (O’Rourke et al., 1998, 
Stambolic et al., 2001, Li et al., 2004, Furnari et al., 2007, Van Meir et al., 2010). 
 
The standard of care for GBM is surgical resection where possible and 
radiotherapy with concomitant Temozolomide (TMZ) (Stupp et al., 2005). 
Radiotherapy has been of key importance to the treatment of GBM and the 
conventional radiotherapy (Wen and Kesari, 2008, Van Meir et al., 2010) consists 
of 60 Gy of partial-field external beam irradiation delivered 5 days per week in 
fractions of 1.8 to 2.0 Gy. However, approximately 90% GBM always recur at the 
original site and within the high-dose region (Wen and Kesari, 2008, Van Meir et al., 
2010, Hochberg and Pruitt, 1980) after standard radiotherapy treatment. Dose 
escalation to 70-80 Gy can achieve local control but the relapse then occurs 
elsewhere in the brain when brachytherapy is used. The prognostic factors for 
GBM are World Health Organization (WHO) classification, age of patients, tumour 
location, neurologic performance status, extent of surgical resection, proliferative 
indices and genetic alterations (Louis et al., 2007). 
 
The current 5 year overall survival rate for radiotherapy with concomitant and 
adjuvant TMZ is 9.8% (Stupp et al., 2009).  The prognosis is therefore still poor for 
GBM patients. Moreover, the prognostic factors for GBM are WHO classification, 
age of patients, tumour location, neurologic performance status, extent of surgical 
resection, proliferative indices and genetic alterations (Louis et al., 2007). As GBM 
are radio-resistant to photons therapy, with 90% inevitable relapses, an 
alternative superior efficacy of radiation treatment is sought after. 
 
The principle of radiation therapy is to deposit enough energy through ionization 
of atoms to damage and inactivate or kill the tumour cells but to spare the normal 
tissues or organs surrounding the tumour. Ideally, the higher the delivered energy 
to the tumour tissue, the higher is the probability that the tumour will be fatally  
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damaged. Hence, radiation type that can localize the deposited energy within the 
tumour and within a well-defined volume would greatly benefit radiotherapy. 
 
Charged ions demonstrate precisely this characteristic with its pristine and sharp 
Bragg peak. The Bragg peak of ions provides the quality of the sharp lateral 
margin; has excellent precision at targeting of tumours by depositing maximum 
energy at the tumour and minimizing dose to critical organs at risk. The highest 
damage is achieved at the end of the range which is most suitable for small 
tumours located close to radiation sensitive organs in the body (Durante and 
Loeffler, 2009). Figure 1:1 demonstrates the excellence precision of ions at 
targeting of tumour as it uses the benefit of the Bragg peak energy deposition 
properties as compared to photons (Durante and Loeffler, 2009). Moreover, the 
spread out Bragg peaks could encompass the tumour accurately with precise 
imaging. 
 
 
 
Figure 1:1 Charged ions have an advantageous radiation dose-tissue depth dose compared 
with photons. Adapted from Durante and Loeffler (Durante and Loeffler, 2009). 
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Charged ion radiotherapy was first proposed by Robert Wilson in his seminal 
paper ‘Radiological Use of Fast Protons’ (Wilson, 1946). Charged ion/particle 
therapy is also so called ‘Hadron therapy’ which refers to the particles ability to 
participate in nuclear interactions in addition to atomic interactions based on 
charge (Allen et al., 2011). The first clinical centre proton therapy was at Harvard 
proton based therapy. Charged ions have the potential for treatment of GBM 
patients because of their high relative biological effectiveness (RBE- see Sections 
2.5.6.2 for details) and the Bragg peak that gives the ability to deliver a maximum 
dose to the tumour cells, sparing the healthy tissue of the brain. The RBE of 
charged ion is important as it is used to calculate the gray equivalent dose (GyE) in 
clinical practice. Charged ion radiotherapy has the potential to treat tumours that 
are radio-resistant and are located near to critical organs/tissues (Durante and 
Loeffler, 2009). Glioblastoma is a primary tumour of the brain that are resistant to 
conventional radiotherapy and aggressive multi-modalities treatments with 
frequent post-treatments local relapses. There is still much endeavour to treat 
GBM effectively.  
 
 
1.2 Ion beam research for space radiation 
 
Space radiation biology is of interest as exposures to the heavier particles found in 
galactic cosmic rays (GCS) are a health hazard risk to space travellers especially to 
the central nervous system (CNS) (Cucinotta et al., 2014, Lonart et al., 2012, Britten 
et al., 2011). These high charge and energy particles (HZE) is a risk to the CNS, 
resulting in altered cognitive function, reduced motor function and behavioural 
changes and other long term chronic brain diseases (Cucinotta et al., 2014).  GCS 
are made up of a mixture of multiple charged particles such as protons, neutrons, 
4He, 28Si, 56Fe and other heavy ions (Chancellor et al., 2014, Simpson, 1983) as 
shown in Figure 2:21. 28Si and 56Fe are related to space radiation and there is a  
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lack of data on the biological response to these high charged and energy (HZE) 
particles in space. The relative abundance of GCR radiation nuclei; the energy 
range and spectrum are presented in Figure 2:21 (see section 2:8.2 Ion beam 
radiation for space radiation – Galactic cosmic radiation). This opportunity of 
ground based experiments with GBM exposure to HZE particles could be used to 
infer the effects of the cosmic environment. 56Fe ion is ideal for ground-based 
experiments that could simulate the HZE particles in the cosmic environment to 
study its effects. Its deleterious effects on GBM could be inferred to space travellers 
and it is acknowledged that the response of tumour cells and healthy cells of other 
organs may be different thus limiting the accuracy of this inference. It is also 
acknowledged that there are benefits and limitations of using GBM cell lines to 
study space radiation. Using GBM cell line which arises from the brain may infer 
the effects of space radiation to the brain. As some strains of GBM cell lines are low 
dose hypersensitive and very low doses that were used to study space radiation 
could be relevant. The limitation is that they are not normal cells such as the 
lymphocytes or fibroblast; hence, restrictions may have to be applied when 
interpreting these results.  
 
 
1.3 Summary 
 
The main motivation of this project is that charged ion radiotherapy can enhance 
the efficacy of radiotherapy for GBM patients. The purpose of this study was to 
determine the effects of different charged ion species, 4He, 12C, 20Ne, 28Si and 56Fe 
on three different established glioblastoma multiforme (GBM) cell lines, T98G, U87 
and LN18 with known different genetic alterations as shown in Table 3:1, in 
comparison with photon 200 kVp X-ray (1.7 keV/µm) in Table 3:2. The focus was 
to investigate the influence of each ion species and LET on each GBM type; and to 
determine the individual GBM RBE10, RBE2 Gy, RSF2 Gy, α, β and α/β values of each   
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ion type and LET.  And to reveal the response of each GBM type to the same 
energies and charged ion, LETs and dose.  
 
Additionally, it is of interest to investigate one of the causes of GBM’s radio-
resistance, the capability of GBM cells to repair radiation induced potential lethal 
damage. Hence, potential lethal damage repair (PLDR – see section 2:5:4 Radiation 
Repair) of the three GBM cell lines were studied. For PLDR study, GBM cells were 
exposed to ion beams LETs of 55, 100 and 200 keV/µm, in comparison to an X-
ray’s 1.7 keV/µm. GBM cells were allowed to repair for 24 hours post radiation 
before plating out for colony assay. 
 
This research aims to underpin charged ion radiotherapy in GBM by providing 
biological evidence to support the viability of hadron therapy for GBM patients. 
The main motivation of this project is that charged ion radiotherapy can enhanced 
the efficacy of radiotherapy for GBM patients together with other modality of 
treatments such as chemotherapy post-surgery. 
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Chapter 2  
  
 
 
Background 
 
 
 
2.1 Brain 
 
The brain is composed of neurons which perform signalling, and glial which are 
the support cells of the neurons in the central nervous system (CNS).  At least half 
the volume of the brain is composed of glial cells (Barres, 2008).  
 
 
2.2 Types and function of glial cells 
 
There are three main types of glial cells in the central nervous system namely 
astrocytes, oligodendrocytes and microglia. While in the peripheral nervous 
system, the supporting glial are the Schwann cells. Barres (Barres, 2008) describes 
astrocytes as two main classes according to morphology, antigenic phenotype and 
location. Protoplasmic astrocytes are found in the gray matter with their processes 
ensheathing synapses and blood vessels. The fibrillary astrocytes are found in 
white matter in close contact with nodes of Ranvier and blood vessels. In essence, 
astrocytes provide physical support (scaffold of the brain), control the chemical 
environment (homeostasis), and provide nutrition to the neurons. They are  
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responsible for the phagocytises of the debris of dead neurons and also maintain 
the blood brain barrier (Barres, 2008). As with astrocytes, the oligodendrocytes 
also provide physical support to the neurons and produce the myelin sheath that 
insulates the axons and are responsible for the normal propagation of action 
potentials. 
 
Astrocytes, as the name implies are ‘star-like’ with branching extension 
cytoplasmic processes in all directions. Their foot-like processes line every surface 
where the central nervous tissues are in contact with other body tissues including 
blood vessels and capillaries (blood brain barrier). Oligodendrocytes have fewer 
processes with each process ending in a sheet of myelin which wraps around a 
segment of an axon. Microglias have similarities with peripheral blood 
macrophages. They are smaller than the other glial and have small elongated 
irregular nuclei and relatively little cytoplasm which form fine, highly branched 
processes. When activated by tissue damage, they transformed into large 
amoeboid phagocytic cells (Barres, 2008). Figure 2:1 shows the schematic picture 
(http://library.thinkquest.org/C0126536/main.php?).  
 
 
 
Figure 2:1 Schematic pictures of types of glial cells supporting the neurons 
(http://library.thinkquest.org/C0126536/main.php?). 
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2.3 Glioblastoma 
 
Most of the central nervous system (CNS) tumours involve astrocytes as they 
constitute about half of the cells in the human brain (Barres, 2008). Tumours 
arising from glial cells are known as gliomas. Tumour classification is used to 
predict prognosis and dictate the choice of treatments. The WHO classification of 
brain tumours is based on the concept that each type of tumour arises from the 
abnormal growth of a specific cell type and is graded according to the degree that 
its behaviour correlates to the basic cell type. This grading is use to predict the 
biological behaviour of the tumour but does not describe fully the pathological 
diversity of the tumour. The grading system is helpful for clinicians to determine 
the choice of therapies and establishes a common dialogue for communication of 
tumour types across the world. A spectrum of malignancy is graded by the WHO 
from low grade (Grade I) to high grade tumours (Grade IV). Grade I glioma has low 
proliferative potential and has possibility of cure by surgery alone; Grade II 
tumours are usually infiltrative in nature with low-level proliferative activity, are 
prone to recur and can progress to higher grade of malignancy. While, Grade III 
glioma show histological evidence of malignancy with nuclear atypia and brisk 
mitotic activity and Grade IV shows cytological evidence of malignancy with 
infiltration and necrosis; and active mitosis. Grade IV gliomas, including GBM are 
difficult to treat with fatal outcome (Louis et al., 2007).  
 
Glioblastoma are designated as primary and secondary; a terminology that was 
first coined by Scherer in 1940 (Scherer, 1940) where the author stressed that 
secondary GBM had longer clinical duration as compared to primary GBM.  
Kleihues and Ohgaki described that due to the inherent tendency of astrocytoma to 
diffusely infiltrate into neighbouring brain structure, low grade astrocytoma (WHO 
grade II) or anaplastic astrocytoma (WHO grade III) tend to recur with transition 
to a higher grade of malignancy which then becomes secondary GBM 
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(Kleihues and Ohgaki, 2000, Ohgaki and Kleihues, 2007). While primary GBM 
which are ‘de novo’ in origin develop rapidly in older patients (mean age of 62 
years), secondary GBM occur at a slower pace and more in a younger patient 
population (mean age of 45 years) (Ohgaki and Kleihues, 2007). Although the two 
types could not be distinctly separated histologically by their morphological 
features, genetically, they are quite distinct. Furnari et al. have describes 
excellently the malignant astrocytic glioma genetics, biology, and paths to 
treatment as shown in Figure 2:2 (Furnari et al., 2007).  
 
Glioblastoma is the commonest form of Grade IV brain tumour in adults accounting 
for approximately 70% of high grade glioma (Wen and Kesari, 2008). Genetically, 
in brief, see Figure 2:2 (Furnari et al., 2007), primary GBM has the hall mark of 
over expression of MDM2 and EGFR amplification, loss of heterozygosity of 
chromosome 10q, deletion of the phosphatase and tensin homologue on 
chromosome 10 (PTEN), and p16 deletion. Secondary GBM shows a p53 (tumour 
suppressor gene) protein accumulation and mutation with amplification and over 
expression of PDGFR-α (Kleihues and Ohgaki, 2000, Furnari et al., 2007, Wen and 
Kesari, 2008). There is an overlapped of PTEN mutation and loss of chromosome 
10q for both primary and secondary GBM. The survival time of GBM patients 
depended very much on the genes/loci status and grading (Furnari et al., 2007). 
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Figure 2:2 Chromosomal and genetic aberrations involved in the genesis of glioblastoma. 
[From (Furnari et al. 2007)] shows the relationships between survival, pathobiology, and the 
molecular lesions that lead to the formation of primary (de novo) and secondary 
(progressive) glioblastomas. Although histologically indistinguishable, these grade IV 
gliomas occur in different age groups and present distinct genetic alterations affecting 
similar molecular pathways. For example, inactivation of p53 function occurs due to direct 
mutation in progressive GBMs or INK4aARF mutation/decrease in expression or MDM2 
amplification in de novo GBMs. Similarly, activation of the PI3K pathway is achieved by 
several cooperative mechanisms, including EGFR amplification and mutation as well as 
PTEN mutation, although underexpression of PTEN in the absence of mutation is frequently 
seen as well. See the text and details on the molecular function of implicated genes. (OE) 
Overexpressed; (amp) amplified; (mut) mutated. 
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Given GBM‘s extensive genomic instability, The Cancer Genome Atlas (TCGA) 
studied GBM as its first cancer type. The TCGA catalogues and discovers major 
cancer causing genome alterations in large cohorts of human tumours through 
integrated multi-dimensional analyses. The intention is to establish the feasibility 
and power to rapidly expand knowledge of the molecular basis of cancer and the 
patterns of mutation that may inform future therapeutic decisions, setting the 
stage for a new era in the discovery of new cancer intervention (Chin et al., 2008). 
Following to TCGA catalogued of the recurrent genomic abnormalities in GBM, 
Verhaak et al. further defined four subtypes; namely, Proneural, Neural, Classical 
and Mesenchymal using a robust gene expression-based molecular classification 
(Verhaak et al., 2010). The importance of these subtypes lies in the different 
therapeutic approaches that different subtypes may require. The authors 
concluded that this comprehensive genomic- and genetic based classification of 
GBM would improve the molecular understanding of GBM pathway signalling that 
could ultimately result in personalised therapies for groups of patients with GBM 
(Verhaak et al., 2010). Since the genotypes of CNS tumours are of such vital 
importance, Louis et al. (Louis et al., 2016) has incorporated molecular parameters 
into the 2016 WHO classification of tumours of CNS entities including GBM with 
the objective of diagnostic accuracy, improved patient management; and more 
accurate determination of prognosis and treatment response.  
 
GBM is a well know resistant tumour that have heterogeneous genetic alterations 
and is difficult to treat by standard of care. Besides, there were few biomarkers of 
favourable prognosis and few therapies have strong influence on disease outcome.  
For these reasons, Van Meir et al. (Van Meir et al., 2010) proposed that due to each 
individual GBM tumour’s uniqueness in its expression profile, personalized 
medicine may be indicated by defining for subgroups homogenous response 
defined therapies. In addition, as charged particles are costly, E.C. Halperin has 
predicted in his review of particle therapy and treatment of cancer that in the  
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future, the insights of molecular biology might clarify the ideal particles of choice 
for clinical situations (Halperin, 2006).  
 
Moreover, GBM are difficult to treat as neuro radiologic techniques are incapable 
of localizing the gross or microscopic extent; its multi-centricity; 90% of the 
tumours recur at the original site and its inherent radio-resistance (Hochberg and 
Pruitt, 1980). Besides, with their space limited location, the complexities of the 
organ itself, and the vital function it plays in life, treating it effectively is a challenge.  
Furthermore, unlike other parts of the body such as the liver or gastro-intestinal 
tract, mature astrocytes do not have the ability to repair and divide regularly nor 
undergo division in a replenishing manner during adult life. Of all the brain 
tumours, GBM is known to be one of the most refractory to multi-modality 
treatments. 
 
 
2.4 Treatments of GBM 
 
This brain tumour aptly named as ‘glioblastoma multiform’ described by Furnari et 
al. (Furnari et al., 2007) has the hallmarks of uncontrolled cellular proliferation, 
diffuse infiltration, propensity for necrosis, robust angiogenesis, and intense 
resistance to apoptosis and extensive heterogeneous genomic instability which 
makes it one of the most difficult cancers to understand and to treat. Also, due to 
the highly infiltrative and invasive nature of GBM (Van Meir et al., 2010), there is 
no contemporary treatment for the effective ‘cure’ of the disease. No single 
treatment is effective on its own. The conventional treatments that are used thus 
far are usually palliative and comprise of surgery, radiotherapy and chemotherapy.   
 
Although conventional radiotherapy has been the mainstay treatment for GBM, it is 
one of the most radio-resistant tumours due to its persistently hypoxic nature; its  
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ability to repair radiation-induced injury is accomplished by aberrant and or 
amplified growth, (Noda et al., 2009, Van Meir et al., 2010) and survival signalling 
pathways. Of interest, mutated phosphatase and tensin homolog (PTEN) on 
chromosome 10 and p53 are both tumour suppressor genes that have been linked 
to radio-resistance (O’Rourke et al., 1998, Li et al., 2004, Halliday et al., 2014, 
Stambolic et al., 2001, Van Meir et al., 2010). 
 
The Standard of Care for GBM is surgery where possible and chemo-radiotherapy. 
Stupp et al. (Stupp et al., 2005) in their landmark report have shown that 
postoperative X-ray radiotherapy and adjuvant chemotherapy prolong survival 
time significantly compared to surgery or radiation alone. The two-year survival 
rate was 26.5 percent compared to 10.4 percent with radiotherapy alone. The 
current photon radiotherapies provide a median survival of 12.1 months. With 
combined chemo-radiation therapy the median survival has increased to 14.6 
months with Temozolomide (TMZ) and the long term control rates to 9.8% (Stupp 
et al., 2009). The efficacy of treatments is measured in term of overall survival, 
progression free survival and quality of life. 
 
Surgery or a biopsy is the routine recommendation to GBM patients as it is useful 
for several reasons (Hess, 1999). This will aid in a pathological diagnosis which is 
essential for the planning of effective treatment. It also removes the ‘mass effect’ 
on the surrounding brain that causes volume compression due to its limited space 
and obviously, the reduction in the number of malignant cells. It also makes it 
easier for patients to tolerate radio-chemotherapy. Although neuro-surgeons 
would prefer radical resection for most of the GBM patients, limitations such as, 
tumour size and their location (deeply seated tumour or near some functional 
tissue), patient’s age, general and neurological status will have to be considered 
and ultimately the choice of patients (Hess, 1999).  To improve maximal removal of  
GBM tumour, Stummer et al. used fluorescence-guided surgery with 5- 
aminolevulinic acid in their randomised controlled multicentre phase III trial and  
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reported a clinical benefit for patients, in terms of completeness of tumour 
removal and progression-free survival (Stummer et al., 2006).  
 
An efficient complete resection is not feasible even though the survival rate of the 
patient depended on the extent of resection and the volume of residual tumour left 
(Stupp et al., 2009, Van den Bent, 2005, Hess, 1999). This is because of fear of 
damage to the surrounding brain structure that leads to irreversible neurological 
disability. The astrocytic nature is also not helpful as it could be a great distance 
away from the primary site of disease. Therefore, radiation and adjuvant 
chemotherapy is recommended after surgery to improve survival rates. 
 
Chemotherapy uses cytotoxic drugs to target cancer cells.  It is commonly used in 
combination with other modes of treatments. When a tumour has spread from the 
primary site, and is no longer curable with local therapies, chemotherapy is the 
recommended choice. Chemotherapy works by employing various modes of action 
to target the tumour cells such as direct cytotoxic effects, targeting pathways such 
as angiogenesis and also as a growth inhibiting agent, radiation sensitizer or as a 
combination of these effects. For chemotherapy to be effective in the brain the 
drug must be able to cross over the blood brain barrier to reach the tumour and 
spare the normal brain cells. Chemotherapy agents when given after both surgery 
and radiotherapy are known as adjuvant therapy, while concomitant 
chemotherapy is when chemotherapy drugs are given simultaneously with 
radiotherapy. Chemo-radio sensitization is to administer cytotoxic drugs to 
sensitize the tumour cells to enhance the effects of radiotherapy; this is given 
commitantly with radiation therapy (Stupp et al., 2005). Since 2005, TMZ has 
become the dominant chemotherapy drug used for glioblastoma treatment.  Before 
TMZ was approved for the treatment of GBM patients, nitrosourea based drugs 
such as carmustine (BCNU) and lomustine (CCNU) were the standard agents used 
with radiation (Wolff et al., 2008). Nimustine hydrochloride (ACNU) were 
administered by Mizoe et al. instead of TMZ in their Phase I/II trials with GBM  
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patients using carbon ion as a boost (Mizoe et al., 2007). The limitation of TMZ is 
GBM patients with the expression of O6 Methylguanine Methyltransferase (MGMT) 
protein will receive little benefit from this treatment (Friedman et al., 2000, Hegi et 
al., 2005). 
 
The MGMT gene encodes a key DNA-repair protein that removes mutagenic, 
cytotoxic adducts from O6 position of guanine in DNA; the preferred point of attack 
by alkylating agents has the ability to repair cytotoxic DNA damage. The high level 
of MGMT activity in tumour cells results in therapeutic resistance to alkylating 
agents, and MGMT expression is induced by ionizing radiation. Methylation of 
MGMT promoter silences MGMT expression, diminishing the cell’s capability to 
repair chemo-radiation induced DNA damage, thus, results in cell death. The two 
mechanisms of resistance to TMZ and other alkylating drugs are the enzyme alkyl 
guanine alkyltransferase (AGT), a DNA repair protein and a deficiency in the 
mismatch repair pathway (Friedman et al., 1998, Friedman et al., 2000). MGMT 
methylation status is used to predict response and long-term survival in GBM 
patients treated with radiation and TMZ (Hegi et al., 2005). 
 
The conventional recommended dose for GBM is 60 Gray (Gy) in standard daily 
fractions (Stupp et al., 2005).  Higher dose increases the risk of brain radiation 
necrosis and vasculopathy (Barker et al., 1996, Siu et al., 2012). 
 
 
2.5 Radiation 
 
Radiation is the emission of energy or particle in the form of waves or particles 
from an atom or nucleus in the form of waves or particles. The two main forms of 
radiations are particulate radiation which is directly ionizing and electromagnetic 
radiation which is indirectly ionizing. Particulate radiation consists of atomic or  
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subatomic particles (such as electrons, neutrons, protons and heavy charged ions) 
which carry energy in the form of kinetic energy of mass in motion. While, 
electromagnetic radiation’s energy is carried by oscillating electrical and magnetic 
fields travelling through space at the speed of light. 
 
 
2.5.1  Photon radiation 
 
X and γ rays are electromagnetic radiations that are sparsely ionizing and have no mass 
or charge. X-rays are produced by interaction of accelerated electrons with tungsten 
nuclei within the X-ray tube and there is no involvement of radioactive material and are 
from atomic electron shell. Conversely, γ-rays are from atomic nucleus, emitted through 
the radioactive decay of elements such as 
60
Co and 
137
Cs. The difference between how 
X- and γ-rays are produced is demonstrated in Figure 2:3 (https://www.nde-
ed.org/EducationResources/CommunityCollege/RadiationSafety/theory/interaction.htm). 
X- and γ-rays energies are deposited via secondary electrons set in motion by the 
incident photon at all depths and are widely dispersed within the target tissue until they 
are stopped completely. Photons are low LET radiation and the peak dose is located 
relatively close to the surface (Allen et al., 2011), with decreasing in energy as it 
traverses the target. 
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Figure 2:3 The difference in the origin of X- and γ-rays. (https://www.nde-
ed.org/EducationResources/CommunityCollege/RadiationSafety/theory/interaction.htm). 
 
 
2.5.2  Radiation therapy 
 
Radiation therapy is based on the use of direct or indirect ionizing radiation (Hall 
and Giaccia, 2012). Directly ionizing radiations have sufficient kinetic energy to 
disrupt the atomic structure of the absorber through which they pass directly and 
produce chemical and biological changes. Ionizing radiation is able to remove 
tightly bound electrons from their atomic orbits, causing the atom to become 
charged or ionized. The atom can then react with neighbouring atoms, forming 
new chemical bonds. The energy released by one ionizing event is 33 eV  which 
could easily break a strong chemical bond, for example, a C=C bond with an 
associated energy of 4.9 eV (Hall and Giaccia, 2012). The charged atom can further 
interact with several atoms or molecules, which in turn, lose kinetic energy with 
each successive interaction until all energy has been absorbed by the material.  
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Charged particle radiations are directly ionizing radiations. Directly ionizing 
radiation causes direct and indirect actions in cell damage by radiation. Charged 
particle radiation induces approximately 70% direct action and 30% in-direct 
action damages on cells, while, photon radiation induces 30% direct action and 
70% in-direct action damages (Hall and Giaccia, 2012).  
 
In direct action of directly ionizing radiation, the radiation interacts directly with 
the critical target in the cell; the atoms of the target itself may be ionized or excited 
through Coulomb interactions, leading to disruptions of the atomic structure, 
producing chemical and biological changes. Densely ionising radiation of charged 
particles with high LET produces direct action damage that are more severe such 
as clustered damage as compared to sparsely ionizing radiation (Ward, 1985, 
Schipler and Iliakis, 2013). As LET increases, the clustered damages also increases, 
as shown in Figure 2:4 by Schipler and Iliakis (Schipler and Iliakis, 2013). The 
computed ionization patterns show the increased ionization density generated by 
an alpha particle as compared with an X-ray-generated secondary electron (the 
high energy one) and H202. Large dots represent ionizations and small dots 
represent excitations along the radiation track. With increasing LET from 10 to 0.5 
keV e- up to 4 MeV α particle show the damage clustering increases (Schipler and 
Iliakis, 2013). 
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Figure 2:4 Comparisons of different types of damages induced by OH· radicals, low and 
high LETs (Schipler and Iliakis, 2013). 
 
 
Conversely, in indirect action, the radiation interacts with other molecules and 
atoms within the cell to produce free radicals (mainly water, as approximately 
80% of a cell is composed of water), which are able to diffuse into the cell and 
damage the critical region within the cell. Indirect actions damage critical site by 
reactive species produced by ionization in water which creates free radical that 
damage the target. Examples of radicals are reactive free radicals such as H2O+ 
(water ion) and •OH (Hydroxyl radical), which are able to damage the DNA of the 
cell (see Figure 2:5 and 2:6). These free radicals damage the cell by breaking the 
chemical bonds and producing chemical changes via their ‘unpaired valence 
electrons’ which are highly chemically reactive. These hydroxyl free radicals has 
the ability to diffuse in tissue about twice the diameter of a DNA double helix and 
causes approximately two third of all biological damage (Hall and Giaccia, 2012). 
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Figure 2:5 In-direct action of radiation on DNA (http://teachnuclear.ca/all-things-
nuclear/radiation/biological-effects-of-radiation/effects-of-ionizing-radiation-on-dna/). 
 
 
Indirect ionization process occurs when non-charged ‘particles’ such as photons or 
neutrons interact with atoms and molecules resulting in the release of charged 
particles (such as electrons) that interact with atoms and molecules by direct 
ionization mechanism. These non-charged particles do not produce chemical or 
biological damage themselves but when they are absorbed in the material through 
which they pass, they give up their energy to produce fast moving charged 
‘particles’ (electrons) that in turn are able to produce damage. Photons have to 
first undergo interactions to produce free electrons, which are then ionized. 
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Figure 2:6 Direct and in-direct action of radiation (Hall and Giaccia, 2012). 
The structure is shown schematically. In direct action a secondary electron resulting from 
absorption of an x-ray photon interacts with the DNA to produce an effect. In indirect action 
the secondary electron interacts with for example, a water molecule to produce a hydroxyl 
radical (·OH), which in turn produces the damage to the DNA. The DNA helix has a diameter 
of about 20 Å (2nm). It is estimated that free radicals produced in a cylinder with a diameter 
double that of the DNA helix can affect the DNA. Indirect action is dominant for sparsely 
ionizing radiation, such as X-rays. S=sugar; P=phosphorus; A=adenine; T=thymine; 
G=guanine; C=cytosine (Hall and Giaccia, 2012). 
 
 
There are four basic photon interactions with matters namely; Rayleigh scattering, 
photoelectric effect, Compton’s effect and pair production that produces a high 
energy electron. Rayleigh or coherent scattering is a type of scattering that occurs 
between a photon and an atom where, essentially, no loss of energy occurred; but 
only a slight deflection of the incident photon (Cherry et al., 2003). Figure 2:7  
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demonstrate the three main types of photon interactions with matter 
(https://clinicalgate.com/basics-of-radiation-therapy-2/). 
 
 
 
 
Figure 2:7 Schematic pictures show the three basic types of photon interactions with 
matter. 
Photon interactions with matter; top: Compton Effect; middle: Photoelectric Effect 
and bottom: Pair Production.  (https://clinicalgate.com/basics-of-radiation-therapy-2/). 
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2.5.3  Radiation and types of cell damage 
 
Ionizing radiation induces several basic types of response from the cells such as 
oxidative stress, activating and inactivating of different signalling pathways, 
deoxyribonucleic acid (DNA) damage such as base loss, base modification, dimer, 
single and double strand breaks (DSB) as shown in Figure 2:8 (Scholz, 2003, 
Schardt, 2016); and cell cycle delay  response of the cells will then modify the 
effects of irradiation and affect the radio sensitivity status (Hall and Giaccia, 2012) 
[describe with more details in the 5 Rs of Radiobiology – see below: 
Redistribution/Reassortment that involves the different phases of cell-cycle 
sensitivity in radiation]. 
 
 
 
Figure 2:8 The various forms of DNA-damages induced by ionizing radiation (Schardt, 
2016, Scholz, 2003). 
Legend: The basic types of radiation induced damages are base loss, base modification, dimer, 
single and double strands break (from Schardt and Scholz). 
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2.5.4  Repair of irradiated cells 
 
Mammalian cells have the ability to repair radiation damage induced by radiation 
depending on the doses. Although, it is essential to allow normal tissues to repair 
all repairable radiation damage, the tumour cells can also be repaired. Withers was 
the first to describe the repair of sublethal injury in normal and neoplastic cells 
(Withers, 1975). In mammalian cells, the three radiation damage categories 
produced by ionizing radiations as describe by Hall et al. (Hall and Giaccia, 2012, 
Hall and Kraljevic, 1976) are: Lethal damage which are irreversible and 
irreparable and that leads to cell death; Sublethal damage (Elkind and Sutton, 
1959), damage that could be repaired in hours, usually considered to be completed 
within 24 hours; unless sublethal damage are added within this time which could 
interact to form lethal damage; and Potentially lethal damage (PLD), that was first 
described by Phillips and Tolmach (Phillips and Tolmach, 1966) is a component of 
radiation damage that can be modified by post-irradiation environmental 
conditions, such as allowing the radiated cells to remain in a non-dividing state. 
Under normal circumstances without interference post irradiation, PLD causes cell 
death but changing cellular growth conditions and the microenvironment of cells 
influences PLDR. Hence, PLDR (Weichselbaum, 1986, Weichselbaum et al., 1982, 
Weichselbaum et al., 1984, Weichselbaum et al., 1985, Weichselbaum and Beckett, 
1987, Guichard et al., 1984, Weichselbaum et al., 1986) indirectly affect the 
radiosensitivity of cells and the radiocurability of tumours.  
 
These three types of damages are related to DNA DSBs which are the critical 
lesions responsible for radiation-induced cell inactivation. In mammalian cells, 
radiation induced DNA DBSs spontaneously trigger a DNA damage response (DDR) 
process. The DDR process comprises of a complex network of proteins that initiate 
and coordinate DNA damage signalling and repair activities. DNA repair depends 
on several factors, such as types of damages, cell cycle phase of cell (cell cycle  
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check points) and repair pathways. Briefly, for single-strand break (SSB), the three 
modes of excision repair are Base Excision Repair (BER), Nucleotide Excision 
Repair (NER) and Mismatch Repair (MMR). And for DNA DSBs, the two major 
pathways of repair are Homologous Recombination (HR) repair and Non 
Homologous End-Joining (NHEJ) repair. HR required an undamaged DNA strand as 
a template to repair without error by the damaged cells and occurs primarily in the 
late S/G2 phase.  On the other hand, NHEJ occurs primarily during G1 phase of the 
cycle, does not require a template and they are error prone repair. Incorrect DNA 
repair can results in genetic aberrations or tumour cell death. Cell death occurs 
when there is significant DNA damage that could not be repaired (Hall and Giaccia, 
2012). Tumour cells that have the capacity to repair damage induced by radiation 
are said to be radio-resistant.   
 
Figure 2:9 shows the effects of radiation-induced DNA damage and repair 
succinctly (Morgan and Lawrence, 2015). Morgan and Lawrence have portrayed 
precisely the major types of radiation-induced DNA damage and their repair. In 
panel A, the types of DNA damage, chromatin architecture and damage sensors 
proteins are shown. There are two forms of DNA in the nucleus and they are 
euchromatin and heterochromatin.  These two forms of DNA reflect the level of 
activity in the cells. Euchromatin is prevalence in cell during active transcription; 
and is a lightly packed form of chromatin that are made up of DNA, RNA and 
protein that is enriched in genes. Conversely, heterochromatin is a tightly packed 
form of DNA and is in a less active or inactive phase of cells. In Panel B, the repair 
pathways, kinetics and cell cycle phases are demonstrated together with the 
proteins involved. Panel C shows the cell cycle checkpoints and also the proteins 
involved in the repair. There are many types of proteins involved and have been 
described (Morgan and Lawrence, 2015). 
To describe the details of the proteins involved in the entire DNA repair system 
would be beyond the scope of this literature, kindly refer to (Morgan and Lawrence, 
2015). 
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Figure 2:9 The effects of radiation induced DNA damage and repair (Morgan and Lawrence, 
2015). 
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Legends to Figure 2:9: Panel A: the major types of radiation-induced DNA damage with 
respective DNA damage sensor proteins are illustrated. Radiation induces SSBs either 
directly or indirectly as intermediates of BER. Simple DSBs involve two broken DNA ends in 
close proximity and occur in euchromatin (EC). Complex DSBs involve two broken DNA ends 
(i.e., two-ended DSB) in proximity to additional DNA damage (e.g., cross-links, SSBs, etc.) or 
within heterochromatin (HC), or a DSB within a replication fork (one-ended DSB). Panel B: 
SSBs and simple DSBs are repaired with fast kinetics by SSB repair and NHEJ pathways, 
respectively. Alt-EJ is a slow, compensatory repair pathway activated when DNA-PKcs is 
absent or when NHEJ/HR attempt, but fail to complete repair. Alt-EJ likely contributes to 
repair of complex two-ended DSBs. HR operates under slow kinetics and is partly responsible 
for repair of complex two-ended DSBs and exclusively responsible for repair of one-ended 
DSBs. These repair pathways function in a cell-cycle–dependent manner, as illustrated. Panel 
C: cell-cycle checkpoints are activated in response to DNA damage to prevent propagation of 
cells with damaged DNA and to permit time for DNA repair. The major checkpoints include 
those occurring in G1, S, and G2. While ATM activation is the initial response to radiation-
induced DNA DSBs, ATR is subsequently activated and contributes to a sustained cell-cycle 
checkpoint response. Dashed lines represent incompletely understood pathways. ATRIP, ATR 
interacting protein (Morgan and Lawrence, 2015). 
 
 
2.5.5  The 5 Rs’ of radiotherapy 
 
Sparsely ionizing radiations are limited by the 5 Rs of radiobiology  (Steel et al., 
1989, Hall and Giaccia, 2012). The 5 Rs by Steel, McMillan and Peacock (Steel et al., 
1989) is an extension of the 4 R’s by Wither (Withers, 1975) where the additional 
‘R’ represent cells from different types of tumour have different inherent 
radiosensitivity. The 5 ‘Rs’ are Reoxygenation, Redistribution, Repopulation, 
Radiosensitivity and Repair, (Steel et al., 1989). The goal of radiation is to kill all 
tumour cells without incurring serious damage to the normal surrounding tissues 
and organ at risk (OAR). To achieve this goal, fractionation radiotherapy was 
implemented to spare normal tissues surrounding the tumour as one single high  
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dose could be detrimental not only to tumour but also to normal tissues. It also 
allows tumour cells to reassort or redistribute into the mitotic phase which is 
radio-sensitive. In addition, it reduces hypoxia (see paragraph below) by 
reoxygenation and is based on the theory of the 4 ‘R’s  (Withers, 1975). These 5 Rs 
determine the effectiveness of fractionation in radiotherapy. Fractionation in 
radiotherapy increases damage to a tumour because of reoxygenation and 
reassortment of cells into radiosensitive phases of the cycle as discuss below. 
 
Reoxygenation - oxygen plays an important role in radiation as it enhances 
radiation effect; known as the Oxygen Enhancement Ratio (OER). Oxygen is 
required in photon radiation to help fix the radiation damage as shown by Hall and 
Giaccia (Hall and Giaccia, 2012) in Figure 2:10. The OER is a measure of tumour 
sensitivity to radiation in the presence or absence of oxygen. It is expressed as the 
ratio of radiation dose required to produce a given effect in the absence of oxygen 
to the dose required to produce the same effect in one atmosphere of air (Hall and 
Giaccia, 2012). Tumours that are hypoxic (low oxygen level) are radio-resistant to 
photon radiation and they require higher dosage of radiation to inactivate them.  
 
Gray et al. were the first to demonstrate that oxygen plays an important role on 
biological response by affecting the chemical changes produced directly in the cells 
by radiations (Gray et al., 1953). Re-oxygenation has accounted for the success of 
fractionated radiotherapy of hypoxic tumour cells; when a radiations tumour has 
shrunk and re-oxygenation of tumour occurs (Withers, 1975) due to reopening of 
temporarily occluded blood vessels; and also resorption of dead cells which lead to 
decreased distance from capillaries to tumour cells (thus improving oxygen 
supply). Most malignant tumours contain a proportion of hypoxic cells and GBM is 
known for its necrotic and hypoxic features (Amberger-Murphy, 2009).   
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Figure 2:10 Hall and Giaccia oxygen fixation hypothesis (Hall and Giaccia, 2012). 
The oxygen fixation hypothesis, about two-thirds of the biologic damage produced by X-rays 
is by indirect action mediated by free radicals. The damage produced by free radicals in DNA 
can be repaired under hypoxia but may be ‘fixed’ (made permanent and irreparable) if 
molecular oxygen is available (Hall and Giaccia, 2012). 
 
 
The detail of how oxygen fixed the radiation damaged DNA is clarified in Figure 
2:11 by Grimes and Partridge. The high energy electrons formed in the body 
through interaction with photon radiation when they impinge upon the water 
molecules which are abundant in the body, hydroxyl radicals are formed. These 
radicals are highly unstable and extremely reactive (chemically) and could damage 
DNA. However, these damages are repairable and the damaged DNA can be 
restored and cell kill prevented. This kind of damage which is common in photon 
radiation makes radiotherapy less effective. But, if the radical reacts with oxygen 
prior to the collision, it forms a new type of radical called a ‘peroxy radical’ that is 
difficult and impossible to repair chemically, consequently ‘fixing’ DNA into a 
permanent irreparable state (Grimes and Partridge, 2015). This is the basis of the 
importance of oxygen in radiotherapy. 
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Figure 2:11 Grimes and Partridge’s mechanistic oxygen fixation hypothesis (Grimes and 
Partridge, 2015). 
The detail oxygen fixation hypothesis—a high energy electron created by an x-ray photon (e-
) impinges upon a water molecule, liberating a proton (p+) and creating a hydroxyl radical 
(OH•). This reactive molecule then impacts upon DNA, resulting in ionization damage, DNA •. 
This can be readily repaired to its original state (DNA-H), but in the presence of molecular 
oxygen a peroxy radical is formed (DNA-OO •), ‘fixing’ damage into a permanent irreparable 
state (Grimes and Partridge, 2015). 
 
 
Redistribution also known as Reassortment refers to radiation-induced cell cycle 
effects (Withers, 1975).  The cell cycle is divided into four phases that is G1, S, and 
G2 and mitosis. In interphase (G1, S, and G2), the cell grows, duplicates its DNA 
content and prepares for mitosis. Mitosis involves the process of nuclear division 
and cytokinesis, resulting into two genetically identical daughter cells. G0 phase is 
where the cell stops dividing. Figure 2:12 shows a simple cell cycle 
(http://cyberbridge.mcb.harvard.edu/mitosis_3.html). Cells have different 
radiation sensitivities at different phase of the cell cycle; the most radiation 
sensitivity is late G2/M phase of the cell cycle and S phase is the most resistant  
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(Tobias, 1985). S is the synthesis phase where damage repair can occurs and any 
damaged induced can be repaired (see 2.5.4 Repair of irradiated cells). G2 is the 
gap phase between Synthesis and Mitosis. Radiation induces slowing of cell cycle 
progression by molecular checkpoint genes that tend to block irradiated cells in 
the G2 phase (Hall and Giaccia, 2012, Yamada and Puck, 1961). Tumour cells are 
more sensitive in G2/M phases of the cell cycle than G1/S and when they are 
blocked in G2/M due to a functional G2 checkpoint after exposure to radiation, they 
are more susceptible to the subsequent irradiation. Moreover, tumour cells have 
shorter cell cycle times in comparison with normal tissues. In contrast, normal 
cells are mostly in G0/G1 due to G1 checkpoint and are thus less susceptible to this 
type of sensitization (Ng et al., 2013). Fractionation in radiotherapy permits 
tumour cells to reassort themselves into a more sensitive phase of the cell cycle to 
allow effective killing (results in therapeutic gain) and favour survival of normal 
late responding tissues (Withers, 1975, Hall and Giaccia, 2012). 
 
 
 
 
Figure 2:12 Schematic of cell cycle (http://cyberbridge.mcb.harvard.edu/mitosis_3.html). 
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Repopulation, another name for Regeneration ~ fractionation radiotherapy allows 
normal tissues to repopulate which is important to reduce overkill and severe side 
effects for radio-sensitive tissues such as the skin or mucosa and surrounding 
normal tissues. For the early responding normal tissues, fractionation interval 
brings about increase in radiation tolerance with increasing overall treatment time. 
When the interval time between two dose fractions exceeds the cell cycle, there 
will be an increase in the number of cells surviving due to cell proliferation. Just as 
normal cells can proliferate, tumour cells can also respond with an increase rate of 
repopulation. At the same time as tumour shrinks post treatment, surviving 
tumour cells proliferate at an accelerated rate as tumour cells have uncontrolled 
growth rate, and this counteracts the cell killing effect of radiotherapy. 
Repopulation time of tumour cells varies during radiotherapy (Withers, 1975). 
Repopulation has a negative effect on fractionated doses. 
 
Radio-sensitivity - different types of cells exhibit different intrinsic radio-
sensitivity which is unique to the individual cell (Steel et al., 1989). Radiation 
repair is the ability of cells to repair sublethal damage (Withers, 1975, Elkind and 
Sutton, 1959) and potential lethal damage (Phillips and Tolmach, 1966). 
 
These 4 and 5 Rs constraints the effectiveness of photon radiotherapy for tumours  
(Withers, 1975, Steel et al., 1989, Hall and Giaccia, 2012, Elkind and Sutton, 1959, 
Phillips and Tolmach, 1966).  Faced with the limitations of photon radiotherapy 
especially for radio-resistant tumours, such as gliomas and GBM; prostate and 
pancreatic cancers and many others; an alternative treatment modality is charged 
ion radiotherapy, which uses beams of protons or other charged ions such as 4He, 
12C, 20Ne  or other ions instead of photons.  
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2.5.6  Charged ion radiation 
 
Photons have low LET.  In contrast, charged ions like protons, neutrons, α particle, 
4He ion, 12C ion, 20Neion, 28Si ion, 56Fe ion; and others are densely ionizing radiation 
with high LET. These high LET charged particles have more potential in killing 
tumour cells due to the increased ionization density. In addition, photons deposit 
energy in a highly dispersed mode, displaying a very broad energy distribution in 
tissue with the peak dose located relatively close to the surface and the absorbed 
dose by the body shows an exponential decrease in radiation dose with increasing 
tissue depth. In contrast, charged ions deposit minimal energy at the body’s 
surface, when the velocity is high, and deposit most of their energy just before they 
come to rest in tissue; this release of energy is termed the Bragg peak (Bragg, 
1906). Moreover, due to the large mass of ions; it travel in straight paths with a 
relatively well defined stopping range and the pattern of energy deposition is 
characterized by a dense core of ionization that is localised along the path of the 
ion (Allen et al., 2011). Together with the Bragg peak of the ions that exhibit an 
inverse dose profile (an increase of energy deposition with penetration depth) and 
the dense core of ionization, this provide an excellent dose distribution in patients 
(Wilson, 1946). As charged ions exhibit an increase in ionization density (high 
LET), the DNA damage is more complex and are difficult to repair, leading to 
increased biologic effectiveness which results in an increase in RBE.  
 
Furthermore, the majority of DNA damage by low or high LET is understood to 
arise indirectly through production of reactive oxygen species (ROS) and required  
oxygen to fix DNA damages as discussed earlier (Hall and Giaccia, 2012, Grimes 
and Partridge, 2015). High LET radiation is known to reduce the requirement of 
oxygen with hypoxic cells being more sensitive to this type of radiations (Tobias et 
al., 1982). This reduction in the oxygen enhancement ratio (OER) is of importance 
in the treatment of radio-resistance hypoxic tumours.  The OER is the ratio of the 
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doses required to produce the same biological effect with a given type of radiation 
in the presence or absence of oxygen (as explained in 2.5.5: The 5 Rs’ of 
Radiotherapy: Reoxygenation above). Tobias et al. demonstrate the reduction in 
oxygen requirement as Oxygen gain factor = OER photon/OER ion  (Tobias et al., 1982). 
The reduced in OER by high LET could be due to the more clustered DNA damage 
induced which are difficult to repair by the cellular DNA repair systems (Hada and 
Georgakilas, 2008). Moreover, the cell cycle dependence of cell inactivation with 
photon irradiation is also reduced with high LET; near the Bragg peak region, it is 
less affected by variation in cell cycle-related radio-sensitivity and the damaged 
caused is lethal to the cell (Orecchia et al., 2004, Durante and Loeffler, 2009). 
Charged ion radiations are less affected by the 5 Rs of photon irradiation.  
 
Additionally, ions have the quality of a sharp lateral margin and depth dose 
depending on ions and energy of ions.  Chu describes this sharp lateral margin  as 
lateral dose falloff (often called the apparent penumbra) that is of clinical 
importance because of radiation exposure of the normal tissues adjacent to the 
target volume that often limits the therapeutic dose (Chu, 2006). Figure 2:13 
compares the penumbra of a carbon beam to that of a proton beam and the 
penumbra of a carbon beam is much sharper than that of a proton beam of a 
comparable range (Chu, 2006). Moreover, it also has excellent precision at 
targeting of a tumour as it uses the benefit of the SOBP energy deposition 
properties to minimize the maximum dose to critical body structures.  It is most 
suitable for small tumours located close to radiation-sensitive organs in the body.  
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Figure 2:13 The penumbra (lateral margin) of a carbon beam is shaper than that of a 
proton beam of a comparable range (Chu, 2006). 
 
 
Charged ions have different depth-dose distribution (inverted dose profile) and 
most of the energy is deposited in the last final millimetres of their trajectory when 
the speed slows. The initial energy (speed) of the charged ion determines how 
deep in the body the Bragg peak will form. The intensity of the beam determines 
the dose that will be deposited to the tissues. By adjusting the energy of the 
charged particles and by adjusting the intensity of the beam, pre-specified doses 
can be delivered anywhere in the patient’s body with high precision. To irradiate a 
whole tumour area, multiple Bragg peaks (SOBP) of different energies and 
intensities are combined (Trikalinos et al.).   
 
Charged ions interact with tissues to cause complex damage to the target, the same 
amount of radiation can have more pronounced biologic effects. Moreover, high 
LET radiation causes clustered DNA damage which Ward coined as locally multiple   
damaged sites (LMDS), also known as clustered damage which are not easy to 
repair to the original structure  (Ward, 1985, Hall and Giaccia, 2012). 
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Charged ion radiotherapy potentially possesses physical and biological advantages 
over photons (megavoltage X-rays). The physical benefits of heavy charged ions 
provided by the Bragg peak allow precise delivery of high radiation doses to 
tumours while minimizing destructive irradiation to normal tissues and critical 
organs at risk. Besides, its depth-dose distributions that can be modulated/shaped 
to cover tumours of different shapes (SOBP); and the increase in ion density (LET) 
as shown in Figure 2:14 (Gray, 1946), also makes it a more superior modality of 
radiation compared to photons.  
 
 
2.5.6.1 Physical benefits – linear energy transfer 
 
LET describes the linear rate of energy absorption by the absorbing medium as the 
charged particles traverse the medium (Zirkle and Tobias, 1953). LET also 
describes the number of ionisations per unit distance and reflects the rate at which 
ionization is produced along the track of charged particles and has dimensions of 
energy per unit length in keV/µm. In contrast, ‘stopping force’ is the energy loss by 
an energetic charged particle moving through a medium To simplify, stopping 
force has a typical unit of MeV/cm,  while the unit for LET used is usually keV/µm 
(Cherry et al., 2003). 
 
The ICRU defines LET as follows:  
‘LET of charged particles in a medium is the quotient dE/dl, where dE is the average 
energy locally imparted to the medium by a charged particle of specified energy in 
traversing a distance of dl.’ (ICRU, 1970). 
 
As the LET of radiation increases, the ability of the radiation to produce biological 
damages also increases Figure 2:14 (Gray, 1946).  Figure 2:14 shows separation of 
ion clusters in relation to the size of a virus particle 27 µm in diameter, from Gray’s  
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Comparative studies of the biological effects of X-rays, neutrons and other ionizing 
radiations. It illustrate the increase radiobiological effects of high LET. Particles 
with higher LET are more likely to produce irreparable damage (Gray, 1946). 
 
 
 
Figure 2:14 The radiobiological effects of high LET (Gray, 1946). 
 
 
LET is an average quantity and it can be calculated in various ways. Hall and 
Giaccia describe the most common method is to calculate the track average or 
energy average as demonstrated in Figure 2:15 (Hall and Giaccia, 2012). The track 
average is acquired by dividing the track into equal length, calculating the energy 
deposited in each length, and finding the mean energy. While, the energy average is 
achieved by dividing the particle track into equal energy increments and averaging 
the length of track over which these energy increments are deposited (Hall and 
Giaccia, 2012). The energy average is more appropriate in term of average dose 
used in radiotherapy.  
 
 
 
Figure 2:15 LET measured as track and energy average (Hall and Giaccia, 2012). 
  
 Chapter 2 
71 
 
 
The biological damages increases with LET until the optimum LET that is about 
100 – 200 keV/µm (Hall and Giaccia, 2012). Hall and Giaccia describe the reason 
for this optimum LET in producing a biologic effect is because at this density 100 
keV/µm, the average separation between ionizing events just about coincides with 
the diameter of the DNA double helix (20 Å = 2 nm). Since DNA of the nucleus is the 
main target of radiation, this density has the highest probability of causing a DSB 
by the passage of a single charged particle (see Figure 2:16). In contrast, high LET 
> 200 keV/µm which is much more densely ionizing; the ionizing events are too 
close together and easily produce DSB but the extra energy is ‘wasted’ as the cell 
can only be killed once (Hall and Giaccia, 2012). The RBE of this densely ionizing 
radiation is lower than the optimal LET radiation as the RBE is the ratio of doses 
producing equal biologic effect, hence, this densely radiation has a lower RBE 
(Figure 2:16).  
 
 
 
 
Figure 2:16 The effects of 100 keV/µm on DNA double helix (Hall and Giaccia, 2012). 
Figure illustrating why radiation with a LET of 100 keV/µm has the greatest RBE for cell 
killing, mutagenesis or oncogenic transformation (Hall and Giaccia, 2012). 
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2.5.6.2 Biological benefits – relative biological effectiveness 
 
The biological benefit of charged ion radiotherapy is that it increases in RBE. It was 
first coined by Zirkle and Tobias (Zirkle and Tobias, 1953), it compares the 
efficiency of different types of radiation to produce a defined biological 
effectiveness referenced to photon radiation; defined as a ratio of the dose of the 
reference radiation to that of the test radiation required to yield the same 
biological endpoint effect, such as cell inactivation, complex DNA damage and 
lethal chromosome aberrations. RBE is not a single value for a given LET. RBE is 
dependent on many factors such as cell and tissue type, biological endpoint, 
culture condition, dose, dose rate or fractionation, charged ion species, LET and 
oxygenation status and many other influences (Held et al., 2016, Hall and Giaccia, 
2012, Skarsgard, 1998). The standard type of radiation is usually X- or γ rays 
(60Co). 
 
The RBE is defined by the ratio below:  
 
RBE = Dose from standard radiation to produce a given biological effect 
 Dose from test radiation to produce the same biological effect       2.1  
 
 
Clinically, RBE plays an important role as it is used to calculate the Gy Equivalent 
dose (GyE); that is the physical doses multiplied by the RBE of the related ion used; 
for example, at NIRS/HIMAC, a RBE of 3 is used to calculate the carbon dose for 
treatments (Tsujii et al., 2007, Mizoe et al., 2007, Matsufuji et al., 2007).  
 
Densely ionizing radiation produces higher RBE because it causes greater 
biological damage to the tumour cells compared to the equivalent less dense 
ionizing radiation exposure. In general, the RBE increases with the LET and is ion-
dependent to reach a maximum RBE at around 100 – 200 keV/µm; RBE is also 
dependent on the level of cell kill, as shown in Figure 2:17 and then decreases,  
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(Hall and Giaccia, 2012) because of ‘thin down’ as described by Katz et al. (Katz, 
1996) or overkill (Skarsgard, 1998). ‘Thin down’ indicates the decrease in the 
inactivation cross section while the LET of the ion increases and as the ion 
approaches the end of its range. Thus, the RBE of LET above the optimal LET 
radiation will be lower. The more densely ionizing radiation (> 200 keV/µm) is just 
as effective per track, but less effective per unit dose (Hall and Giaccia, 2012). 
 
 
 
Figure 2:17 RBE is dependent on cell survival levels (Hall and Giaccia, 2012). 
Figure 2:17 shows the variation of RBE with LET for survival of human cells lines. The RBE 
rises to a maximum at about LET 100 keV/µm, and subsequently falls to higher values of LET. 
Curves 1, 2 and 3 refer to cell survival levels of 0.8, 0.1 and 0.001, respectively, illustrating the 
absolute value of the RBE is not unique but depends on the level of biologic damage and, 
therefore, on the dose level. (Hall and Giaccia, 2012). 
 
 
Of interest is that, an increase in RBE in itself is of no therapeutic advantage unless 
there is a wide therapeutic window/index between RBE of tumour and normal 
tissues (Hall and Giaccia, 2012, Joiner and Van der Kogel, 2016). Also, of 
importance is the peak to plateau biological effective dose ratio as it can spare the 
normal tissue before hitting the tumour (Skarsgard, 1998).  
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2.6 Uncertainties and limitations of charged ion 
radiation 
 
It is worth mentioning that energetic heavy ions not only deposit their energy 
within tracks created by the particle’s traversal through the cells but also generate 
secondary electrons, termed ‘delta rays’ (δ), which arise from the initial ionisation 
event, can traverse in multiple directions and give rise to double strands breaks 
closely localised (nanometre dimension) within the particle track (Rossi, 1959, 
Katz et al., 1971). These γ-kill represent the probability for the inactivation of cells 
by the cumulative overlapping δ rays of bombarded ions and is appropriate to the 
low LET limit (Katz et al., 1971). The paths of heavy ions and their δ-electrons 
traversing matter according to energy MeV/u using Monte Carlo calculations is 
illustrated in Figure 2:18 [M. Krӓmer http://bio.gsi.de/RESEARCH/track.html 
(scale in nanometres)]. 
 
Moreover, there are multiple scattering and range straggling to contend with. 
Multiple scattering of an incident ion are Coulomb interactions with nuclei, similar 
to the interactions of the Coulomb interactions with electrons; where, numerous 
small angle deflections in an ion beam lead to lateral spreading of the incident ions 
away from the central trajectory (Lomax, 2009, Chu, 2006). This contribution to 
beam width at the Bragg peak is approximately 2% of the range of the Bragg peak 
in water for protons (Goitein, 2008, Lomax, 2009). Conversely, range straggling 
occurs due to energy loss through interactions of ion with orbiting electrons, losing 
a varying amount of energy with each interaction and is governed by statistics 
(Lomax, 2009). This results in blurring out the pristine Bragg peak at about 1% of 
the Bragg peak’s range for protons (Lomax, 2009). This clinically uncertain range 
is typically 3% uncertainty. Lomax and Chu define ‘range straggling as the 
dispersion of the path length of a particle beam due to statistical fluctuations in the 
energy-loss process (Lomax, 2009, Chu, 2006). These two effects for ion beams  
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vary approximately inversely to the square-root of the mass of the particle and 
could be minimize by removing material from the beam line (Chu, 2006). 
 
 
Figure 2:18 Monte Carlo calculations that illustrate the paths of heavy ions and their delta-
electrons traversing matter (http://bio.gsi.de/RESEARCH/track.html). 
 
 
Another factor is the nuclear fragmentation of heavy ions near the end of Bragg 
peak which may give rise to unaccounted additional dose. As a particle beam 
penetrates through matter, the primary particles suffer fragmentation collisions, 
which decrease the number of primaries with the corresponding increase of lighter 
fragments along the penetration path. This degrades the accuracy of the treatment 
planning and undermines the primary benefits of heavy ion radiotherapy by 
contributing to a significant over dosing within the spread-out Bragg peak and  
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beyond the actual stopping range of the primary particle (Jäkel, 2006, Chu, 2006, 
Ballarini et al., 2008, Zeitlin and La Tessa, 2016). In general, the higher the Z 
particle, the larger the fragmentation dose is delivered in the region beyond the 
Bragg peak and contribute significantly to the dose within the spread-out Bragg 
peak (Chu, 2006). Figure 2:19 shows the fragmentations of each ion type 
(http://becquerel.jinr.ru/movies/movies.html).  
  
More details of the physical uncertainties of charged particle beam (proton) have 
been described (Lomax, 2009); heavy ion effects from track structure to DNA and 
chromosome damage has been modelled (Ballarini et al., 2008).  
 
 
 
Figure 2:19 Fragmentations of different ions on target.  
(http://becquerel.jinr.ru/movies/movies.html). 
Photomicrographs above showing fragmentations of heavy ions on target are not in uniform 
scale. The incident beam is from the left. From top the fragmentation of 56Fe, 28Si, 20Ne, 12C 
and 4He (http://becquerel.jinr.ru/movies/movies.html).  
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After considering all the physics and statistical uncertainties, the greatest 
consideration of having a charged ion/particle therapy facility is the cost (financial 
consideration), where Lodge et al. (Lodge et al., 2007) have reported that there is 
not enough evidence-based data concerning the relative cost-effectiveness of 
hadron therapy. J. A. Nickoloff compared the current cost of X-Ray therapy (XRT), 
proton radiotherapy (PRT) and carbon Ion radiotherapy (CIRT) machines as USD3-
5 million (M), USD25-50M, and USD100+M respectively; and this does not include 
another USD20-40M to house the CIRT machine and ancillary equipment 
(Nickoloff, 2015). Although, it may be the most expensive radiotherapy treatment 
on offer currently, cost effective studies of PRT and CIRT has been evaluated 
(Lundkvist et al., 2005, Ohno, 2013). Recently, the cost-effectiveness of carbon ion 
radiotherapy compared with conventional multimodality therapy in the treatment 
of patients with locally recurrent rectal cancer has been evaluated and found to be 
a potential cost effective treatment modality (Mobaraki et al., 2010). Lastly but not 
the least, Michael Goitein (Goitein, 2010) discussed the ethics of randomized 
clinical trials in his ‘Trials and tribulation in charged particle radiotherapy’. The 
ethics of randomized clinical trials is that the arms of any study must be in 
equipoise, the endpoints and patients’ interest is paramount to the doctors 
running the trials (for more details, refer to (Goitein, 2010)). 
 
 
2.7 Glioblastoma treated with charged ion therapy 
 
Treating GBM with neon ions was first initiated by Linstadt et al. in their phase I/II 
trial (Linstadt et al., 1991) and they reported that treatment improved outcome 
was favourable for other tumours except GBM. Castro et al. (Castro et al., 1997) 
followed up by treating 14 GBM patients with neon ion radiotherapy and reported 
that an optimal neon dose was not demonstrated but that there was a trend 
toward better results with higher neon doses. There was only one GBM patient  
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treated entirely with helium ions (Castro et al., 1982). Si ions were not used to 
treat GBM patients, even though they were once deemed to be the particle of 
choice for maximizing high LET particle effects (Tobias et al., 1982, Castro et al., 
1982) as they have a depth-dose profile in between that of 20Ne and 40Ar-ion and 
are suitable for deep tumour radiotherapy. Further work could not be done as the 
Berkeley accelerator was shut down due to budgetary reasons. 
 
Carbon ion radiotherapy has been made available in Japan at the National Institute 
of Radiological Science (NIRS) since June 1994. Since the successful report of 
carbon ion radiotherapy by Tsujii et al. from NIRS using the HIMAC, Japan (Tsujii et 
al., 2007), much attention has been focused on carbon ions. The first GBM phase 1-
II trial using carbon as a boost for treatment has been reported as successful by 
Mizoe et al. (Mizoe et al., 2007). Thirty two GBM patients and 16 patients with 
anaplastic astrocytoma were treated with surgery and post-operative concurrent 
chemo-radiotherapy with X-rays followed by carbon ion radiotherapy. Patients 
were first treated with X-ray radiation of 50 Gy in 25 fractions in 5 weeks, followed 
by carbon ion radiotherapy of 8 fractions in 2 weeks. Carbon ion dose was 
escalated from 16.8 to 24.8 Gy Equivalent (GyE) in 10% incremental steps. 
Nimustine hydrochloride were administered instead of TMZ (Mizoe et al., 2007) 
and the doses of carbon ion were expressed in photon equivalent doses (GyE), that 
is physical doses multiplied by the RBE of the carbon ion and the RBE of carbon ion 
was assumed to be 3.0. It was concluded that the survival rate tends to increase 
with an increase in carbon ion dose.  
 
Combs et al. had two randomized clinical trials for GBM patients; namely phase II-
CLEOPATRA-Study to investigate the benefit of a carbon ion boost (18 GyE) versus 
a proton (10 GyE) boost on GBM patients at primary diagnosis in addition to 
photon radiotherapy (50 Gy) after surgery and standard chemotherapy with TMZ 
(Combs et al., 2010b). The other Phase I/II-CINDERELLA-trial concerns treatment  
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with re-irradiation using carbon ions versus fractionated stereotactic radiotherapy 
in patients with recurrent or progressive gliomas (Combs et al., 2010a). 
 
Here, it is worth mentioning in brief, clinical trials with proton radiotherapy have 
also been conducted for GBM patients. Fitzek et al. in a phase II trial studied 23 
GBM patients treated with 90 GyE using proton and X-rays with hyper-
fractionation radiotherapy improved local control and survival was the outcome. 
The median survival time (MST) of all the patients was 20.0 months and patients 
with radiation necrosis lived longer (Fitzek et al., 1999). All patients suffered 
radiation necrosis but those with only necrosis and no recurrence live significantly 
longer. Similarly, Mizumoto et al. also concluded hyper-fractionated concomitant 
boost proton radiotherapy (96.6 GyE in 56 fractions) was tolerable and benefitted 
GBM patients in their Phase I/II trial and suggested the possibility of dose-
escalation in the treatment of GBM patients using proton therapy and ACNU 
(Mizumoto et al., 2010). MST was extended to 21.6 months, which is one of the 
most favourable results reported at that time. Mizumoto et al. in their follow up 
study of the phase I/II study evaluated the GBM survivors after postoperative 
hyper-fractionated concomitant boost X-ray and proton radiotherapy 
demonstrating that GBM could be effectively control if the treatment area could 
completely cover infiltration (Mizumoto et al., 2015).   
To describe all other types of particle therapy is beyond the scope of this 
background study. 
 
 
2.8 Ion beam research for space radiation 
 
Space radiation biology is of interest as astronauts and cosmonauts are at risk to 
being exposed to irradiation by heavy ions in the cosmic environment which is full 
of radiation. Space radiation covers radiation protection in space flight as these   
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irradiations seem to be the limiting factor for a long term space flight. Moreover, it 
is also a health hazard to commercial human space travel. At low altitude, muons 
that decay with products of electrons are the main contributor to dose (Friedberg 
and Copeland, 2011). 
 
Air and space travellers (atmosphere and in space) are constantly at risk to 
exposure to galactic cosmic radiation (GCR) which is ionizing radiation from 
exploding stars (described in more details in 2.8.2 below). In space, another 
constant source of ionizing radiation is the solar wind from the sun which consist 
mostly of electrons and protons with energies between 10 and 100 keV described 
in detail in 2.8.3 below (Friedberg and Copeland, 2011). At high altitude 
environment, space travellers are constantly exposed to different types of 
radiations as illustrated by Tristan Matthew in Figure 2:20 
(https://www.slideshare.net/TristanMatthews?utm_campaign=profiletracking&ut
m_medium=sssite&utm_source=ssslideview).  
 
  Chapter 2 
81 
 
 
Figure 2:20 Radiation exposures to space travellers at high altitude environment. 
(https://www.slideshare.net/TristanMatthews?utm_campaign=profiletracking&utm_medium=sssite&utm_source=ssslideview). 
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2.8.1  Earth’s magnetic field 
 
In W. Friedberg and K. Copeland Report on ‘Ionizing radiation in earth’s 
atmosphere and in space near earth’ for the U.S Federal Aviation Administration; 
ionizing radiation was addressed as a health hazards in air travel and in 
commercial human space travel (Friedberg and Copeland, 2011). This report gave 
an excellent description of Earth’s Magnetic Field and space radiations. Briefly, at 
Earth’s surface, the geomagnetic field is at the dipole, with magnetic field lines 
radiating between its north and south magnetic poles. These magnetic field lines 
indicate the strength and direction of a magnetic field, where the denser the field 
lines, the stronger the magnetic field. At the geomagnetic equator where 
geomagnetic field lines are parallel to Earth’s surface, only particles ≧ 100 MeV can 
reach Earth’s atmosphere. At the magnetic poles, the field lines are perpendicular 
to the Earth’s surface and ions of any energy can reach Earth’s atmosphere.  This 
means, when an aircraft flies at a constant altitude from the geomagnetic equator 
towards the north or south magnetic pole, the dose rate would increase with 
distance from the equator; and at high latitude, shielding by the geomagnetic field 
is minimal. The geomagnetic field traps charged particles in the Van Allen radiation 
two belts. These two belts encircle the earth and are confined to an area from 
about 65°N to 65°S of the geographic equator (Friedberg and Copeland, 2011).  
 
The inner radiation belt nearest to Earth extends above Earth’s surface, from about 
200 km to 11,000 km above the geomagnetic equator and is centred at about 3,000 
km. It consists mostly of electrons and 10-100 MeV protons, which contribute the 
most to the dose. Proton > 50 MeV are believed to originate from the decay of free 
neutrons backscattered into the inner belt after being dislodged from atmospheric 
atoms by Galactic Cosmic Radiation (GCR) particles. At the geomagnetic equator, 
protons from a continuous distribution, with peak fluences of 400 MeV protons at 
2,000 km, 4 MeV protons at 6,000 km, and 0.3 MeV protons at 13, 000 km. As the 
dipole axis of Earth’s magnetic field is tilted 11.1° from the rotation axis and offset 
515 km from the rotation axis, resulting in the lower boundary of the inner  
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radiation belt dips closest to Earth in a region off the coast of Brazil called the 
South Atlantic Anomaly (SAA). The daily dose of ionizing radiation to the 
occupants of the International Space Station (ISS) is ~ 0.5-1.2 mSv but when it 
passes through the SAA, approximately 25% of the dose comes from proton and 
the rest galactic cosmic radiation (Friedberg and Copeland, 2011).  
 
The outer radiation belt, that is furthest from Earth (about 11,000 km to 70,000 
km in altitude) consist mostly of electrons (Friedberg and Copeland, 2011). The 
most energetic electrons have energies > 1.0 MeV and are centred at around 
19,000-25,000 km and the main radiation hazard to space travellers in the outer 
belt is soft X-rays, produced when electrons decelerate in the shell of the space 
vehicle. The earth’s atmosphere content is approximately 78% nitrogen, 21% 
oxygen, 0.93% argon, 0.039% carbon dioxide and trace amounts of other gases 
(samples.jbpub.com/9781284032307/9781284028775_CH02_Rohli3e_SECURE.p
df). The aurora borealis (northern lights) and aurora australis (southern lights) are 
produced by these fast moving electrons interaction with the oxygen and nitrogen 
in this outer radiation belt. The electrons cause excitation to the oxygen and 
nitrogen atoms and molecules through the energy transferred. When the gases 
return to their normal state, photons are emitted, i.e. small burst of energy in the 
form of light. 
 
 
2.8.2  Galactic cosmic radiation 
 
Space radiations contain a mixture of low LET and high LET. The Earth is 
continuously irradiated from all directions by high-energy charged particles of GCR. 
Outside the geomagnetic field, the composition of the GCR is 98% proton plus 
heavier nuclei stripped of orbital electrons and 2% electrons and positrons. The 
nuclei component of the radiation, in the energy range 100 MeV to 10 GeV per  
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nucleon consist of 87% proton, 12% alpha particle and 1% with an atomic number 
Z higher than helium (Friedberg and Copeland, 2011). The percentage of the GCR 
particles varies with authors. The GCR spectrum consists particles of high charged 
and energy (HZE) nuclei ranging from Z=1 to Z=26 which are biological harmful to 
astronauts’ CNS. 56Fe is an important HZE particle because of its significance 
contribution to GCR dose and its high LET (Friedberg and Copeland, 2011). HZE 
particles are not a concern to airline flight altitudes as these particles are broken 
apart at higher altitudes in the atmosphere. The relative abundance of GCR nuclei 
are shown in Figure 2:21. Some of these GCR nuclei are hard to shield from within 
the spacecraft (Chancellor et al., 2014, Simpson, 1983). Both GCR and SPE are of 
concern for the CNS risk (Cucinotta et al., 2014). GCR is believed to derive from 
supernovae or exploding stars and cannot be shielded with current spacecraft 
design for space travellers.  
 
 
 
Figure 2:21 The Relative Abundance of Galactic Cosmic radiation nuclei (Simpson, 1983, 
Chancellor et al., 2014). 
Relative abundance of GCR nuclei from hydrogen (Z = 1) to iron (Z = 26). 
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2.8.3  Solar particles events 
 
The Sun undergoes an approximately 11-year cycle of rise and decline in activity 
and during its active phase, there is an increased emission of the solar wind and 
occasional eruptions of high-energy particles coronal mass ejections (CME) 
(Friedberg and Copeland, 2011). The term solar flare refers to the electromagnetic 
energy and particles released suddenly from a relatively small volume of the sun; 
is a light-speed travelling burst of X-rays and energy. While, CME occurs when a 
magnetic disturbance in the Sun results in an explosive ejection of huge amounts of 
matter and embedded magnetic fields from the solar corona. Solar flare and CME 
are emitted from the sun and both affect the earth in different ways and can occur 
together. Conversely, solar proton evens is a surge of subatomic particles from the 
sun and measured in three consecutive 5-minutes periods an average solar proton 
flux ≧ 10 particles/ (cm2·steradian·second) with all proton energies > 10 MeV. 
This type of particle surge is most likely the result of a CME. The radiation 
encountered in space is elegantly represented in Figure 2:22  by Tristan Matthews  
(https://www.slideshare.net/TristanMatthews?utm_campaign=profiletracking&ut
m_medium=sssite&utm_source=ssslideview). 
 
There is lack of data on the biological response to HZE particles in space and these 
ground based experiments with GBM simulate the HZE particles in the cosmic 
environment to study its effects.  Using GBM cells has limitation when compared to 
response of normal cells such as the fibroblast or lymphocytes. However GBM is 
also hypersensitive to low doses of radiation. Moreover, most of the doses used 
with rodents’ experiments are 0.2 Gy which is within the low dose range for GBM 
low-dose hypersensitivity (Britten et al., 2011, Lonart et al., 2012, Short et al., 
1999b, Joiner et al., 2001). Although, normal cells such as lymphocytes and 
fibroblast are used for space radiation biology studies with respect to mutation 
(radiation protection) and typically chromosome aberrations (Wu et al., 1999, 
Kawata et al., 2001), GBM cells were used as it is a radio-resistant tumour yet  
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hypersensitive to low doses of radiations; like a two-edged sword. Furthermore, it 
can simulate the effects and the results can be inferred.  The most harmful of GCR 
on the CNS is the HZE particles 56Fe. Ground-based experiments of rodents 
exposed to HZE particle radiation has been shown to induce pronounced deficits in 
its hippocampus-dependent learning and memory but the exact mechanisms are 
mostly unknown. Machida et al. exposed rodents to 0.6 Gy of 1 GeV 56Fe ions and 
established an impact on hippocampal glutamatergic neurotransmissions at 3 and 
6 months post exposure. Their results show that hippocampal glutamatergic 
transmission is sensitive to relative low doses of 56Fe ions (Machida et al., 2010). 
Britten et al. showed Wister rats that received 0.2, 0.4  and 0.6 Gy 1 GeV/u 56Fe 
ions results in severe deficits in hippocampus dependent neurocognitive tasks and 
suggested that this could arise due to the perturbation of multiple processes in 
addition to killing of neuronal cells (Britten et al., 2011). Similarly, Lonart et al. 
reported that 0.2 Gy of 1 GeV/n 56Fe ions is sufficient to impair the ability of rats to 
conduct attentional set-shifting inferring the possibility that astronauts on 
prolonged deep space mission could subsequently develop deficits in executive 
function (Lonart et al., 2012).  To describe all the reported studies of the effects of 
low doses of 56Fe ions on the brain will be beyond the scope of this literature study. 
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Figure 2:22 Radiation in outer space environment. 
(https://www.slideshare.net/TristanMatthews?utm_campaign=profiletracking&utm_medium=sssite&utm_source=ssslideview). 
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2.9 Concept of clonogenic assay 
 
There are many methods to study radiation effects on cells, depending on the aim 
of the study and how the induced damaged of the cells could be measured. Briefly, 
radiation can induced many types of damages on cell such as; DNA damaged; 
modes of cell death, chromosomes aberrations, signalling pathways, genetics and 
genomic changes, proteins and enzymes changes and even bystander effects. To 
name a few, for example; DNA damaged can be measured in term of nucleotide and 
base damage, SSB (Comet assay for single cell) and DSB (γH2AX). Modes of cell 
death can be measured in term of apoptosis, mitotic death, autophagic cell death 
and senescence. Chromosomes study based on micronuclei assay and cytokinesis-
blocked micronuclei cytome assay as described in Appendix B are generally used 
for non-colony forming cells. Currently, genetic and genomic changes studies are of 
interest to many cancer researchers as it could inform of therapeutic decisions and 
interventions. For this study purposes, colony assay, a simple reproductive 
integrity (reproductive index) of the cells post irradiation is employed. Colony 
assay method is known to be the ‘gold standard’ for cell irradiation study. It is 
accepted and understood internationally and it is easy to perform. Moreover, the 
results of colony assay could be compared easily with others. 
 
Clonogenic assay was first developed by Puck and Marcus (Puck and Marcus, 
1956) and is a cell biology technique use to study the effectiveness of treatment to 
cells. It determines the ability of a cell to reproduce indefinitely post treatment. It 
is essentially done in in-vitro experiments to demonstrate the effectiveness of 
specific agents or radiation in cell inactivation (Hall and Giaccia, 2012). To be 
clonogenic active, each cell will have to reproduce a colony of more than 50 
daughter cells. A detailed description of colony assay is describe by Franken et al. 
(Franken et al., 2006). 
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2.9.1  Cell survival curve 
 
A cell survival curve (SC) describes the relationship between the survival fraction 
(SF) of cells and the treatment; the fraction of irradiated cells that maintain their 
reproductive integrity and the absorbed dose. The SF of cells as a function of 
radiation dose is graphically represented by plotting the SF on a logarithmic scale 
and the ordinate against dose on a linear scale on the abscissa. The cell SF curves 
are influence by the types of radiation quality; such as a high LET radiation which 
will exhibit a survival curve that is almost an exponential function of dose, shown 
by an almost straight line on the log-linear plot. In contrast, low LET survival 
curves show an initial slope followed by a shoulder region and then at higher dose 
become nearly a straight line. A simple illustration of SC is shown below in Figure 
2:23 and more complex SCs are presented in Figure 2:25. 
 
 
 
Figure 2:23 A survival curve. 
A survival curve plotted in LQ model that shows Dose in Gy on the X-axis and Surviving 
fraction in logarithmic scale on the Y-axis. The survival curve demonstrates the sensitivity or 
radio-resistance of the cells to treatment. 
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2.10 Mathematical models of radiation action on cells 
 
 
Introduction 
 
In radiobiological research, the ability to predict the responses of cells to different 
radiation qualities is vital and the choice of cell survival and dose response model 
employed will greatly influence the results. Cell survival curve models use a 
mathematical formula to describe and elucidate the shape of cell survival curves 
and quantify cell death/survival. Each model has its own scopes of application.  
 
Briefly, Puck and Marcus were the first to describe survival fraction conforms to a 
decreasing exponential-like law (Puck and Marcus, 1956). The target theory of 
radiation action on cells was postulated and investigated by  D.E. Lea (Lea, 1955) 
and the molecular theory of cell survival by Chadwick and Leenhouts (Chadwick 
and Leenhouts, 1973). The Linear Quadratic (LQ) model was introduced by 
Kellerer and Rossi (M. Kellerer and H. Rossi, 1971) and variant of LQ have been 
formulated for high-dose effect (Douglas and Fowler, 1976). Besides LQ model, 
various models based on DNA damage repair such as Repair-MisRepair (RMR), the 
Lethal-Potential Lethal (LPL) and the saturated repair models were formulated by 
Tobias (A. Tobias, 1985), Curtis (B. Curtis, 1986) and Goodhead (Goodhead, 1985) 
respectively. Furthermore, Joiner et al described the low dose hypersensitive 
model (Joiner et al., 2001). There are many more models for cell survival curve and 
to describe them all in detail will be beyond the scope of this background study.  
 
For more details, refer to Bodgi et al., who have done a historical and critical 
review of mathematical models of radiation action on living cells (Bodgi et al., 
2016) and have succinctly produced a historical synopsis related to the cell 
survival models and their variants as shown in Figure 2:24. A summary of the  
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major cellular models describing cell survival curves with the corresponding 
mathematical formulas linking clonogenic cell survival and radiation dose are 
presented in Figure 2:25 (Bodgi et al., 2016). They concluded that LQ model was 
the preferred model because of its good fitting qualities (best cell survival data fit) 
based on a very permissive second degree polynomial function (Bodgi et al., 2016). 
 
Linear quadratic model was chosen to analyse the survival curves because the 
charged ions radiations used are at low doses and also X-rays radiations is used as 
comparison.  LQ model is also in agreement with low-dose phenomenon (Joiner et 
al., 2001) and this is appropriate for low-dose hypersensitive GBM such as T98G 
and U87. In addition, LQ model can demonstrate a range of radio-sensitivity of 
cells;  from hyper-sensitive to immediate radio-sensitive and to radio-resistant 
cells (Bodgi et al., 2016). The LQ relationship between cell survival and dose is 
described in Section 2.10.1. 
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Figure 2:24 Historical synopsis related to the cell survival models and their variants (Bodgi et al., 2016). 
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Figure 2:25 Summary of the major cellular models describing cell survival curves with the 
corresponding mathematical formulas linking clonogenic cell survival and radiation dose 
(Bodgi et al., 2016).
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2.10.1  LQ relationship between cell survival and dose 
 
The linear quadratic (LQ) mathematical model derived by Chadwick and 
Leenhouts (Chadwick and Leenhouts, 1973) is the most used model to describe 
cell survival curve. There are two components to cell kill by radiation in the LQ 
model where the equation is as:  
 
S= exp (-αD-βD2)              2.2 
 
Where: 
S (D) is the fraction of cells surviving an absorbed dose D; 
α is a constant describing the initial slope of the cell survival curve; 
β is a smaller constant describing the quadratic component of cell killing. 
The α/β ratio is the dose in Gy, where cell inactivation caused by the linear α 
(single hit) and the quadratic β (double hit) components are equal. The higher the 
α/β ratio, the more linear the cell survival curve will be. Low α/β ratio implies high 
β relative to α; thus the more curved the cell survival curve will be. 
 
 
2.11 Summary 
 
Although this background study is not exhaustive, GBM is depicted as a resistant, 
yet delicate and challenging tumour. The support role of the astrocytes to the brain 
has been disrupted. The complexities of the brain and space limited organ present 
a great contest to treat it effectively. In addition, in adult life, astrocytes do not 
have the ability to repair and divide regularly in a replenishing manner unlike 
most other organs of the body. Furthermore, many studies have shown that GBM is 
one of the most recalcitrant tumours to multimodality treatment. However, its 
known radio-resistance to photon radiation has prompted radiation oncologist to 
seek an alternative modality of radiotherapy. Charged ion radiotherapy has the  
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potential to treat tumours that are radio-resistant and are located near to critical 
organs/tissues. With the potential capabilities of charged ion radiotherapy 
physical and biological benefits, there is hope of success in radiotherapy treatment 
for GBM.  
 
With this hope in mind, the aim of this work is to underpin charged ion 
radiotherapy in GBM by providing biological evidence to support the viability of 
charged ion radiotherapy for GBM patients. The main motivation of this project is    
that charged ion radiotherapy can enhance the efficacy of radiotherapy for GBM 
patients in synergy with other modalities of treatment such as chemotherapy after 
surgery. 
 
Thus, three different GBM strains and different charged ions and LETs were used 
to study the potential of charged ion radiotherapy for GBM. The ability of GBM to 
repair potential lethal damage was also investigated. The following chapter defines 
the materials and methods for the study. 
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Materials and Methods 
 
 
 
3.1 Cell lines and cell maintenance 
 
Three human Grade IV glioblastoma lines T98G, U87 and LN18 with different 
genetic alterations, different doubling time and cell size were used in this study as 
shown in Table 3:1. T98G cells were a gift from Mick Woodcock, Gray Institute for 
Radiation Oncology and Biology, Oxford, UK; U87 cells were obtained from the 
Health Protection Agency Culture Collections (HPACC, Wiltshire, UK) and LN18 
were from the American Type Culture Collection (ATCC, Middlesex, UK). All the cell 
lines were confirmed Mycoplasma free using Lonza MycoAlert® Mycoplasma 
Detection Assay.  
 
All cell lines were individually maintained in a 75 cm2 plastic flask (T75 BD 
FalconTM 353084) in Eagle’s Minimum Essential Medium (MEM: Nissui 
Pharmaceutical Co. Ltd., Tokyo) supplemented with 10% fetal bovine serum (FBS: 
Hyclone, Thermo Scientific, USA) in a humidified 95% air/5% CO2 incubator at 
37°C. Cells were subcultured from a T75 plastic flask by rinsing in calcium and 
magnesium free phosphate-buffered saline (PBS) and exposed to 0.2% Trypsin 
solution containing 0.5 mM EDTA. Cell numbers were determined by Coulter  
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Counter. For all experiments, 3 x 105 number of cells for each cell line was seeded 
into a 25 cm2 plastic flasks (T25 BD Falcon 353014) for each dose point, three days   
before irradiation for the cells to be approximately 85-90% confluent (plateau) 
stage for all irradiations including x-rays. The medium was changed on the day of 
radiation. At least two to three independent experiments were perform with each 
ion species and LET, except for 4He – LN18, where only one experiment is 
performed and non for U87; and also only one experiment for U87 with 20Ne (30 
keV/µm) were carried out due to beam time availability. 
 
 
Cell size 
 
There are many ways to measure cell size but the easiest and best way to estimate 
cell size is to use both ocular and stage micrometers under the microscope. Cells 
are approximately ellipse in shape. A minimum number of 50 – 100 cells size 
counted would provide an accurate estimated cell size. The equation of a circle 
area is A = π x r2.  As the cell is ellipse in shape, the cell area can be calculated by 
using A = π x a/2 x b/2; where a, represent the horizontal diameter of the cell and 
b the vertical diameter of the cell. The final r2 obtained is then multiply by 3.14 (π) 
and unit is squared as shown in Figure 3:1.  
 
 
Cell morphology 
 
The morphology and size of the three GBM strains is demonstrated with both 
Papanicolaou and May-Grünwald-Giemsa stains as shown in Figure 3:2. 
Papanicolaou stain differentiates the cells nuclear and cytoplasm distinctly 
showing nuclear abnormalities and will display the differentiation of the cells but 
with these GBMs cells; only one type of cell differentiation is observed. As for May-
Grünwald-Giemsa staining is used to study cell morphology in air-dried smears. 
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Table 3:1 Characteristic of the GBM cell lines used. 
 
 
 
 
 
 
 
 
 
 
Figure 3:1 A schematic picture of cell shape with A = π x a/2 x b/2. 
 
Cell p53 status/genotype PTEN Doubling time Cell size Morphology 
T98G Mutated/Homozygous Mutated 22 ± 3 hours 14.5 ± 1.5 µm2 Fibroblastic 
U87 Wild type/Homozygous Mutated 35  ± 4 hours 13.0 ± 1.3 µm2 Epithelial 
LN18 Mutated/Heterozygous Wild type 33 ± 4 hours 12.0 ± 1.0 µm2 Epithelial 
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Figure 3:2 T98G, U87 and LN18 glioblastoma cells demonstrated with both May-Grünwald-Giemsa and Papanicolaou stains. 
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3.2 Irradiations 
 
Cells were irradiated with monochromatic 4H, 12C, 20Ne, 28Si and 56Fe ion beams 
accelerated by HIMAC at NIRS, Chiba, Japan. The layout of the HIMAC facility 
treatment rooms including both the beam lines for physics research and laboratory 
for biological experiments is displays in Figure 3:3 (Kamada et al., 2015).  
 
Torikoshi et al. provided an overview of the irradiation systems at HIMAC as 
demonstrated in Figure 3:4 (Torikoshi et al., 2007). Briefly, the energy of 
monoenergetic heavy ions at the entrance position was obtained by a range of 
measurement. Through changing the absorber thickness of the range shifter, the 
experimental dose distribution was measured with a small ionization chamber 
placed at the irradiation site. The measured dose distribution was compared with 
the calculated depth-dose distribution and the entrance energy was then deduced 
when compared to the depths of the Bragg peak (Kanai et al., 1993). The 
experimental dose distributions were measured with a small parallel-plate 
ionization chamber placed at the irradiation site. Different LETs were obtained 
using Lucite absorbers with various thicknesses to change the energy of the beam. 
LET of the monoenergetic beams were measured using a parallel-plate 
proportional counter (Kanai et al., 1997). The estimated LET values (dose-
averaged LET) of all experiments were estimated at the sample position. The 
details of the HIMAC beam delivery system, physical characters, biological 
irradiation procedures and dosimetry have been described by Kanai et al. and 
Torikoshi et al. (Kanai et al., 1999, Torikoshi et al., 2007).  
 
The different energies and LETs range from 1.7 to 200 keV/µm for the different 
ions used are shown in Table 3:2. Doses were calculated from particle fluence and 
the dose-averaged LET values as in Equation 3.1. For ions, fragmentations were 
taken into consideration and applied to convert particle fluence (Φ) to dose as  
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shown in the Equation 3.1 (Matsufuji et al., 1999, Suzuki et al., 2000b, Matsufuji et 
al., 2003): 
 
Absorbed Dose (Gy) = 1.6021 x 10-9 x LET (keV/µm) x Φ (1/cm2).       3.1 
 
The dose-rate of all ion beams used was approximately 3 Gy/min. The total 
irradiation time for each experiment was limited to less than 15 minutes to 
prevent cells from drying (Kanai et al., 1997). Figure 3:5 shows the scene behind 
the irradiation system with the Lucite absorbers and the auxiliary system and 
Figure 3:6 the set up for irradiation at HIMAC biology laboratory.  
 
For a comparison, 200 kVp X-rays (20 mA) filtered with 0.5 mm Cu and 0.5 mm Al 
by a TITAN 320 irradiator (Ge Inspection Technologies Shimadzu, Japan) was used, 
delivering dose at a dose rate of 1.00 ± 0.02 Gy/min. All the irradiations were 
carried out at room temperature.  
 
Table 3:2 Ions, energies and LETs used [standard deviation (SD)]. 
MeV/n X-ray 
 
LET keV/µm 
 
  Low/ plateau  
 
High 
 
 200 kVp 1.70 ± 0.02  
4He 150  2.30 ± 0.04 13.0 ± 0.05 
12C 290  13.3 ± 0.19 85.0 ± 0.32 
20Ne 400  30.0 ± 0.45 85.0 ± 0.25 
12C 135   100  ± 1.77 
28Si 490  55.0 ± 0.06 200  ± 3.12 
56Fe 500   200  ± 0.01 
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Figure 3:3 The Heavy-Ion Medical Accelerator in Chiba (HIMAC) facility (Kamada et al., 
2015). 
 
 
Figure 3:4 Beam delivery systems showing both horizontal beam and vertical beam ports. 
Both beam ports have the same configuration. The horizontal beam port supply beams to 
the biology laboratory (Torikoshi et al., 2007). 
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Figure 3:5 Lucite absorbers and auxiliary system behind the irradiation set up in the 
HIMAC biology laboratory. 
 
 
 
Figure 3:6 Experiment set up for irradiation at NIRS/HIMAC. 
T25 flasks of cells of different doses are arranged on a rack with the beam coming from 
behind the flasks. Three sets of GBM cell lines are irradiated at the same time, the control 
flasks were kept at the edge of the bench top away from the beam line. Figure shows 
experiment set up for irradiations at NIRS, HIMAC at Chiba, Japan.  
  
 Chapter 3 
104 
 
 
3.2.1  Potential lethal damage repair irradiations 
 
For the PLDR study, two identical sets of 25 cm2 plastic flasks with cells prepared 
as described above were irradiated with 12C and 28Si monochromatic ion beams of 
C-135 MeV/n ~ 100 keV/µm; and Si-490 MeV/n at 55 and 200 keV/µm. A range of 
doses in Gy was tested depending on the LET used. For comparison with photons, 
X-rays irradiations as described above were also performed with two identical sets. 
All the irradiations were carried out at room temperature.  The doses were also 
calculated as Equation 3.1. 
 
 
3.3 Cell survival assay 
 
The SF was measured using the colony formation assay to assess reproductive 
death. Post irradiation, cells were removed from the T25 flask and inoculated into 
triplicate 60 mm plastic dishes (Falcon 353002) to produce 60-70 colonies per 
dish, cell were counted using [Coulter Counter (ZZZ Counter) (Coulter Electronics 
Ltd. Japan, Tokyo)] for the survival assay. The Platting Efficiency (PE) for T98G is ± 
0.46 ±0.007; U87 0.15 ± 0.002 and LN18 0.95 ± 0.03 with standard error of mean. 
Although, U87 has a low PE, approximately 40 colonies survived after ≦ 4 Gy at 
LET of 85 – 200 keV/µm. Post 14 days incubation, colonies were fixed and stained 
with 20% methanol and stained with 0.2% crystal violet. Triplicate dishes of each 
dose point colonies consisting of more than 50 cells were counted using a 
stereomicroscope and an automatic counting ‘colony counter pen’. The SF of each 
dose was calculated as the ratio of live colonies in the treated dish relative to the 
untreated/control.  Error propagations were accounted for by counted number of 
cells/cells inoculated/PE. The mean values, and standard deviations of triplicate 
samples were calculated. Figure 3:4 from Hall and Giaccia demonstrates how the 
plating out and the calculations of the colonies were done (Hall and Giaccia, 2012). 
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Figure 3:7 Cell culture technique-colony assay (Hall and Giaccia, 2012). 
The cell culture technique used to generate a cell survival curve. Cells from an irradiated T25 
flask are prepared into a single-cell suspension by trypsinization, and the cell concentration 
is counted. Known numbers of cells are inoculated into triplicate plastic dishes and incubated 
for 14 days. After 14 days, colonies are fixed and stained (see text cell survival assay for 
details-ignore the X-ray dose part). The Plating Efficiency and how to obtain Survival 
Fractions are shown on top right. From Hall and Giaccia (Hall and Giaccia, 2012). 
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3.3.1  PLDR cell survival assay 
 
The concept of PLDR was first reported by  Phillips and Tolmach using Hela cells 
(Phillips and Tolmach, 1966) where they found that post irradiation, unrepaired 
damaged cells will lead to cell death and appropriate post-irradiation treatment 
can lead to an increase or decrease in the cell capacity to repair this damage.  
 
There are various methods to study the capacity of cell to repair radiation damage 
and is generally based on the purpose of the study. For this study, colony assay was 
chosen because it demonstrates the proliferative capability of cell after radiation 
induced damage repair. The ability of radiated cell to reproduce after repairing 
radiation damage is analogue to in-vivo tumour cells ability to grow after 
radiotherapy. Detail study of DNA DSBs repair of radiation induced damaged such 
as the phosphorylation of the histone of H2AX (γH2AX) is not employed as it is 
more suitable for studying the induction and repair mechanism of DNA DSBs. Even 
though, the level of γH2AX detected is directly linked to the absorbed dose, 
radiation quality, LET, cell type, dose and etc (Staaf et al., 2012), the ability to 
proliferate after radiation damage repair could not be determined. Moreover, a 
fluorescence microscope is required. Cytogenetic techniques study the effects of 
radiation damage on the chromosome level. Common methods such as the 
micronucleus assay, chromosome aberrations and premature chromosome 
condensation (PCC) have been used. Micronucleus assay is described briefly in 
Appendix B. Chromosome aberrations, PCC method and other cytogenetic methods 
are generally used to study the repair efficiency and fidelity of chromosome break 
joining (Liu et al., 2013). Ultimately, the method used in PLDR study has to 
correlate with the aim of the study. 
 
For this study, the colony formation assay was also used to measure PLDR 
reproductive death. Two identical sets of plateau phase GBM cells in T25 flask (set  
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A and B) were irradiated at the same time. After irradiation, set A, T25 flasks were 
immediately placed in the incubator in a humidified 95% air/5% CO2 incubator at 
37°C for 24 hours.  For set B, T25 flasks, post irradiation, cells were removed from 
the T25 flask, counted and inoculated into triplicate 60 mm plastic dishes (Falcon 
353002) to produce 60-70 colonies per dish. The same method as described above 
was used to count cells for the survival colony assay. Set A, T25 flasks after 24 
hours delay (see sub-heading 5.2 PLDR discussions) were plated out in triplicate 
60 mm plastic dishes similar to set B. The only difference was that, Set A T25 flask 
cells were allowed 24 hours to repair any induced potential lethal damages. After 
14 days incubation, colonies were fixed with 20% methanol and stained with 0.2% 
crystal violet. Triplicate dishes of each dose point colonies consisting of more than 
50 cells were counted under a stereomicroscope and an automatic counting 
‘colony counter pen’. The SF at each dose point was determined as the ratio of live 
colonies in the treated dish relative to the untreated/control. The mean values, and 
standard deviations of triplicate samples were calculated with error propagation.  
 
 
3.4 Data analysis using LQ model 
 
Survival Fraction data are obtained from the mean of at least two or more 
independent experiments fitted by least squares Linear Quadratic (LQ) Model 
equation: 2.2. Although, it is well accepted that there is an almost linear 
relationship between charged particle dose and cell killing, a linear equation was 
not used to fit the survival curves due to inherent low dose radio-hypersensitivity 
of some GBM species (Short et al., 1999b, Short et al., 2001, Joiner et al., 2001) and 
also the doses used were ≦ 8 Gy.  
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3.4.1  Relative biological effectiveness 
 
Relative biological effectiveness is defined as the ratio of a photon dose Dγ and a 
corresponding ion dose DI yielding the same effect:  
 
RBE = Dγ/DI               3.2 
 
RBE10 is the ratio of survival fraction at 10% for ions relative to X-rays.  
 
RBE2 Gy is the RBE at 2 Gy instead of at 10% survival (RBE10).  RBE2 Gy is of interest 
as the normal tissue in the brain is sensitive to radiation. Moreover, most of the 
fractionated doses given clinically are between 1.8 to 2 Gy (Rossi, 1959). RBE10 for 
charged particle therapy may underestimate or overestimate the actual RBE.  
 
On the other hand, Relative Survival Fraction at 2 Gy (RSF2 Gy) is the survival 
fraction at 2 Gy of ion as compared to survival fraction of 2 Gy X-rays and the ratio 
of both survival fractions [SF2 Gy X-ray/SF2 Gy ion]. Survival fraction at 2 Gy (SF2  Gy) 
is of interest as some strains of GBM are known to be hypersensitive to low doses 
(Short et al., 1999b, Joiner et al., 2001, Short et al., 2001). RSF2 Gy and RBE2 Gy are 
two different entities. 
 
The survival fractions graphs were plotted using KaleidaGraph by Synergy 
software (version 3.5). α and β values were derived from the survival curves. The 
RBE10 and α parameter as a function of LET of the three GBM were plotted using 
Excel 2010. The trend lines of correlation and regressions were also plotted and 
analysed using Excel 2010. 
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3.4.2  Potential lethal damage repair ratio 
 
The PLDR time is defined as the interval between irradiation and subculture 
(Weichselbaum et al., 1985). The PLDR ratio is the SF Delay Plating (R) divided by 
SF Immediate Plating (R0) at a single dose (Weichselbaum et al., 1982, 
Weichselbaum et al., 1986).  
 
PLDR ratio: SF (R)              3.3 
  SF (R0) 
 
KaleidaGraph by Synergy software (version 3.5) was also used to plot the SF 
graphs and to determine α and β parameters and RBE10 and RBE2 Gy. 
 
 
3.5 Statistical analysis 
 
 
3.5.1  ANOVA 
 
The difference in α and RBE10 mean of each GBM with each ion type and LET were 
statistically analysed to test for significance. 
 
H0: The null hypothesis states that there is no difference between the means: 
 
H0: µ1 = µ2 = µ3 
 
H1: The alternative hypothesis is that there is at least one difference between the 
means. 
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As there were three different means to be tested, ANOVA of single factor was 
employed to test for significance. ANOVA measures: the variation of the individual 
values around their population means and the variation of the population means 
among the groups (overall mean). When there is variability between groups, it 
implies that the means are different from each other. 
 
Analysis of variance (ANOVA) of the mean value of α and RBE value for each 
individual GBM and ion were analysed using Xcel ANOVA for single factor (Analysis 
Tool-kit) with p value < 0.01. The null hypothesis is rejected when p value < 0.01, F 
stat > f critical value (see Table 4:5 and 4:6). There is significant evidence to 
suggest that there is at least one pair of means which differs. 
 
 
3.5.2  Linear Regression and correlation 
 
A linear Regression line has an equation of y = a + bx, where x is the descriptive 
variable and y is the dependent variable. The slope of the line is b, and a, is the 
intercept (the value of Y when X= 0). A line of least-squares (line of best fit) is 
plotted among the scatter plot to obtain the regression line.  
Regression analysis statistic is used to predict or estimate the strength and 
direction of the relationship between the variables within the range of the 
observed data. 
 
Pearson correlation coefficient or Pearson product-moment correlation coefficient, 
r is a measure of the strength of a linear association between two variables. The 
value of co-efficient (r) of correlation is between +1 and -1. When r is positive, it 
implies the line has a positive slope and has a positive linear relationship.  The 
closer r is equal to 1 the better the linear relationship. When r is -1, it is a negative 
slope and has a negative linear correlation. When r is close to 0, it indicates that 
there is minimal or no linear relationship.  
  
 Chapter 3 
111 
 
 
3.6 Summary 
 
The description above summarised how the experiments were performed. The 
cells maintenance and treatment is paramount to arrive at accurate and reliable 
results. Coherent data analysis is paramount to enable precise and correct results 
that are fit for use. The subsequent chapter describes the findings of this research. 
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Chapter 4  
 
 
 
Results 
 
A summary of α, β, α/β ratio D10 and RBE10 of different ions at different energies 
and LETs with the Standard Error of the Mean (SEM) of T98G, U87 and LN18 are 
displayed in Table 4:1. RBE10 and RBE2 Gy values calculated from dose at D10 (10% 
survival) and 2 Gy and the ratio of D2 Gy/D10 are presented in Table 4:2. A summary 
of the Relative Survival Fraction at 2 Gy (RSF2 Gy) as compared to RBE10 of the three 
cell lines is shown in Table 4:3. The comparison of RBE different endpoints at 10% 
survival, 2 Gy and RSF at 2 Gy is shown in Table 4:4. The different endpoints RBE 
and RSF reflect the ions of choice and its effectiveness in cells inactivation even at 
2 Gy. 
  
Table 4:5 and 4:6 represent the statistical analysis of the mean RBE and mean α 
value of each individual GBM respectively with each ion and LET using Xcel-Tool 
Kit ANOVA. 
 
Table 4:7 displays a close proximity of α and RBE10 regression line between the 
three GBM cell lines as a function of LET. Table 4:8 to 4:11 demonstrate a close 
correlation (almost 1) for both α and RBE10 ~ 100 keV/µm as a function of LET. 
Including ~ 200 keV/µm in the analysis resulted in a reduction of the linear 
correlation closeness as a function of LET. 
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The survival curves (SC) for X-ray 1.7 keV/µm to ions of LET 200 keV/µm for the 
three GBM cells is shown in Figure 4:1 to Figure 4:5. Figure 4:1 panel ‘A’ displays 
the SC of X-rays of the three GBMs and panel ‘B’, SC of 13.3 keV/µm of 12C-ion.  
 
Figure 4:2 panels ‘A’ and ‘B’ shows SC of 4He ion irradiation ~ 2.3 and 13 keV/µm. 
Figure 4:3 exhibits the SC of the three cell lines irradiated with 20Ne 30 (panel A) 
and 28Si 55 keV/µm (panel B). Figure 4:4 demonstrate the SC of T98G, U87 and 
LN18 of 28Si and 56Fe ions ~ 200 keV/µm. A comparison of both 12C and 20Ne ions 
at 85 and 100 keV/µm 12C ions are presented in Figure 4:5. All error bars are 
standard deviation (SD).  
 
Regression lines of α and RBE value as a function of LET for T98G, U87 and LN 18 
were plotted using Xcel 2010, are presented in Figure 4:6 to 4:8. Figure 4:9 
demonstrates the comparisons of the trend lines of the three GBM cell lines. 
Regression lines determine the degree of linear relationship between α and RBE as 
a function of LET. Figure 4:10 shows the β parameter as a function of LET. 
 
The genetic alterations and mutations of p53 and PTEN of T98G, U87 and LN18 are 
summarised in comparison with α and RBE10 in Table 4:14. 
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Table 4:1 Summary of the three GBM’s α, β, α/β ratio, D10 and RBE10 of the ions used and 
LET with SEM. 
 
 
NA=not available. 
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Table 4:2 Summary of the three GBM’s RBE10 and RBE2 Gy with the ratio of RBE2 Gy/RBE10. 
 
 
 
SF* = survival fraction.
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Table 4:3 Summary of the three GBMs’ RBE10 and RSF2 Gy and the ratio of RSF2 Gy/RBE10. 
 
 
SF* = survival fraction and RSF* =Relative Survival Fraction at 2 Gy. 
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Table 4:4 RBE at different end points 10%, 2 Gy and RSF 2 Gy. 
 
 
 
RSF* =Relative Survival Fraction at 2 Gy.
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Table 4:5 Summary of ANOVA statistical analysis of mean of RBE10 of the three GBM with 
different ions and LET. 
 
 
 
 
Table 4:6 Summary of ANOVA statistical analysis of mean of α of the three GBM with 
different ions and LET. 
 
 
 
Energies LET p value < 0.01         Anova: Single Factor
MeV/n keV/µm RBE10 F P-value F crit
12C 290 13.3 ± 0.19 Significant 36.006 0.0011 5.7861
20
Ne 400 30.0 ± 0.45 Significant 109.02 0.0016 9.5521
28Si 490 55.0 ± 0.06 Significant 70.560 0.0030 9.5521
12C 290 85.0 ± 0.32 Significant 17.460 0.0106 6.9443
20Ne 400 85.0 ± 0.25 Significant 18.173 0.0028 5.1433
12C 135 100  ± 1.77 Not significant 6.9028 0.0754 9.5521
28Si 490 200  ± 3.12 Significant 26.851 0.0122 9.5521
56Fe 500 200  ± 0.01 Significant 91.377 0.0000 5.1433
Energies LET p value < 0.01         Anova: Single Factor
MeV/n keV/µm  α  F P-value F crit
200kVp  1.70 ± 0.02 Significant 628.41 1.0E-05 6.9443
12C 290 13.3 ± 0.19 Significant 1331.6 1.1E-08 5.1433
20Ne 400 30.0 ± 0.45 Significant 1452.3 3.3E-05 9.5521
28
Si 490 55.0 ± 0.06 Not significant 8.2961 6.0E-02 9.5521
12C 290 85.0 ± 0.32 Significant 87.787 5.0E-04 6.9443
20Ne 400 85.0 ± 0.25 Not significant 1.3305 3.3E-01 5.1433
12C 135 100  ± 1.77 Not significant 2.3824 2.4E-01 9.5521
28Si 490 200  ± 3.12 Significant 194.76 6.7E-04 9.5521
56Fe 500 200  ± 0.01 Significant 90.311 3.3E-05 5.1433
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Table 4:7 Summary of the three GBMs’ α and RBE10 Regression lines. 
 
 
 
 
Table 4:8 Summary of α Correlation of T98G, U87 and LN18 as a function of LET including 
200 (top) and up to 100 keV/µm (bottom). 
 
 
 
Table 4:9 Summary of α Regression of T98G, U87 and LN18 as a function of LET including 
200 (left) and up to 100 keV/µm (right).
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Table 4:10 Summary of RBE Correlation of T98G, U87 and LN18 as a function of LET 
including 200 (top) and up to 100 keV/µm (bottom). 
  
 
 
Table 4:11 Summary of RBE Regression of T98G, U87 and LN18 RBE as a function of LET 
including 200 (left) and up to 100 keV/µm (right).    
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Figure 4:1 SC of T98G, U87 and LN18 ~ X-rays 1.7 keV/µm and 12C 290 MeV/n ~ 13.3 keV/µm. 
Panel A- SC of T98G-U87-LN18 with X-ray doses ≧ 4 Gy, U87 is the most resistant. Panel B: 12C 290 MeV/n ~ 13.3 keV/µm, SC shows that T98G 
is the most radio-resistant. Error bars = SD. 
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Figure 4:2 SC of T98G and LN18 irradiated with 2.3 and 13 keV/µm 4He 150 MeV/n 
Panel A and B - SC of T98G and LN18 ~ 2.3 – 13 keV/µm shows at ≧ 4 Gy; LN18 is more radio-resistant. Error bars = SD. 
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Figure 4:3 SC of T98G, U87 and LN18 irradiated with 20Ne 400 MeV/n ~ 30 and 28Si 490 MeV/n ~ 55 keV/µm. 
Panel A: SC of plateau LET of 20Ne 400 MeV/n - 30 keV/µm shows U87 is radio-resistant at ≧ 4 Gy. Panel B: LET ~ 55 keV/µm of 28Si 490 MeV/n, 
T98G is the most sensitive and U87 is the most resistant. Error bars = SD. 
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Figure 4:4 SC of T98G, U87 and LN18 irradiated with 28Si 490 MeV/n and 56Fe 500 MeV/n ~ 200 keV/µm. 
Panel A and B is SC of 28Si 490 MeV/n and 56Fe 500 MeV/n 200 keV/µm respectively (note: scale is different); T98G is the most resistant with 
28Si- and 56Fe ions at low doses but sensitive at higher doses. U87 is radio-sensitive at low doses and resistant at high doses. Error bars = SD. 
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Figure 4:5 SC of T98G, U87 and LN18 irradiated with 12C 290 MeV/n and 20Ne 400 MeV/n ~ 85 keV/µm and 12C 135 MeV/n ~ 100 keV/µm. 
Panel A and B ~ LETs 85 keV/µm of 12C 290 MeV/n and 20Ne 400 MeV/n respectively; and Panel C ~ 12C 135 MeV/n -100 keV/µm. LN18 is the 
most radio-sensitive and T98G most radio-resistant with 12C 85 and 100 keV/µm. U87 most resistant with 20Ne 85 keV/µm.  Error bars = SD. 
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Figure 4:6 Regression lines of T98G α and RBE10 as a function of LET. 
 
 
 
Figure 4:7 Regression lines of U87 α and RBE10 as a function of LET. 
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Figure 4:8 Regression lines of LN18 α and RBE10 as a function of LET. 
 
 
 
Figure 4:9 Comparison of trends of T98G, U87 and LN18 α and RBE10 as a function of LET.
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Figure 4:10 T98G, U87 and LN18 β parameter as a function of LET. 
 
 
4.1 RBE10, RBE2 Gy and RSF2 Gy 
 
The ratios for RBE10, RBE2 Gy and RSF2 Gy were obtained to compare the differences 
in 10% survival to 2 Gy and RSF at 2 Gy. Moreover, RBE2 Gy and RSF2 Gy were 
investigated to accommodate for the low PE of U87 cells as 10% survival 
measurement for U87 is difficult (Combs et al., 2009). In addition, RBE2 Gy could 
detect low dose hypersensitivity as RBE10 might conceal this low doses effect as 
discussed in section 5.2.1. 
 
From Table 4:1, the RBE10 values of T98G relative to X-ray show a range from 1.00 
(0.88 for 12C ion 13.3 keV/µm) to 2.03 for 28Si ion 200 keV/µm. RBE2 Gy ranges from 
1.02 to 3.55 at LET of 2.3 – 200 keV/µm (Table 4:2). The ratio of RBE2 Gy to RBE10 
ranges from 1.02 to 1.80 (highest ~ 100 keV/µm). The RSF2 Gy RBE (Table  
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4:3) ranges from 1.01 to 4.42 (highest 200 keV/µm of 28Si ion) and the ratio to 
RBE10 from 1.01 to 2.18.  
 
For U87, the RBE10 values range from 1.23 to 2.35 (Table 4:1), which increases 
with LET up to 28Si ion 200 keV/µm; however with 56Fe ion 200 keV/µm, the RBE10 
dropped to 2.23. The RBE2 Gy ranges from 1.42 to 3.83 and the ratio to RBE10 is 
from 1.15 to 1.81 (Table 4:2). There is a significant larger RBE2 Gy as compared to 
RBE10. The RSF2 Gy RBE (Table 4:3) ranges from 1.39 to 5.59, with the ratio to RBE10 
ranging from 1.13 to 2.64 (both highest ~ 100 keV/µm). 
 
Table 4:1 shows LN18 RBE10 value ranges from 0.76 to 2.11 and the increase in 
RBE10 are seen in both 12C ions 85 and 100 keV/µm; and 56Fe ions at 200 keV/µm. 
LN18 RBE2 Gy ranges from 0.79 to 2.62 and the ratio of RBE2 Gy to RBE10 ranges 
from 1.04 to 1.27. Only with LN18, there is a lower than one unity ratio of RBE2 Gy 
to RBE10 (13.3 keV/µm). The RSF2 Gy RBE ranges from 0.80 to 5.36, with the ratio to 
RBE10 ranging from 0.96 to 2.54 (Table 4:3). Table 4:4 compares RBE at different 
endpoints (10%, 2 Gy and RSF 2Gy) for the three GBMs. RSF2 Gy RBE are higher 
compares to RBE10 and RBE2 Gy.  
 
 
4.2 α and β 
 
T98G α value ranges from 0.045 Gy-1 (4He ion) to 0.935 Gy-1 (12C ion). For LET ≧ 85 
≦ 100 keV/µm, T98G α value dominates and decreases at 200 keV/µm (Table 4:1). 
An increase in β values is only observed at low LET (plateau LET); from X-ray 1.7 
keV/µm (0.109 Gy-2) to 28Si ion 55 keV/µm (0.213 Gy-2). U87 shows a trend of α 
value progressively increasing with ion mass and LET from 0.315 Gy-1 to 1.102 Gy-1 
(100 keV/µm 12C ion). The increase in α value is prominent and consistent 
compared to β values. The β values of U87 do not increase with LET and heavier  
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ion mass. LET of ≧ 85 keV/µm showed very low and negligible β values except 
with 85 keV/µm 12C ion as presented in Table 4:1. LET ≧ 85 keV/µm express 
minimal β values. No 4He ion experiments were carried out for U87. For LN18 
plateau LET, α value also increases according to ion mass; and there is an obvious 
trend of α value increasing with LET. The peak α value is at 56Fe ion 200 keV/µm 
with 1.192 Gy-1. The β values did not show any trend with LET. Figure 4:10 shows 
the β parameter as a function of LET. 
 
 
4.3 α/β ratio  
 
T98G has low α/β values in the range of 0.39 Gy to 8.57 Gy except for 20Ne and 12C 
ions which have values of 21.1 Gy and 37.4 Gy at 85 and 100 keV/µm respectively 
(Table 4:1). U87 α/β values range from 2.31 Gy to 530 Gy and the high values are 
for 20Ne, 12C, 28Si and 56Fe ions with LETs ≧ 85 keV/µ (except for 20Ne ion 30 
keV/µm). No 4He ion experiments were carried out for U87 due to limited 
availability of beam time. For LN18, the α/β values above 20 Gy are seen in LET ≧ 
85 – 200 keV/µm. 
 
 
4.4 α versus LET 
 
T98G α peaks at 100 keV/µm and higher LET does not produce any more increase 
but instead it decreases. Conversely, LN18 α values increase with LETs and ion 
mass (Figure 4:8). However, U87 α values increase with LET up to 100 keV/µm 
and higher LET does not see any gain (Figure 4:7). There is a statistical significance 
(p < 0.01) between the three GBMs means α-values. There is no significant 
difference between the mean α-values at 55 28Si ion, 85 20Ne ion and 12C ion 100 
keV/µm (Table 4:5). 
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4.5 RBE10, RBE2 Gy and RSF2 Gy versus LET 
 
T98G RSF2 Gy and RBE10, both peak at LET of 200 keV/µm of 28Si-ion but RBE2 Gy 
100 keV/µm (Table 4:1 to 4:3). In contrast, U87 RBE10 peaks at 200 keV/µm 28Si 
ion but RBE2 Gy and RSF2 Gy ~ 100 keV/µm 12C ion. Contrariwise, LN18 RBE10 and 
RSF2 Gy both peak at LET of 85 keV/µm of 12C ion except RBE2 Gy ~ 200 keV/µm 
56Fe ion. There is a (p < 0.01) statistical significant between the three GBM RBE10 
except 100 keV/µm 12C ion. 
 
 
4.6 Ion beam research for space radiation 
 
Results show that a minimal 0.2 Gy of heavy ions such as 12C, 20Ne, 28Si and 56Fe 
ions could kill almost 8 – 27 % of GBM cells which may be pertinent for space   
radiation protection. The result could infer the toxicity of the ions at low doses. 
The data could only demonstrate the deleterious effects of GBM cells exposed to 
high LET of heavy ions. 
 
 
4.7 Potential lethal damage repair  
 
The results presented are the mean of at least two separate experiments and the 
error bars in the SC depict the SD. Figures 4:11 to Figure 4:14 show the SF versus  
dose for T98G, U87 and LN18 from LET 1.7–200 keV/µm [Immediate Plating (IP) 
and Delay Plating (DP)]. The Recovery/PLDR ratios of the three GBM strains, the 
doses and LETs are summarised in Table 4:12. PLDR ratios portray the capability 
of the cells to repair potential lethal damage (quantitatively-see section 4.7.3). 
Table 4:13 summarised the PLDR effects of the three GBM cell lines on α, β, α/β 
ratio, D10, D2 Gy and RBE10, RBE2 Gy and RSF2 Gy (with SD for LET and SEM for all  
  
 Chapter 4 
132 
 
 
other parameters). The results clearly display post radiation, IP cells are more 
radio- sensitive than the delayed 24 hours plated after X-rays radiations (1.7 
keV/µm); there is noticeable PLDR ~ 55 keV/µm, minimal PLDR ~ 100 keV/µm 
and no PLDR at 200 keV/µm.  
 
For X-rays, PLDR increases for T98G ≧ 4 Gy upwards; U87 ≧ 0.5 Gy onwards. 
However, PLDR for LN18 cells increases with dose ≧ 3 Gy onwards (Figure 4:11). 
LET of 55 keV/µm shows T98G and U87 PLDR appear ≧ 1 Gy onwards (Table 4:12).  
In contrast, LN18 PLDR shows a consistent rise with increase in dose (Figure 4:12). 
There is minimal PLDR for all three GBM ~ 100 keV/µm (Figure 4: 13); note: U87 
IP has a negative β value). There is no PLDR in all three GBM strains with 200 
keV/µm, see Figure 4:14 and Table 4:12. 
 
 
4.7.1  PLDR RBE10, RBE2 Gy and RSF2 Gy  
 
All three GBM DP RBE10, RBE2 Gy and RSF2 Gy decrease with X-rays, 55 and 100 but 
not 200 keV/µm; indicating there is PLDR. Table 4:13 displays T98G, U87 and 
LN18 D10 DP showed a decrease in dose for 200 keV/µm radiations, which leads to 
an increase in RBE. A decrease in DP D10 dose indicates there is no PLDR. X-rays, 
55 and 100 keV/µm demonstrate an increase in D10 (Gy) and thus, a decrease in 
RBE, signifying PLDR is present (more dose is required to inactivate the cells).  
 
 
4.7.2  PLDR α, β and α/β  
 
All three GBM DP α values increase with X-ray and 200 keV/µm. X-rays DP 
increase could be due to low dose hypersensitivity (see Discussion 5.2.1), while, DP 
200 keV/µm denote there is no PLDR.  DP of T98G shows an increase in α/β ratio  
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with X-rays (1.7 keV/µm) and 200 keV/µm. DP of U87 shows an increase in α/β 
ratio in X-ray, 55 and 100 but not at 200 keV/µm. In contrast, from Table 4:13, 
LN18 100 keV/µm DP does not show an increase in α/β ratio. 
 
 
4.7.3  PLDR ratio 
 
PLDR ratio indicates the ability of the cells to repair potential lethal damage 
induced by radiation. PLDR ratio of ≦ 1 implies that there is no PLDR. X-ray PLDR 
ratios for the three GBM show the ability of all three GBM cells to repair photon 
radiation damage. Significant repair is seen ≧ 4 Gy (Table 4:12). PLDR ratios ~ 55 
keV/µm indicates that the three GBM are able to repair the radiation damage as 
the dose increases from 2 Gy onwards. Minimal PLDR is observed at 100 and no 
PLDR ~ 200 keV/µm. 
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Table 4:12 Summary of T98G, U87 and LN18 PLDR’s dose point’s ratio.* 
 
 
 
Ratio of ≦ 1 indicates no PLDR. *PLDR ratio = SF of delayed plating/ SF of immediate plating (DP/IP), see section 3.4.2. 
LET
T98G U87 LN18 T98G U87 LN18 U87 LN18 T98G U87 LN18
Dose Dose Dose Dose Dose 
(Gy) (Gy) (Gy)  (Gy) (Gy)
0.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00 1.00
0.50 0.88 1.40 1.05 0.25 1.03 0.90 1.19 0.20 1.10 1.15 0.20 1.36 0.20 0.99 0.87 0.95
1.00 0.77 1.13 0.98 0.50 0.95 1.02 1.24 0.40 1.08 1.24 0.40 1.08 0.40 0.95 0.86 0.93
2.00 0.87 1.30 0.96 0.75 0.89 1.00 1.23 0.80 1.22 1.15 0.80 1.18 0.60 0.71 0.65 0.97
3.00 0.99 1.04 1.16 1.00 0.85 1.06 1.24 1.20 1.25 1.07 1.20 1.17 1.00 0.83 0.84 0.93
4.00 1.23 0.87 1.51 2.00 1.07 1.22 1.33 2.40 0.88 1.13 2.40 1.13 2.00 0.79 0.97 0.88
6.00 3.01 1.85 2.38 4.00 2.64 1.91 2.05 4.80 0.75 1.06 3.60 1.18 4.00 1.00 0.99 0.87
8.00 21.00 4.72 5.21 6.00 2.56 3.95 8.10 6.00 1.00 0.29 0.68
T98G
1.7 keV/µm 200 keV/µm55 keV/µm 100 keV/µm
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Table 4:13 Summary of IP and DP, α, β, α/β ratio, D10, D2 Gy and RBE10, RBE2 Gy and RSF2 Gy of T98G, U87 and LN18. 
 
 
IP = Immediate Plating, DP = Delayed Plating.
T98G α β D10 D10 D10 2 Gy SF D2Gy
Ions LET (Gy-1) (Gy-2) (Gy) RBE α/β (Gy) RBE 2 Gy RSF
200kVp -IP  1.7 ± 0.02 0.049 ± 0.001 0.109 ± 0.009 4.57 ± 0.023 1.00 ± 0.005 0.45 1.00 ± 0.001 0.588 ± 0.021 1.00 ± 0.035
200kVp-DP  1.7 ± 0.02 0.226 ± 0001 0.039 ± 0.001 5.33 ± 0.001 0.86 ± 0.001 5.80 1.06 ± 0.001 0.545 ± 0.001 1.08 ± 0.001
28Si 490-IP 55.0 ± 0.06 0.451 ± 0.058 0.213 ± 0.009 2.43 ± 0.027 1.88 ± 0.020 2.12 2.37 ± 0.012 0.173 ± 0.014 3.40 ± 0.275
28Si 490-DP 55.0 ± 0.06 0.327 ± 0.004 0.202 ± 0.001 2.65 ± 0.002 1.72 ± 0.001 1.62 1.81 ± 0.001 0.232 ± 0.002 2.53 ± 0.023
12C 135-IP 100 ± 1.77 0.935 ± 0.010 0.025 ± 0.004 2.32 ± 0.003 1.97 ± 0.002 37.4 3.55 ± 0.010 0.140 ± 0.000 4.20 ± 0.021
12C 135-DP 100 ± 1.77 0.821 ± 0.006 0.062 ± 0.001 2.37 ± 0.016 1.93 ± 0.013 13.2 2.85 ± 0.009 0.151 ± 0.001 3.89 ± 0.013
28Si 490-IP 200 ± 3.12 0.791 ± 0.004 0.095 ± 0.001 2.25 ± 0.045 2.03 ± 0.040 8.33 3.17 ± 0.026 0.133 ± 0.031 4.42 ± 1.091
28Si 490-DP 200 ± 3.12 1.026 ± 0.007 0.055 ± 0.001 2.07 ± 0.035 2.22 ± 0.038 18.7 3.49 ± 0.021 0.103 ± 0.001 5.71 ± 0.050
U87 α β D10 D10 D10 2 Gy SF D2Gy
Ions LET (Gy-1) (Gy-2) (Gy) RBE α/β RBE 2 Gy RBE
200kVp -IP  1.7 ± 0.02 0.157 ± 0.006 0.068 ± 0.004 4.81 ± 0.078 1.00 ± 0.016 2.31 1.00 ± 0.001 0.559 ± 0.002 1.00 ± 0.005
200kVp-DP  1.7 ± 0.02 0.248 ± 0.004 0.034 ± 0.001 5.35 ± 0.009 0.90 ± 0.001 7.29 1.03 ± 0.001 0.531 ± 0.003 1.05 ± 0.005
28Si 490-IP 55.0 ± 0.06 0.515 ± 0.001 0.069 ± 0.001 3.15 ± 0.004 1.53 ± 0.002 7.46 2.00 ± 0.004 0.270 ± 0.001 2.07 ± 0.003
28Si 490-DP 55.0 ± 0.06 0.497 ± 0.002 0.034 ± 0.003 3.70 ± 0.005 1.30 ± 0.002 14.6 1.70 ± 0.003 0.323 ± 0.001 1.73 ± 0.004
12C 135-IP 100 ± 1.77 1.102 ± 0.101 0.039 ± 0.038 2.27 ± 0.034 2.12 ± 0.032 28.3 3.84 ± 0.011 0.100 ± 0.034 5.59 ± 2.133
12C 135-DP 100 ± 1.77 1.039 ± 0.004 0.033 ± 0.002 2.40 ± 0.002 2.00 ± 0.002 31.5 3.36 ± 0.008 0.110 ± 0.001 5.09 ± 0.067
28Si 490-IP 200 ± 3.12 1.079 ± 0.015 0.014 ± 0.003 2.05 ± 0.047 2.35 ± 0.054 77.1 3.72 ± 0.021 0.109 ± 0.002 5.13 ± 0.101
28Si 490-DP 200 ± 3.12 1.138 ± 0.049 0.025 ± 0.019 1.98 ± 0.020 2.43 ± 0.025 45.5 3.64 ± 0.006 0.093 ± 0.002 6.03 ± 0.002
LN18 α β D10 D10 D10 2 Gy SF D2Gy
Ions LET (Gy-1) (Gy-2) (Gy) RBE α/β RBE 2 Gy RBE
200kVp -IP  1.7 ± 0.02 0.316 ± 0.001 0.076 ± 0.001 3.81 ± 0.010 1.00 ± 0.004 4.16 1.00 ± 0.001 0.392 ± 0.002 1.00 ± 0.001
200kVp-DP  1.7 ± 0.02 0.355 ± 0.003 0.045 ± 0.001 4.22 ± 0.020 0.90 ± 0.005 7.89 0.98 ± 0.001 0.411 ± 0.002 0.95 ± 0.005
28Si 490-IP 55.0 ± 0.06 0.642 ± 0.001 0.105 ± 0.001 2.54 ± 0.001 1.50 ± 0.001 6.11 1.64 ± 0.004 0.182 ± 0.001 2.15 ± 0.004
28Si 490-DP 55.0 ± 0.06 0.592 ± 0.002 0.056 ± 0.001 3.02 ± 0.010 1.26 ± 0.004 10.6 1.50 ± 0.004 0.244 ± 0.001 1.60 ± 0.006
12C 135-IP 100 ± 1.77 1.079 ± 0.002 0.052 ± 0.001 1.95 ± 0.001 1.95 ± 0.002 20.8 2.40 ± 0.002 0.094 ± 0.001 4.17 ± 0.007
12C 135-DP 100 ± 1.77 0.941 ± 0.010 0.079 ± 0.003 2.09 ± 0.001 1.82 ± 0.001 11.9 2.27 ± 0.001 0.111 ± 0.001 3.51 ± 0.030
28Si 490-IP 200 ± 3.12 1.126 ± 0.016 0.011 ± 0.010 2.00 ± 0.016 1.91 ± 0.017 102 2.42 ± 0.001 0.098 ± 0.002 4.00 ± 0.075
28Si 490-DP 200 ± 3.12 1.205 ± 0.002 0.006 ± 0.001 1.89 ± 0.001 2.00 ± 0.001 201 2.72 ± 0.002 0.088 ± 0.001 4.43 ± 0.002
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Figure 4:11 SC of T98G, U87 and LN18 irradiated with X-rays 1.7 keV/µm; IP and DP. 
T98G (A), U87 (B) and LN18 (C), IP versus DP. Error bars = SD. 
 
 
 
 
Figure 4:12 SC of T98G, U87 and LN18 irradiated with 28Si 490 MeV/n 55 keV/µm: IP and DP. 
T98G (A), U87 (B) and LN18 (C), IP versus DP. Error bars = SD. 
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Figure 4:13 SC of T98G, U87 and LN18 irradiated with 12C 135 MeV/n 100 keV/µm: IP and 
DP.  
T98G (A), U87 (B) and LN18 (C). IP versus DP. * Note: U87 IP has a negative β value. Error 
bars = SD. 
 
 
 
Figure 4:14 SC of T98G, U87 and LN18 28Si 490 MeV/n 200 keV/µm: IP and DP. 
T98G (A), U87 (B) and LN18 (C). IP versus DP. Error bars = SD.
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Table 4:14 Comparison of genetic mutations effects on T98G, U87 and LN18 α and RBE10. 
 
 
 
4.8 Summary 
 
The analysis of the data supports the aim of the research. RBE, α, β, α/β ratio and 
PLDR ratio are reported separately to show the differences in the three different 
GBM strains. Results show that diverse GBM with different genetic alterations and 
strains have their own unique response to different types of radiations. Data show 
clearly the same tumour name with different genetic alteration has different 
responses to treatments. The results will be discussed in the following chapter. 
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Discussion 
 
 
There are few reports of the effects of 4He, 20Ne, 28Si, and 56Fe ions on different 
GBM cell lines as compare to that of 12C ion (Suzuki et al., 2000b, Tsuboi et al., 1998, 
Combs et al., 2009, Suzuki et al., 2000a). There is also limited study on the LET and 
ion species dependence for cell inactivation using 12C, 20Ne, 28Si and 56Fe (Tsuruoka 
et al., 2005, Furusawa et al., 2000). 
 
Normal glial cells were not used as the cells took a long time to grow. As astrocytes 
grow slowly and have a limited number of population doubling before undergoing 
senescence making them difficult to work with unless they are immortalised with 
SV40 large T onco-protein and human telomerase (hTERT) (Li et al., 2004). 
 
The plateau LET of each ion used such as; 4He 150 MeV/n (2.3 keV/µm); 12C 290 
MeV/n (13.3 keV/µm); 20Ne 400 (30 keV/µm); 28Si 490 MeV/n (55 keV/µm) are 
also studied for the benefits of normal tissue it traversed through before it reaches 
the tumour, albeit it is through inference as GBM cells are used and not fibroblasts.  
At HIMAC/NIRS, the 12C ion beam used is assumed to be clinically equivalent to fast 
neutrons at the point where the dose-averaged LET value is 80 keV/µ (12C 290 
MeV/n) (Kanai et al., 1999). Hence, clinically relevant LET of 12C and 20Ne ions 85 
keV/µm was studied for comparison. 12C ion 100 and 28Si ion 200 keV/µm were  
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experimented on GBM to determine the maximum LET before overkill, as 
Barendsen et al. (Barendsen et al., 1963) had defined from their study using 
cyclotron-accelerated α particles and deuterons, with LETs range between 5 – 100 
keV/µm that LET below 85 keV/µm the ionizations are not spaced closely enough 
along the greater part of the tracks to produce damage to the capacity for clone 
formation, whereas at higher LET along the greater part of the tracks more 
ionizations are produced than required. Moreover, 28Si ion was once deemed to be 
an ion of interest for maximizing high LET particle effects and also it has depth-
dose profile which is intermediate between that of 20Ne and 40Ar and has 
therapeutic potential for hypoxic tumours (Tobias et al., 1982, Castro et al., 1982, 
Castro et al., 1985). 56Fe ion 200 keV/µm radiations is an opportunistic study that 
is related to space radiations as it simulates space radiation. 
 
 
5.1 LET dependence and cellular inactivation 
 
Cell inactivation depends on many factors such as radiation quality, its associated 
track structure, absorbed dose, cell types and LET. The density (densely 
ionization) of radiation and energies measured in term of LET is a key factor in 
charged particle/ion therapy as the amount of energies deposited on the tissue will 
determine its biological effects on the cells treated.   
 
 
5.1.1  LET, RBE10 and α 
 
The RBE10 maximum was 200 keV/µm for T98G and U87 except LN18 (12C ion 85  
keV/µm) which concurs with Weyrather et al. (Weyrather et al., 1999) where they 
found repair-proficient cell lines RBE maximum at LET between 150 - 200 keV/µm 
for 12C ion. They concluded that RBE correlated with the repair capacity of the cells.  
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LN18 RBE10 peaks at 85 keV/µm does not agree with the findings of others (using 
different cell lines) where the expected RBE10 peaks at LET 100 - 200 keV/µm 
(Sørensen et al., 2011, Tsuruoka et al., 2005). On the other hand, the results concur 
with the review reported by Sørensen et al. (Sørensen et al., 2011) that different 
ions at different energies with the same LET have different RBE as shown in 85 
keV/µm for both 20Ne and 12C ions (Table 4:1 and Figure 4:5). In fact, for U87, 85 
keV/µm 12C ion is sufficient to inactivate more cells. 100 keV/µm 12C ions D10 and 
RBE10 (2.12) are lower than 85 keV/µm (2.14) (see Table 4:1); and the same for 
LN18, 12C ion 85 keV/µm is more efficient than 100 keV/µm in cell killing (in terms 
of RBE10).   
 
The results concur with Tsuruoka et al. that LET per se is not a good parameter to 
measure cell inactivation (Tsuruoka et al., 2005). Using colony assay but human 
skin fibroblast cells in their study to determine LET and ion species dependence of 
RBE for cell killing with a variety of ions and LETs, they reported that the 
differences in the energy deposition track structures of the different ion sources 
have an effect on cell killing. They described that different ion RBE-LET curves 
peak at different LET; their RBE 12C ion curve increased steeply up to around 98 
keV/µm and the RBE was 4.07, in contrast to 20Ne, 28Si and 56Fe ions that has 
maximum peaks around 180 keV/µm and the RBEs at the peak position ranging 
from 3.03 to 3.39 (Tsuruoka et al., 2005). The results in this study are similar to 
their study in that higher LET does not equate higher RBE. In addition, Suzuki et al. 
also showed that the peak position of the LET-RBE curves for cell death and 
induction of chromatin break for normal human embryo cells by 20Ne ions shifted 
to higher LET region than that of 12C ions (Suzuki et al., 1997). When Tsuruoka et 
al. plotted RBEs as a function of Z*2/β2 (where Z* is the effective charge and β is the 
relative velocity of the ion) as an alternative to LET, they found the differences 
between the RBE-LET curves for the different ion beams were reduced. The Z*2/β2  
track structure models were formulated by Katz et al. (Katz, 1996, Katz et al., 
1971).  
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The same ion species 12C, 20Ne, 28Si and 56Fe for LET-dependent biological effects 
was study by Tsuruoka et al. but they experimented with a minimum of five LETs 
for each ion species, and because this study used only two LETs of each ion species, 
to plot the results with Z*2/β2 as a function of LET will not be appropriate 
(Tsuruoka et al., 2005).  
 
Results are also in agreement with Tobias et al. (Tobias et al., 1984) that RBE10 is 
dependent on cell types as each individual GBM studied has different genetic 
alterations. The GBM cells intrinsic and genetic alteration may be the parameters 
that determine the radio-sensitivity. In general, there is a trend of RBE10 increasing 
with the Z values of 12C ion and 28Si ion LET values ~ 200 keV/µm. With 56Fe ion 
200 keV/µm, the RBE values decrease for all three GBM cell lines as compared to 
the highest RBE of the individual GBM.   
 
It is worth mentioning that 4He ion LET of 2.3 and 13 keV/µm were not as efficient 
to killing GBM cells effectively as shown in the survival curve (Figure 4:2). 
Saunders et al. reported in their 4He ion radiation therapy trial at the Lawrence 
Berkeley Laboratory that photon resistant carcinoma of the pancreas and 
oesophagus did not responded well to 4He ion radiation therapy (Saunders et al., 
1985). This could apply to GBM and the LET could be too low to be effective for 
GBM. 
 
RBE increases with α up to 100 keV/µm for T98G and U87 but up to 200 keV/µm 
for LN18 (Figure 4:6 to 4:8). However, T98G and U87 200 keV/µm results in 
decrease α value but increase in RBE. The increase in RBE is almost directly related 
to α value except in some variations found in T98G and U87 where increase α 
value reduces RBE, for example 12C ion 100 keV/µm. The small differences in α 
value and RBE could be due to the LQ model used to determine the α value. As 
mentioned earlier the LQ model was used to accommodate for low dose radiation 
hyper-sensitivity. 
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As α characterizes the linear component of cell kills (linear component of SC), 
results show α depends strongly on LET up to 100 ~ 200 keV/µm.  T98G and U87 
maximum α values with 12C ion 100 keV/µm agreed with Hall and Giaccia that the 
optimal LET for producing biologic effect is 100 keV/µm, see Figure 2;16 (Hall and 
Giaccia, 2012), as at this density of ionization, the average separation between 
ionizing events just about coincides with the diameter of a DNA double helix which 
is 2 nm in width and has the highest probability of causing a double strand break 
by a single charged particle. LET ≧ 200 keV/µm which is more densely ionizing did 
not add any benefit to T98G and U87, indication of ‘overkill’ effects as mentioned in 
section 2.5.6.1 (Physical benefits of LET) (Hall and Giaccia, 2012).  
 
Conversely, LN18 α peaks ~ 200 keV/µm. Genetically, LN18 has wild type PTEN 
and heterozygous p53 and these are discussed in 5.3 Ion species and 
intrinsic/inherent genetics of GBM. Taken together, peak α value and LET do not 
equate to increase radio-sensitivity. 
 
 
5.1.2  α and β contribution to D10 
 
T98G and U87 α-values peak at 100 keV/µm 12C ion but the D10 do not decrease 
significantly, indicating that maximum killing has not been reached (Table 4:1 
T98G and U87 D10 at 100 keV/µm has a SF of 2.32 and 2.27 as compared to 200 
keV/µm 28Si ion 2.25 and 2.05 respectively. Similarly, LN18 α value peaks at 200 
keV/µm 56Fe ion but the inactivation percentage (D10) is comparable to 85 keV/µm 
12C ion.  The β values are generally higher with LET ≦ 55 keV/µm except U87 ~ 12C 
ion 85 keV/µm (Table 4:1). Photon (X-rays) D10 represents the radio-sensitivity at 
10% and is generally used to compare with ion species. It demonstrates the doses 
required to reduce the survival fraction of a tumour or cell lines studied to 10%. 
T98G and U87 D10 are lowest at 28Si ion 200 keV/µm. However, LN 18 D10 is lowest  
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at 12C ion 85 and 200 keV/µm 56Fe ion corresponding to the lowest and highest α-
values in the range of LET ≧ 85 keV/µm respectively. 
 
 
5.1.3  RBE10, RBE2 Gy and RSF2 Gy 
 
The RBE values of ions are relevant for treatment planning as it is used to calculate 
the Gy Equivalent dose (GyE); but it is dependent on many factors and it has its 
own uncertainties. The classic RBE is conservatively taken from D10, D37 and D1 
(Hall and Giaccia, 2012); but D2 Gy may need to be considered as the doses given to 
the patients are conventionally 1.8 to 2 Gy per fraction.  
 
In fact, Fertil and Malaise reported that 2 Gy irradiation provided the most 
valuable information and could be a good indicator for intrinsic tumour cell radio-
sensitivity for photon radiation (Fertil and Malaise, 1981). The RBE is higher with 
D2 Gy and the ratio demonstrates (infer) the effectiveness of the ions and LET even 
at dose 2 Gy.  
 
Table 4:3, RSF2 Gy indicates that with high LET, approximately 2 Gy easily has 
reduced the SF to 10 – 20% survival. The RBE2 Gy does not vary much to RBE10 and 
from Table 4:2 the peak RBE is similar with ion species and LET. The ratio of D2 
Gy/D10 could point to the potential ion of choice even at RBE2 Gy.  In addition, LET ≧ 
85 keV/µm D10 SF show a dose of 1.80 to 2.71 Gy which is not distant from D2 Gy 
values. From both RBE10, RBE2 Gy  and RSF2 Gy, there is an inference that 20Ne ion 85 
keV/µm is appropriate for T98G; and 12C ion 85 keV/µm is more effective for both 
U87 and LN18 (see Figure 4:5, panel A, B and C; and Table 4:4). 
 
RBE10 is used clinically to calculate the Gy Equivalent Dose (GyE) and RBE2 Gy is 
theoretically higher than RBE10, hence, it usage to calculate GyE could be  
 
  
 Chapter 5 
145 
 
 
appropriate for low dose hypersensitive tumours and normal critical organ at risk 
(OAR).  
 
 
5.1.4  α, β and α/β 
 
The intrinsic radio-sensitivity of a tumour cells are α and α/β parameters which 
determine the ultimate tumour response.   
 
T98G α and β values differed to some extent from Suzuki et al.’s X-rays results 
(0.064 Gy-1/0.046 Gy-2) versus those presented here (0.049 Gy-1/0.109 Gy-2); 13.3 
keV/µm results of 0.127 Gy-1/0.065 Gy-2 versus this study 0.201 Gy-1/0.053 Gy-2 
and 77 keV/µm (0.432 Gy-1/0.895 Gy-2) compared to (0.643 Gy-1/0.075 Gy-2) 
(Suzuki et al., 2000b). This could be due to the dose rate of X-rays differences (0.85 
Gy/min versus 1 Gy/min), dose rate of C-ion (1.2 Gy/min vs 3 Gy/min) and 12C ion 
LET of 77 versus 85 keV/µm. Hence, Suzuki et al.’s α/β ratio is lower and RBE 
slightly higher than this study (Suzuki et al., 2000b). 
 
There is a trend for T98G and U87 α-value to increase with LET up to 100 keV/µm 
12C ion and LN18 to 200 keV/µm 56Fe ion. Results also demonstrate that an 
increase in α-value does not equate to an increase in RBE as shown in Table 4:1. 
Figure 4:10 showed the plot of β parameter as a function of LET. There is no 
definite trend or pattern for β for all GBM except different GBM cells peaks at 
different LET. As there was no significance trend, no statistical analysis was done. 
 
The α/β ratio is the equal dose for both single and double hit in inactivation of cells. 
The ability of the cells to repair is also reflected by the α/β ratio, where a high 
value indicates effective cell killing. The results concur with Suzuki et al. that  α/β 
ratio increased with increasing LET (Suzuki et al., 2000b). From Table 4:1, T98G 
α/β ratio increases up to 12C ion 100 and then decreases ~ 200 keV/µm. In  
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contrast, U87 and LN18 α/β ratio increases with LET (LN18 dropped at 56Fe ion 
200 keV/µm). Suzuki et al. suggested α/β ratio may be one of the predictive 
indicators to indicate which tumours are suitable for heavy-ion radiotherapy 
(Suzuki et al., 2000b). 
 
 
5.1.5  Ions, LET and GBM 
 
Results demonstrate that GBM could be ion specific for effective cell kill; as seen in 
LN18 that demonstrate that 12C ion 85 keV/µm is the most effective ion for cell 
inactivation. In contrast, 20Ne ion is more appropriate for T98. The most suitable 
LET for U87 and LN18 is 12C ion 85 keV/µm as 12C ion 100 keV/µm does not 
increase in effectiveness in term of D10 survival but the reverse is true. Conversely, 
12C ion 100 keV/µm is more effective for T98G. 20Ne ion 85 keV/µm is also effective 
for T98G (Table 4:1). 4He ion LET of 2.3 and 13 keV/µm may be too low for any 
significance effectiveness in inactivation of GBM cells in this study. 
 
 
5.1.6  Ion beam research for space biology 
 
Although, this study used different strains of GBM cell lines with different genetic 
alterations instead of normal lymphocytes, the range of LETs, energies and the 
varieties of ions experimented are comparable to those occur in the GCR spectra 
(except there is no LET ≧ 200 keV/µm), it is possible to infer the results to space 
radiation biology. 56Fe nuclei is known to be the major contributor to these 
radiation effects especially a risk to the CNS (Cucinotta et al., 2014), even though 
GCS light and heavy ions are made up of heavily ionizing particle in the range of 10 
≦ Z ≦ 28 (Chu, 2006). 
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Results show that 0.2 Gy of each ion types kill varieties of percentage of cells; 200 
keV/µm 56Fe ion killed approximately 8% of T98G and 15% for LN18; and 27% of 
U87 cells; and 28Si ion at 200 keV/µm inactivated approximately 12–13% of T98G, 
U87 and LN18; 20Ne ion 85 keV/µm 16–20 % of GBMs and of all the ions and LETs,  
0.2 Gy of 100 keV/µm 12C ions killed the most, approximately 20–22% of the three 
different GBM. The data presented could be pertinent for space radiation 
protection. High LET demonstrate the deleterious effects on GBM to heavy ion 
exposures. Data presented could be infer for assessing risk related to high LET 
radiation exposure; simulating the effects of space radiation. 
 
 
5.2 PLDR discussion 
 
The Plateau phase or stationary phase is the phase of cells where the proliferation 
rate is at its lowest and the numbers of cells remain ‘constant’ (Little, 1969). Hence, 
plateau phase cells was employed as it has certain characteristics of tumours ‘in 
vivo’, where a large proportion of the tumour is in G1 or G0 phase (Little, 1969, 
Little et al., 1973, Weichselbaum et al., 1985, Weichselbaum et al., 1986, Hahn and 
Little, 1972, Hahn et al., 1974, Guichard et al., 1984, Raju et al., 1977, Little and 
Hahn, 1973), and moreover, exponential phase (log phase) culture has been shown 
to display lower PLDR. PLDR occurs post-irradiation when cells are allowed time 
to repair and prevented from proliferation (non-cycling) (Little et al., 1973).  
 
Hahn et al. define some of the post-radiation conditions that allow PLDR after X-
rays, such as reduction in temperature; growth under suboptimal conditions; such 
as in plateau-phase cultures or in situ hypoxia, and inhibition of protein synthesis 
(Hahn et al., 1973). Analogous to solid tumours, where hypoxic regions are present, 
a lack of blood vessels, and a low level of nutrients and acidic extracellular 
environment with high concentration of cellular waste products after the first  
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irradiation may enable cells to repair instead of proliferate and thus, promote 
PLDR (Hahn et al., 1973). 
 
Twenty four hours delay was chosen to ensure the PLDR has been completed as 
has been studied by Yashiro et al. (Yashiro et al., 2007) where they found that at 18 
hours post irradiation, PLDR is thought to be stable.  Moreover, it also simulates 
clinical setting as radiotherapy is typically given on a daily basis.  
 
Other studies have examined a limited number of dose points (Weichselbaum et al., 
1985, Wheeler et al., 1980).  In this study a wide-range of low dose points, starting 
from 0.2, 0.25, 0.4, 0.5, 0.6, 0.75 and 0.80 Gy (to determine low dose 
hypersensitivity) to almost toxic dose were chosen to obtain an approximate 
survival curve at zero hour [immediate plating (IP)]. Moreover, Marchese et al. 
(Marchese et al., 1987) recommended that fitting delayed plating results to 
survival curves increase accuracy of recovery ratio as compared to individual 
single doses. Doses of > 5 Gy 100 keV/µm 12C 135 MeV/n were not chosen for 
T98G as it was estimated to be highly toxic. Similarly, doses of more than 4 Gy for 
U87 and LN18 were not used for fear of ‘overkill’ resulting in no colonies formed. 
More than 8 Gy for high LET radiation was not practical as the large number of 
cells necessary to be used may give rise to uncertainties (in number of colonies 
versus number of cells inoculated). 
 
GBM is known clinically to be radio-resistant and in-vitro, GBM cell lines have 
revealed a large portion of PLDR with photon radiation (Raaphorst et al., 1991). 9L 
Gliosarcoma have shown PLDR following irradiation with carbon ions  (Wheeler et 
al., 1980). Results concur with Raaphorst et al. and Wheeler at al. that glioma has 
PLDR capability even with charged ion radiation and is discussed below.  
 
Neutron irradiation has been reported as having no PLDR (Shipley et al., 1975, Hall 
and Kraljevic, 1976) but all concur there is PLDR with photon irradiation.  
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4He and 12C ions PLDR have also been reported (Guichard et al., 1977, Wheeler et 
al., 1980).   
 
LET of 55 keV/µm display PLDR as early as ≧ 2Gy for T98G and U87, however, the 
PLDR ratio is not as large as X-rays. Conversely, LN18 shows PLDR at doses ≦ 0.50 
Gy and PLDR ratio also increases with dose (Table 4:12). High LET of 100 keV/µm 
exhibit minimal PLDR for all three GBM with T98G showing no PLDR at doses ≧ 
2.4 Gy. U87 and LN18 show consistent minimal PLDR (Figure 4:13). 
 
Conversely, GBM could not repair the damage induced by 28Si ion 200 keV/µm 
(Figure 4:14). Since all three GBMs have no PLDR at this LET, it can be inferred that 
the genetic alteration does not matter but the damage such as locally multiple 
damaged sites (LMDS) is irreparable (Ward, 1985). LMDS are multiple DNA 
damaged sites induced by high LET which are not easy to repair to the original 
structure (Ward, 1985, Hall and Giaccia, 2012). 
 
The results demonstrate that PLDR effects show a minimal change in the shoulder 
of the SF curve with X-rays but have an increase in slope from 4 Gy onwards, thus 
the PLDR survival slope increases as X-ray dose increases (Figure 4:11). T98G, U87 
and LN18 show a change in the slope ≧ 2 Gy (55 keV/µm, see Figure 4:12). LET of 
100 keV/µm shows minimal change in PLDR slope (Figure 4:13). Figure 14:14 
displays no PLDR with high LET 200 keV/µm and the slope is reduced. There is an 
indication that the change in the slope of the SF curve is dose dependent for repair 
processes for low LET radiation.  
 
 
5.2.1  PLDR RBE10, RBE2 Gy and RSF2 Gy 
 
From Table 4:13, comparing RBE10, RBE2 Gy and RSF2 Gy, the distinct difference 
were found with X-ray RBE10, all three GBM shows decrease in DP RBE10. For  
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RBE2 Gy and RSF2 Gy, X-rays DP for T98G and U87 increased but not LN18. Both 
T98G and U87 demonstrate the presence of low dose hypersensitivity to X-rays 
revealed only at RBE2 Gy and RSF2 Gy (Short et al., 1999a, Short et al., 1999b). Low 
dose hypersensitivity was not detected at RBE10. LN18 lower DP RBE2 Gy and RSF2 
Gy demonstrates that there is PLDR at low doses of 2 Gy. RBE2 Gy could be a good 
indicator for intrinsic tumour cell radio-sensitivity especially with high LET 
radiation as it can demonstrates the clinical 2 Gy daily treatment for fractionation. 
 
 
5.2.2  PLDR α, β and α/β ratio 
 
There is a distinct difference in PLDR α value between X-rays and ions radiations; 
X-ray PLDR (DP) α shows increase in all three GBM strains but decreases with 
increase LET except at 200 keV/µm. This differs from Malaise et al. (Malaise et al., 
1989) who reported that X-ray PLDR led to a decrease in the α value in their study 
of published data that were comprised of both fibroblast and tumour-derived cells 
but does not include GBM cell lines. Their report suggested that a link may exist 
between the repair capacity and the intrinsic radio-sensitivity (Malaise et al., 
1989) and Weichselbaum et al. considered PLDR as a determinant of local control  
(Weichselbaum et al., 1986). The X-ray β value is higher at IP concurs with Malaise 
et al. (Malaise et al., 1989). Generally, the trend for PLDR β values decreases as LET 
increases (Table 4:13) except T98G and LN18 PLDR β increases with 100 keV/µm. 
The β values also reflect the repair capability of the cells. 
 
As discussed above, the size and extent of RBE depends on the α/β ratio which 
reflects the repair capacity of the cells. From Table 4:13, T98G and LN18 DP α/β 
ratio increased significantly with X-rays 1.7 and 28Si ion 200 keV/µm. U87 DP α/β 
ratio increase is observed with X-ray and 100 keV/µm but there is a decrease at 
200 keV/µm. The increase in the α/β ratio for high LET radiation may imply that 
fractionation effects are not crucial (although, this is only in-vitro experiments).  
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The intrinsic radio-sensitivity of the individual GBM strains also plays a role in the 
α/β values. It is dependent on GBM cell types and LETs.  
 
 
5.2.3  PLDR ratio 
 
PLDR ratio is a measure of the capability of cells to repair potential lethal damage. 
The range of PLDR ratio is ≧ 1 ≦. Ratio of ≧ 1 indicates that there is repair of 
potential lethal damage by the damaged cells. Less than 1 ratio means there is no 
PLDR present, cells could not repair and lead to cell death.  The PLDR ratios 
indicate the extent of repair of cells with each dose (Table 4:12). For low LET, GBM 
PLDR is dose dependent (Guichard et al., 1984) (see Figure 4: 11 and 4:12, panel A, 
B and C) except T98G cells which demonstrate low dose radio-hypersensitivity 
(HRS) (Short et al., 1999b, Short et al., 1999a). From Table 4:12, it is intriguing to 
note that X-ray PLDR ratio for T98G increases by a factor of 1.23 with 4 Gy; 3.01 
with 6 Gy and 21.00 with 8 Gy. This reveals the potential ineffectiveness of high 
doses for T98G types of tumour. Escalating doses does not help for some varieties 
of GBM in radio-curability (although, this is in-vitro experiments only). Conversely, 
U87 shows a minimal increase in ratio until doses 6 and 8 Gy with the ratio of 1.85 
and 4.72 respectively. LN18 shows a steady increase in the ratio of 1.51, 2.38 and 
5.21 for 4, 6 and 8 Gy respectively. Evidently, with T98G; X-rays, 55 and 200 
keV/µm, the PLDR ratio increases with increase in dosage but its known low dose 
hypersensitivity GBM cell line (Short et al., 1999a) demonstrates no PLDR at 
dosage below 2 Gy (see Table 4:12).  
 
LET of 200 keV/µm shows no PLDR for all three GBM cell lines as the radiation 
damages are too complex and irreparable. Results concur with report that 
reparability decreased with an increase in LET to 150 keV/µm and also LMDS are 
difficult to repair (Averbeck et al., 2014, Ando and Goodhead, 2016, Ward, 1985).  
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Table 4:13 displays high DP α values which imply there is more lethal damage than 
sublethal or potential lethal damage with high LET radiation.  
 
 
5.2.4 PLDR and low dose radio hyper-sensitivity 
 
While GBM are known radio-resistant tumours, the results concur with Short et al. 
that T98G and U87 are low dose hyper radio-sensitive to X-rays irradiation. 
However, U87 only display low dose hyper-sensitivity to 0.25 Gy of 55 keV/µm 
(Short et al., 1999a, Short et al., 1999b). Although, Short et al. describe that low 
dose hypersensitivity usually occurs at doses lower than 1 Gy with X-rays, the 
slightly different results in this work could be due to the dose rate of 1 Gy/min (as 
compared to Short et al.’s at 0.2-0.4 Gy/min); in addition, the methods and medium 
employed are different. Conversely, LN18 show decrease in PLDR with 1-2 Gy 
(Table 4:12). Low dose HRS is common in radio-resistant glioma and is more 
marked in more radio-resistant cell lines (Short et al., 1999b). Therefore, treating 
GBM with high doses for both low and high LET radiation may not be beneficial. 
 
 
5.2.5  PLDR and X-rays irradiations 
 
The X-ray PLDR ratios at 6 Gy are similar to Weichselbaum et al. results 
(Weichselbaum et al., 1985, Weichselbaum et al., 1982); where it was reported a 
PLDR ratio of 2.8 at 7 Gy (based on a single dose point) for GBM; this results show 
a similar but varied range of 1.85 to 3.01 at 6 Gy (Table 4:12 - X-ray column).   
 
The X-rays’ PLDR in this work demonstrate that PLDR is dose dependent; doses ≧ 
4 Gy increases the PLDR ratio (Table 4:12). PLDR in GBM may be responsible for 
failure in radiotherapy (Hahn et al., 1974, Malaise et al., 1989) especially with X- 
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ray treatment. This result shows that GBM are able to induce PLDR at high LET 100 
keV/µm. In contrast, Marchese et al. (Marchese et al., 1987) describe no correlation 
between PLDR and in vitro radiosensitivity or clinical radio-sensitivity of the 
tumour type. 
 
 
5.3 Ion species and intrinsic/inherent genetics of GBM 
 
Although GBM is a known radio-resistant tumour at the standard X-rays doses, 
T98G, one of the strains of GBM, is hypersensitive at doses less than 1 Gy which 
concurs with Short et al. (Short et al., 1999a). There is statistical significance (p < 
0.01) between the mean of RBE10 and α of each GBM demonstrating each GBM is 
distinct.  U87 and LN18 have increased radio-sensitivity to 12C ion than 20Ne ion at 
the identical LET of 85 keV/µm, which concurs with Suzuki et al. where it was 
reported that 12C ions are more effective at the same LET (Suzuki et al., 2006) for 
mutation frequency/yield. Besides, it was suggested that beams of different ion 
species might cause different types of DNA damage (Suzuki et al., 1996); different 
ion species with different structure of energy deposition may cause qualitative 
different damages even if the LET is the same (Suzuki et al., 2006) and a difference  
in the track structure of the core and penumbra exist for different kinds of ions 
with similar LET (Chatterjee and Schaefer, 1976). 
 
The genotypes of GBM are also directly related to radio-resistance. p53 and PTEN 
mutations are well known genetic alterations of GBM (Kleihues and Ohgaki, 2000, 
Wen and Kesari, 2008). Mutated p53 is known to be involved in radio-resistance in 
photons and charged ion radiations and carbon ions can overcome this resistance 
(Tsuboi et al., 1998); U87 and LN18 results for 85 keV/µm show that wild type p53 
(homozygous or heterozygous) are not radio-resistant to high LET 12C ion. In 
contrast, T98G with mutated p53 (homozygous) exhibit a generally lower α values  
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(Table 4:1) as  compared to U87 and LN18 (Tsuboi et al., 1998). Moreover, LN18 
which has wild type PTEN that is radiosensitive concurs with studies by Wick et al., 
Kao et al. and McEllin et al. (Wick et al., 1999, Kao et al., 2007, McEllin et al., 2010). 
In addition, Stambolic et al. reported PTEN locus revealed p53 binding element 
directly upstream of the PTEN gene in their study of the regulation of PTEN 
transcription by p53 (Stambolic et al., 2001). They concluded that PTEN was 
required for p53-mediated apoptosis and demonstrate a functional interaction 
between these two genes. This could be one of the rational for LN18 increase 
sensitivity, U87 intermediate sensitive and T98G less sensitive to radiations. T98G 
is known to be the most resistant has both PTEN and p53 mutation with two 
alleles (homozygous). U87 has homozygous p53 but mutated PTEN. In contrast, 
LN18 has heterozygous p53 (one allele) but wild type PTEN. Because of the genetic 
differences, Linstadt et al. also suggested that individual predictive assays 
(personalised treatment) may prove useful to define growth parameters and 
inherent radiosensitivity suited to high LET therapy (Linstadt et al., 1991). 
 
A summary of the genetic mutation of p53 and PTEN of T98G, U87 and LN18 is 
tabulated in Table 4:14. As α and RBE10 are important parameters in cell killing, 
both were compared in relation to genetic alterations. T98G with both p53 and 
PTEN mutations shows the less radio-sensitive to ion species producing lower α 
values and RBE10 as compared to both U87 and LN18. LN18 has only one allele 
mutation of p53 and has wild type PTEN is the most radio-sensitive. U87 has wild 
type p53 but mutated PTEN shows intermediate sensitivity. 
 
 
5.4 Ion beam research for space radiation 
 
Finally, with regards to space radiation, 56Fe ion was used to simulate cosmic 
irradiation and results here could infer the effects heavy 56Fe ion on brain  
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malignant glial, 0.2 Gy 56Fe (500 MeV/n – 200 keV/µm) ions kill approximately 8% 
of T98G and 15% LN18; and 27% of U87 cells which could be relevant for space 
radiation and space radiation protection (Figure 4:4, panel B). After all, exposures 
to the heavier particles found in galactic cosmic rays (GCS) are health hazard risk 
to space travellers especially to the central nervous system (Cucinotta et al., 2014, 
Lonart et al., 2012, Britten et al., 2011).  
 
Britten et al. and Lonart et al. (Britten et al., 2011, Lonart et al., 2012) have 
demonstrated that 20 cGy (0.2 Gy) of 1 GeV/u 56Fe radiation lead to persistent 
reduction in the spatial learning and executive function ability of Wistar rats. 
Lonart et al. also observed that approximately 20% of the irradiated rats were 
resistant to the deleterious effects of this radiation and proposed that the genetic 
or epigenetic inter-individual variations and intrinsic variability in radiation 
sensitivity for neuro-cognitive impairment needs to be investigated (Lonart et al., 
2012). Results here of 0.2 Gy 56Fe ion show different degree of inactivation; with 
T98G (8%), LN 18 (15%) and U87 (27%) in the order of increasing radio-
sensitivity which may also be linked to intrinsic and genetic properties of each 
GBM type.   
 
 
5.5 Summary 
 
LN 18 RBE10 peaks at 85 keV/µm but T98G and U87 at 200 keV/µm. In contrast, 
LN18 RBE2 Gy peaks at 200 and both T98G and U87 at 100 keV/µm (see Table 4:4). 
The trend shows that RBE10 peaks at 200 keV/µm and depends on the survival 
level, the type of ions and type of GBM cell line.   
 
Different strains of GBM are radio-sensitive to different charged ion and LET and 
the differences are statistically significant (p < 0.01). Genotypes of GBM patients  
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could be exploited and capitalized to identify/stratify patients who could be 
treated effectively with charged ions because of the characteristics of their tumour. 
 
The ratio of plateau to Bragg peak of clinically relevant LET may be significant for 
each GBM; for example, T98G 12C ion 13.3 keV/µm has a RBE10 of 0.88 and the 85 
keV/µm RBE10 is 1.69 (1.69/0.88: ratio of ± 1.92; U87 (2.14/1.23: ratio of ± 1.74) 
and LN18 (2.11/0.95: ratio of  ± 2.22). Obviously, the higher the ratio, the less 
harmful it will be for the normal surrounding tissue. 
 
There is a trend of T98G being more resistant than U87 and LN18 with low LET. 
However this trend is not observed with high LET (not comparing with U87 and 
LN18), where the type of ion used is the dominant factor in determining radio-
sensitivity. 
 
PLDR depends on LET and hypersensitivity of the GBM cells. Results here concur 
with Weichselbaum et al. (Weichselbaum et al., 1982) that the capacity for PLDR is 
a cellular repair characteristic which may differ between cell type and also the 
more radio-resistant the tumour, the higher the PLDR. This inherent cellular radio-
resistance in GBM may play an important factor in clinical radio-curability 
especially with X-ray treatment (Hahn et al., 1974, Malaise et al., 1989). 
 
At the present time one can only estimate the relative importance of the PLD repair 
in different GBM cell lines in relation to this repair and the radio-curability of the 
tumour. Nevertheless, the results described in this study may be helpful in 
identifying the inherent radio-resistance and repair of radiation damage of GBM 
that could contribute to the understanding of radio-resistance of the tumour.  With 
these data made available, hopefully, it can influence the choices of ion, energy and 
treatment schedule for the benefits of GBM patients. 
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Chapter 6 
 
 
 
Conclusion 
 
 
To my knowledge, this is one of the first studies to use three different GBM cell 
lines with various charged ions and different LETs for each ion. Recent studies in 
the literature have mostly concentrated on other cell lines (Furusawa et al., 2000, 
Tsuruoka et al., 2005, Suzuki et al., 2006, Tsuruoka et al., 2010, Liu et al., 2013).  
 
Although, it has been accepted that in-vitro cell culture study is analogous to in-vivo 
tumour conditions, caution must be exercised in the interpretation of in vitro data 
(Weichselbaum et al., 1982, Weichselbaum et al., 1985). Moreover, commercial cell 
lines are not very early passaged as compared to fresh patient specimens 
(Marchese et al., 1987). 
 
This study demonstrates that charged ions kill more GBM cells than X-ray at the 
same dose. The data obtained demonstrates the biological response of different 
GBM to different ions varied. The response of different GBM to the same ion and 
same LET is statistically significant in RBE10 and α means. Differences between 
particles cause disparate results at the same LET especially ≧ 85 keV/µm.  
 
This confirms that each GBM type is very unique in their response to charged ion 
radiation. The genotypes of GBM could be directly related to radio-sensitive and  
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radio-resistance which is statistically proven. There is a statistically significant 
difference (p < 0.01) in mean of RBE10 (except 12C ion 100 keV/µm) and α value 
(except 55 28Si ion, 85 20Ne ion and 12C ion 100 keV/µm). There is evidence that 
personalised charged ion radiotherapy is indicated for GBM patients (Linstadt et 
al., 1991, Halperin, 2006, Van Meir et al., 2010).  Moreover, there is ion specificity 
for GBMs as shown by U87 and LN18 that 12C ion is more effective in inactivation 
than 20Ne ion. On the contrary, T98G is more sensitive to 20Ne ion. 
 
There is not only PLDR with X-rays but also with charged-ion radiation. The 
efficiency of PLDR increases with LET ≦ 100 keV/µm. PLDR is dependent on LET, 
dose and GBM strain; and the more radio-resistant the tumour, the higher the 
PLDR. PLDR is also cell type dependent. 
 
For ion beam research for space radiation, the results (including the high Z nuclei) 
could only imply/infer and demonstrate the deleterious effects of 12C, 20Ne, 28Si 
and 56Fe ions on human CNS since GBM cells are killed at low doses by these 
charged particles with respect to space radiation. Moreover GBM are deemed to be 
radio resistant 
 
The RBE10 and RBE2 Gy, α, β, α/β ratio and PLDR ratio data could be used to design 
new radiotherapy trials for GBM patients. Data could also be used for formulating 
mathematical model for GBM patients charged ion beam treatment planning. 
 
This research is unique and novel and involves expert collaborators at 
international centres that have the appropriate facilities and expertise. 
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Chapter 7 
 
 
 
Future Work 
 
 
 
7.1 Recommendations for Future Work 
 
 
Unfortunately it is a reality that the scope for future work is going to be very much 
dependent on the availability of the beam time.   
 
Although, no molecular studies were performed at this time due to lack of beam 
time availability, from the results, a proposed stratification of GBM patients 
according to genotypes is indicated. With the increasing advances and knowledge 
of the genetic alterations’ heterogeneity in GBM, the data harvested here could be 
used to design new radiotherapy trials. Genotypes of GBM patients could be 
exploited and capitalized to identify/stratify patients who could be treated 
effectively with charged particles because of the characteristics of their tumour 
and the possibility of personalised radiotherapy for individual patients. 
 
An easy and quick immuno-histochemistry for the gene status from biopsies 
material may be of importance for cost-effectiveness to help stratify GBM patients 
for charged particle radiation (retrospective study).  
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Tumour hypoxia is known to be one of the causes of therapy failure. Moreover, 
there are limited data available for hypoxic GBM radiation studies. Thus, it may be 
essential to irradiate GBM cells in hypoxic conditions. It is documented that 
charged ion therapy can reduce the dependence of oxygen for cell kill, decrease 
OER due to its higher ionization density (Orecchia et al., 2004, Durante and Loeffler, 
2009). OER is known to decrease with increasing LET and approach unity around 
200 keV/µm (Hall and Giaccia, 2012) but PLDR with hypoxic condition irradiation 
remains to be investigated for GBM. It may be essential to investigate GBM PLDR 
20Ne and 12C ions at 85 and 100 keV/µm and also under hypoxic environment.  
 
Data harvested in this study could be used to formulate a mathematical model and 
also for designing new radiotherapy trials for GBM patients. 
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Appendix A 
 
 
 
 
I: I As a member of staff at the University of Surrey  
 
In summary, I was employed as a Research Assistant by Professor Karen Kirkby, 
based at the SIBC, also carrying out PhD research on a part-time basis. In regard to 
the latter, my research was funded by The European Commission’s (EC) Marie 
Curie Initial Training Network (MC-ITN) project: Particle training network for 
European radiotherapy (PARTNER) FP7-215840-2/Marie Curie. 
 
My primary role was to set up and manage the Biology Laboratory in the SIBC to 
make it function safely, smoothly and effectively, with specific duties as follows: 
 
 To organise and set up risk assessments and the Control of Substances 
Hazardous to Health (COSHH), with regular update. 
 To implement Health & Safety rules and regulations. 
 To maintain Quality Control and Assurance compatible to the ISO17025 
standard for the ion beam analysis for the Biology Laboratory. 
 To set up standard operating procedures (SOP), validate and verify 
equipment and methodology used in the Biology laboratory. 
 Regulate the maintenance of equipment and apparatus used in the Biology 
laboratory.  
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 To oversee and purchase the Biology laboratory consumables, reagents and 
relevant related substances for research at the best (cost effective) price. 
 To supervise the usage of the Biology laboratory. 
 To provide IBC management with weekly updates on Quality Control/ 
Assurance and Health and Safety Issues in respect of the Biology laboratory. 
 
 
I: II As a researcher 
 
 
I: II A SIBC and St Luke’s Cancer Centre at RSCH, Guildford 
 
 X-rays experiments with commercial GBMs and ‘tumour initiating cells’ 
(TIC) were carried out at St Luke’s Cancer centre, RSCH and SIBC 
respectively. Initial α particle experiments were challenged due to beams 
delivery at SIBC, hence, droplet technique was introduced to speed up 
irradiation of cells using the short beam time produced. TIC cells were a gift 
from Dr Colin Watts and his team from The Brain Repair Centre, 
Addenbrookes Hospital Cambridge, UK. 
 TIC media do not use serum; as such, the TIC cells do not form colonies and 
therefore an alternative method to colony assay has to be used to determine 
the effects of radiation. An alternative method to colony assay, the Cyto- 
kinesis-block micronucleus ‘cytome’ assay (CBMN Cyt) was therefore used 
and the protocols for this are shown in Appendix B. In radiation biology, 
colony assay is used as the ‘gold standard’ to study radiation effects; where 
the ability of treated cells to proliferate (expanding family of daughter cells 
and form colonies) are demonstrated. Moreover, it is a common method  
that is understood by radiation researchers internationally. On the other 
hand, CBMN Cyt studies the effects of radiation through the damages on the  
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chromosomes. The chromosomes damages are seen as chromosomes 
aberrations, and are detected immediately after first cell cycle division with 
the use of Cytochalasin B (see Appendix B for details). Cytochalasin B is a 
microfilament assembly inhibitor (involved in cytoplasm kinesis) that 
prevents cytoplasmic division enabling the accumulations of all dividing 
cells at the bi-nucleated stage. It has the advantage of precision as they are 
not affected by cell cycle effects and sub-optimal cell culture conditions. And 
all the damages of chromosomes are counted only in bi-nucleated cells.  The 
details of this method are found in Appendix B. Before, the method could be 
validated; I was given the opportunity to irradiate GBM cells at 
NIRS/HIMAC through the bridging arrangement of Dr Annelie Meijer from 
the Karolinska Institute (KI), Stockholm, Sweden. 
 I originated the ‘droplet technique’ for irradiation of cells at the SIBC ion 
irradiations when there were difficulties to gain prolonged access to the 
beam time. Seven droplets were placed on each Mylar plate for the ion 
beam irradiations; each droplet represents control and individual dose 
point. Each droplet number of cells was pre-calculated. Post irradiation, the 
cells were all removed by trypsin. The numbers of cells were counted and 
the Mylar plate was checked under microscope to determine all the 
irradiated cells were removed. Although, I did not have the opportunity to 
further use this technique, our group benefited from this technique by using 
it for the ion beam irradiation at the SIBC. This technique was further 
refined by the group which resulted in two papers published using the 
techniques (Jeynes et al., 2013, Barazzuol et al., 2012). 
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I: II B NIRS/HIMAC at Chiba, Japan 
 
 During my first few trips, I assisted in progressing the work of the KI team, 
with beam time allocated to them. In so doing I learned how the cells were 
irradiated and all the protocols involved. Naturally, Health and Safety rules 
first need to be introduced before one can start any such work. 
 The KI team used Melanoma cell line (AA) derived from a Swedish patient; 
U1690, a lung cancer cell line and Fa Du, a head and neck cancer cell line 
and other cell lines. The ions used were 56Fe, 12C and 40Ar and others. As the 
KI team involves several researchers, other methods of radio-sensitivity 
were used, such as different modes of cell death (apoptosis), time-lapsed 
microscopy study for modes of cell death and cell cycle besides colony assay.  
 At this centre, beam times for radiobiology research always start after 10 
pm and could be anytime from 10 pm to 6 am. This is because HIMAC is 
dedicated to patient treatment, with two hours maintenance before 
radiobiology work starts. Beam time is occasionally available on Saturdays. 
The beam time allocation period is typically from 1.5 to 2 hours. Everything 
needs to be prepared before the beam time and the beam time is always 
punctual. Dr Suzuki and his team were there to support and assist me. X-
rays experiments were performed during non-beam time days. 
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Appendix B 
 
 
 
Protocols of preliminary work  
  
 
1.1 Cyto-kinesis block micronucleus/Micronuclei assay 
  
 
Background 
 
Chromosome damage/aberrations (CA) can be detected by using light or 
fluorescence microscope via their morphological changes in number or structure. 
Investigation of CA is helpful as it can provide a greater insight into the mechanism 
of radiation action at the cellular level than inactivation measurements as the 
number of lesions per cell and their distribution between the cells could be 
detected (Ritter, 1996). Micronuclei assay is a modified and simplified 
chromosome aberrations assay that measures the chromosomal loss or breakage 
by expression of micronuclei (MN) after cells have completed one nuclear division 
with the aid of cytochalasin B.  
 
Cytochalasin B is a microfilament assembly inhibitor (involved in cytoplasm 
kinesis) that prevents cytoplasmic division enabling the accumulations of all  
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dividing cells at the bi-nucleated stage. It has the advantage of precision as they are 
not affected by cell cycle effects and sub-optimal cell culture conditions. CBMN 
assay (Fenech, 2007) is a validated biomarker (bio-dosimetry) for radiation 
exposure and has been used frequently to measure radiation exposure in radiation 
accidents and for large scale bio-monitoring. Peripheral lymphocytes of the 
affected are used to measure the radiation exposure. This method has been widely 
used to assess chromosome breakage and loss in human lymphocytes both in-vitro 
and in-vivo (Fenech, 2007). In addition, it has been used for measuring cell survival 
exposed to radiations (Fenech, 2006, Vral et al., 2011, Slowinski et al., 2011). This 
assay is used as a reliable endpoint for cell lines that are not able to form colonies  
such as lymphocytes (Fenech, 2000). The applicability of CBMN was confirmed for 
measurement of cellular radio-sensitivity in glioma cell line in-vitro (Slowinski et 
al., 2011). In addition, CBMN assay can provide a form of proliferation index of the 
treated cells by the percentage of the bi-nucleated cells.  Guo et al. (Guo et al., 
1999) suggested a significance correlation between clonogenic radio-sensitivity 
and assessment of micronuclei (CBMN assay). However there is suggestion that 
MN alone does not always rank cell lines according to radio-sensitivity (Akudugu 
et al., 2000). 
 
 
1.2 Cyto-kinesis-block micronucleus ‘cytome’ assay 
 
 
Background 
 
Recently, Fenech (Fenech, 2007, Fenech, 2010) evolved the CBMN assay into the 
comprehensive CBMN Cyt assay. Fenech defines the ‘cytome’ concept that every 
cell in the system studied is scored cytologically for its viability status [apoptosis,  
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necrosis], its mitotic status [mono-nucleated, bi-nucleated cells (BN), multi-
nucleated (MN)] and its chromosomal damage or instability status [presence of 
MN, nucleoplasmic bridges (NPBs), nuclear buds (NBs)] as shown in Appendix B:1 
is appropriate for radio-sensitivity studies (Fenech et al., 1999). 
 
Briefly, morphologically, apoptotic cells show chromatin condensation with intact 
nuclear membrane or apoptotic chromatin bodies within the cytoplasm but no 
intact nucleus.  Apoptosis occurs when the cell has a significant level of DNA 
damage and could not proceed through the cell cycle and the programmed cell 
death pathway is activated (provided the genes involved are functioning).  
Inhibition of apoptosis may allow cells with significant level of DNA damage to 
continue through the cell cycle and survive as mutated or MN cells (Fenech et al., 
1999). In contrast, necrotic cells are observed with vacuolation, disintegration of 
cytoplasmic membrane and loss of cytoplasm partial or complete with an intact 
nucleus or damaged nuclear membrane with nuclear material leaking from the 
nucleus. Necrosis is induced when there is too many damages within the cell, and 
the intracellular degradative enzymes from the sub-cellular particles for example 
the lysosomes are released (Fenech et al., 1999). This results in the digestion of the 
DNA and the cytoplasm of the cell.  Apoptosis and necrosis can be differentiated 
from the viable cells by cytology. 
 
On the other hand, mono-nucleated cells are cells with a single nucleus, bi-
nucleated cells have two nuclei and multi-nucleated cells contain more than two 
nuclei. Multinucleated cell other than the normal physiological function of the cells 
such as the muscle, osteoclast and others may denote disturbed cell cycle control 
(Fenech, 2007). Vral et al (Vral et al., 2011) demonstrated that MN are induced 
chromosome aberration as the result of unrepaired or misrepair double strands 
breaks by the non-homologous end joining (NHEJ) repair pathway. NHEJ is a repair 
mechanism that does not required a template to repair double strands breaks in 
DNA unlike homologous repair, which requires a homologous template. 
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In contrast, nucleoplasmic bridges (NPB) are biomarkers of DNA misrepair and/or 
telomere end-fusions NPBs originate from dicentric chromosomes (induced by 
misrepair of chromosome break) whose centromeres are pulled apart to opposite 
poles of the cell at anaphase. Dicentric chromosomes are chromosomes with two 
centromeres. Assessment of NPB is a form of measurement of asymmetrical 
chromosome rearrangements (dicentric and ring chromosome) in cells after a 
single cell division (Thomas et al., 2003). 
 
Whereas, nuclear buds (NBs) are biomarkers of the elimination of over-amplified 
DNA and/or DNA repair complexes.  This cellular process is characterized by the 
production of multiple copies of a particular gene or genes to amplify the 
phenotype.  
 
Gene amplification has been linked to drug resistance. NBs have the same 
morphology as MN except that NBs are linked to the nucleus by a narrow or wide 
stalk of nucleoplasmic material (depending on the stage of the budding process) 
and are processed during S phase. Appendix B:2 shows process of genes 
amplification.  According to Fenech and Crott  (Fenech and Crott, 2002), NBs are 
formed because of the capacity of the nucleus to ‘sense’ excess DNA that does not 
fit well within the nuclear matrix (so called nuclear housekeeping). 
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Appendix B:1 The various possible fates of cultured cytokinesis-blocked cells following 
exposure to cytotoxic and genotoxic agents (Fenech, 2007). 
Using these biomarkers within the CBMN assay, it is possible to measure the frequency of 
chromosome breakage (MN), chromosome loss (MN), chromosome rearrangement, for 
example, dicentric chromosome (NPB), gene amplification (NBs), necrosis and apoptosis.  In 
addition, the cytostatic effects are readily estimated from the ratio of mono-, bi- and 
multinucleated cells (Fenech, 2007). 
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Appendix B:2 Gene amplification viva breakage-fusion-bridge cycles (Fenech and Crott, 
2002). 
Broken sister chromosomes (A) fuse at the ‘sticky’ ends to form a dicentric chromosome (B). 
The dicentric chromosome is replicated in S phase (C) and drawn to the cell’s poles during 
anaphase (bridge) (D). In this example, the dicentric chromosomes break in a non-central 
region and one daughter cell will receive chromosomes that contain two copies of the yellow 
and red genes (E1) while the other cell’s chromosomes have a deletion in these genes (E2). 
The chromosome with multiple copy number may fuse again (F) to propagate the 
amplification cycle (back to step C). Alternately, recombination may occur between 
homologous sequences (G) and result in the ‘looping-out’ of a circular acentric DNA 
fragments or double minute (H) which are subsequently extruded from the nucleus via 
budding (I) (Fenech and Crott, 2002). 
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1.3 Materials and Methods 
 
 
1.3.1  Maintenance for commercial glioblastoma 
 
T98G, U87 and LN18 were maintained in Eagle’s Minimum Essential Medium 
(EMEM) containing 10% fetal bovine serum (DE14-801F FBS- Brazilian origin), 1 
% v/v penicillin/streptomycin, 4 mM L-glutamine, 1 mM sodium pyruvate, 1500 
μg/ml sodium bicarbonate and 1% EMEM non-essential amino acids (Lonza 
Berkshire, UK). Cells were grown in a T75 nucleon flask in a 95% humidified 
incubator with 5% CO2 at 37°C. When cells were confluent, harvesting was done 
with 0.25% Trypsin (Gibco Cat.15090) and 1 mM Versene (Invitrogen Cat. 
15040033)) for 5 min at 37°C.  The cells were spun down at 1500 rpm for 3 min, 
re-suspended with media and counted using a haemocytometer. Cells were then 
counted and prepared for experiments.  The GBM cells were irradiated at St Luke’s 
Cancer Centre of RSCH using the Megavoltage X-rays. 
 
 
1.3.2  Clonogenic survival assay 
 
Briefly, the required numbers of cells were seeded in triplicate 6 cm grided Nunc 
plastic dishes for at least 15 hours before irradiation in 4 ml of complete media. 
The number of cells used was first pre-determined based on their plating 
efficiency.  Ten dose points ranging from 0-8 Gy were chosen with triplicate for 
each dose. For control, cells were not irradiated (0 Gy). The dishes were then 
transported to the hospital for X-ray irradiations.  Post irradiation, one ml of media 
was added to make up to 5 ml and further incubated in a humidified 95% air/ 5% 
CO2 incubator at 37°C for 12-14 days.  Colonies were then fixed with -20°C 96% 
ethanol for 15 min and are stained with 5% of crystal violet (Pro Lab Diagnostic)  
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for 10 min.  Colonies are then washed and dried and counted using an inverted 
microscope with x 5 magnification.  The plating efficiency and surviving fraction 
were then calculated.  
 
 
1.4 Maintenance of patient derived tumour initiating 
cells 
 
Two patient derived glioblastoma TIC (G12 and G25) were provided by Dr Colin 
Watts and his team from the Cambridge Centre for Brain Repair.  The cells were 
found to be Mycoplasma (Lonza Mycoplasma alert) free and maintained in a non-
serum based media consisting of Neurobasal A (Invitrogen) with 20 mM L-
Glutamine 1%v/v penicillin/streptomycin, 20 ng/ml hEGF, 20 ng/ml hFGF and 5 
microgram/ml heparin (Sigma H3149), 2% v/v B 27 (Invitrogen, Cat No 17504-
044) and 1% N2 (Invitrogen, Cat No, 17502-048). T75 flasks were first coated with 
Extra Cellular Matrix (ECM) diluted in complete Neurobasal medium (1:10) before 
the cells were seeded.  The cells were left to grow till confluent with replenishment 
of media (5-7 days).  To harvest the cells, 4-5 ml of Accutase (Sigma) was used 
instead of Trypsin to detach the cells from the flask. Flasks were kept in the 
incubator for 5-8 min until all the cells are detached and then cells were spun 
down at 1200 rpm for 3 min. Cells were counted using a haemocytometer for the 
irradiation experiments. 
 
 
1.4.1 Cytokinesis-blocked micronuclei cytome assay (CBMN 
Cyt) 
 
As there is absence of serum in maintaining the TIC cells, they do not form colonies 
and an alternative method has to be used to measure radio-sensitivity of the  
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irradiated cells. G12 and G25 cells doubling time were first determined 
(approximately four days) as shown in Figure 44. Prerequisite cytochalasin B dose 
response curve was also performed to find the optimal amount of cytochalasin B to 
be used. The amount of cells required for the assay was investigated to be 350,000 
cells for each dish before X-ray irradiations. Seven dose points ranging from 0-5 Gy 
were chosen.  Each dose point was performed in duplicate as 2000 bi-nucleated 
cells were required for the scoring (1000 from each dish) (Fenech, 2000, Fenech, 
2006, Fenech, 2007, Thomas and Fenech, 2011). A specific number of cells were 
seeded into ECM coated 6 cm grid Nunc plastic dishes in 4 ml of Neurobasal 
complete 15-18 hours before irradiation. Post irradiation at the hospital, one ml of 
neural basal complete media and 2 µg/ml of cytochalasin B were added 
immediately. Cells were then returned to the incubator and harvested after the 
appropriate doubling time was achieved.  Cells were then fixed in-situ with -20°C 
96% ethanol for 15 min and -20°C acetic acid: methanol (1:3) for 10 min. Dishes 
were left to dry and kept in the fridge.  Before scoring for chromosome aberration, 
the cells were stained with 2 µg/ml of 4’, 6-Diamidino-2-Phenylindole 
Dihydrochloride (DAPI), fluorescence nuclear dye and viewed with a fluorescence 
microscope using an x 95 magnification (oil immersion) objective and scored with 
a fluorescence microscope. The different types of instabilities were counted in 
1000 bi-nucleated cells and tabulated. 
 
The preliminary results are shown in Appendix B:3 to Appendix B:8. Before the 
assay could be validated, I had the opportunity to attend NIRS/HIMAC, Chiba, 
Japan for ion beam radiation. Since, human TIC cells were not approved to be used 
at NIRS/HIMAC, T98G, U87 and LN commercial GBM cells were used instead. 
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Appendix B:3 The doubling time of G12 and G25 tumour initiating cells (TIC). 
 
 
 
 
Appendix B:4 Preliminary results of G12 TIC chromosomes aberrations post X-rays 
irradiations. 
 
 
  
 Appendix B 
175 
 
 
Photos of tumour initiating patient derived glioblastoma cells after cytokinesis-
blocked micronuclei cytome assay.  All photos are taken in oil immersion x 95 after 
(4', 6-diamidino-2-phenylindole) DAPI fluorescence stain. 
 
 
 
Appendix B:5 Panel A – C illustrate chromosomes aberrations induced by X-rays 
irradiations, A: nucleoplasmic bridge, B: nuclear bud and C: micronuclei. 
 
 
 
 
Appendix B:6 Necrotic (left) and apoptotic (right) GBM cells post irradiations. 
 
 
 
 
Scale bar: 50µm  
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Appendix B:7 Instability status of G12 TIC post X-rays irradiations. 
  
 
 
 
 
 
 
Scale bar: 50µm  
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Appendix B:8 Mitotic status of G12 TIC post X-rays irradiations. 
 
 
 
 
 
 
 
Scale bar: 50µm  
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Appendix C 
 
 
 
1.1 Poster presentations 
 
 Assessment of radiation induced damage in a non-clononergic Glioblastoma 
tumour initiating cell line – PARTNER midterm review at the Karolinska 
Institute, Stockholm, Sweden. 3 September 2010. 
 Assessment of radiation induced damage in a non-clononergic glioblastoma 
tumour initiating cell line - PGR conference, University of Surrey, Guildford, 
UK. 23-24 September 2010. 
 Charged particle therapy – a promising radiotherapy for glioblastoma 
patients - poster presented at Advanced Technology Institute Open Day 
2012.  https://www.surrey.ac.uk/ati/files/Poster_MingCHEW.pdf 
 
 
2.1 Oral presentations 
 
 Cell irradiation studies for hadron therapy in glioblastoma at NIRS Heavy 
Ion Radiobiology Research group & Cellular & Molecular Biology Team), 
HIMAC, Chiba, Japan. 31 May 2010. 
 G12 experiments report at Cambridge and Surrey collaboration meeting 
BRC Library, Cambridge Centre for Brain repair, E.D.Adrian Building, Forvie 
Site Cambridge UK. -23 August 2010. 
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 Update on research experiments at the Mid Term Review MCITN PARTNER 
at the Karolinska Institute - 03 September 2010 Stockholm, Sweden. 
 Cell Irradiation Studies for Hadrons Therapy in Glioblastoma. HIMAC/NIRS, 
Chiba, JAPAN. 26 November 2010. 
 Cell irradiation studies for hadron therapy in glioblastoma (update), CNAO, 
Pavia, Italy. 10 April 2011. 
 Cell irradiation studies to underpin hadron therapy in glioblastoma 
presented to the Medical Application Group at Farnham Castle, Surrey, UK. 
3 August 2011. 
 Hadron therapy a better choice for glioblastoma patients? Marburg, 
Germany (PARTNER event). 4 September 2011. 
 Update of particle irradiations at the Heavy Ion Medical Accelerator at 
Chiba (HIMAC) on glioblastoma cell lines - Invited presentation to 
collaborator group at NIRS, Chiba, Japan. 2 November 2011. 
 Spring update results of irradiated Glioblastoma at the International Open 
Laboratory kick off meeting at the National Institute Radiological Sciences 
(NIRS), Chiba, Japan. 22 November 2011. 
 Cell irradiation studies to underpin hadron therapy in glioblastoma. NIRS, 2 
November 2011. 
 Hadron therapy – alternative radiotherapy for glioblastoma patients? CNAO, 
Pavia, Italy, 20-22 January 2012. 
 
 
3.1 Reports 
 
 Predictive assay for hypoxic/anoxic irradiation report submitted to NIRS.  
 Scientific Report on for the European Commission November 2012. 
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4.1 Manuscripts 
 
 Effects of different ion species and LETs on different Glioblastoma cell lines 
– submitted to Radiation Research Journal, under revision. 
 Linear Energy Transfer dependence of potential lethal damage repair in 
Glioblastoma – in preparation. 
 
   
 
181 
 
 
 
 
 
References 
 
 
A. TOBIAS, C. 1985. The Repair-Misrepair Model in Radiobiology: Comparison to 
Other Models. Radiation research, 104, S77-95. 
AKUDUGU, J., SLABBERT, J., SERAFIN, A. & BOHM, L. 2000. Frequency of radiation-
induced micronuclei in neuronal cells does not correlate with clonogenic 
survival. Radiation research, 153, 62-67. 
ALLEN, C., BORAK, T. B., TSUJII, H. & NICKOLOFF, J. A. 2011. Heavy charged particle 
radiobiology: Using enhanced biological effectiveness and improved beam 
focusing to advance cancer therapy. Mutation Research/Fundamental and 
Molecular Mechanisms of Mutagenesis, 711, 150-157. 
AMBERGER-MURPHY, V. 2009. Hypoxia helps glioma to fight therapy. Current 
cancer drug targets, 9, 381-390. 
ANDO, K. & GOODHEAD, D. T. 2016. Dependence and independence of survival 
parameters on linear energy transfer in cells and tissues. Journal of 
radiation research, 57, 596-606. 
AVERBECK, N. B., RINGEL, O., HERRLITZ, M., JAKOB, B., DURANTE, M. & TAUCHER-
SCHOLZ, G. 2014. DNA end resection is needed for the repair of complex 
lesions in G1-phase human cells. Cell Cycle, 13, 2509-2516. 
B. CURTIS, S. 1986. Lethal and Potentially Lethal Lesions Induced by Radiation --- A 
Unified Repair Model. Radiation research, 106, 252-270 
BALLARINI, F., ALLONI, D., FACOETTI, A. & OTTOLENGHI, A. 2008. Heavy-ion 
effects: from track structure to DNA and chromosome damage. New Journal 
of Physics, 10, 075008. 
 
  
 References 
182 
 
 
BARAZZUOL, L., JENA, R., BURNET, N. G., JEYNES, J. C. G., MERCHANT, M. J., KIRKBY, 
K. J. & KIRKBY, N. F. 2012. In Vitro Evaluation of Combined Temozolomide 
and Radiotherapy Using X Rays and High-Linear Energy Transfer Radiation 
for Glioblastoma. Radiation research, 177, 651-662. 
BARENDSEN, G., WALTER, H., FOWLER, J. & BEWLEY, D. 1963. Effects of different 
ionizing radiations on human cells in tissue culture: III. Experiments with 
cyclotron-accelerated alpha-particles and deuterons. Radiation research, 18, 
106-119. 
BARKER, F. G., PRADOS, M. D., CHANG, S. M., GUTIN, P. H., LAMBORN, K. R., LARSON, 
D. A., MALEC, M. K., MCDERMOTT, M. W., SNEED, P. K. & WARA, W. M. 1996. 
Radiation response and survival time in patients with glioblastoma 
multiforme. Journal of neurosurgery, 84, 442-448. 
BARRES, B. A. 2008. The mystery and magic of glia: a perspective on their roles in 
health and disease. Neuron, 60, 430-440. 
BODGI, L., CANET, A., PUJO-MENJOUET, L., LESNE, A., VICTOR, J.-M. & FORAY, N. 
2016. Mathematical models of radiation action on living cells: From the 
target theory to the modern approaches. A historical and critical review. 
Journal of Theoretical Biology, 394, 93-101. 
BRAGG, W. 1906. On the Ionization of Various Gases by the α Particles of Radium-
No 2. Proceedings of the Physical Society of London, 20, 523. 
BRITTEN, R. A., DAVIS, L. K., JOHNSON, A. M., KEENEY, S., SIEGEL, A., SANFORD, L. 
D., SINGLETARY, S. J. & LONART, G. 2011. Low (20 cGy) doses of 1 GeV/u 
56Fe-particle radiation lead to a persistent reduction in the spatial learning 
ability of rats. Radiation research, 177, 146-151. 
CASTRO, J., CHEN, G. & BLAKELY, E. 1985. Current considerations in heavy 
charged-particle radiotherapy: a clinical research trial of the University of 
California Lawrence Berkeley Laboratory, Northern California Oncology 
Group, and Radiation Therapy Oncology Group. Radiation research, 104, 
263-271. 
  
 References 
183 
 
 
CASTRO, J. R., PHILLIPS, T. L., PRADOS, M., GUTIN, P., LARSON, D. A., PETTI, P. L., 
DAFTARI, I. K., COLLIER, J. M. & LILLIS-HEARNE, P. 1997. Neon heavy 
charged particle radiotherapy of glioblastoma of the brain. International 
Journal of Radiation Oncology* Biology* Physics, 38, 257-261. 
CASTRO, J. R., SAUNDERS, W. M., TOBIAS, C. A., CHEN, G. T. Y., CURTIS, S., LYMAN, J. 
T., MICHAEL COLLIER, J., PITLUCK, S., WOODRUFF, K. A. & BLAKELY, E. A. 
1982. Treatment of cancer with heavy charged particles. International 
Journal of Radiation Oncology* Biology* Physics, 8, 2191-2198. 
CHADWICK, K. H. & LEENHOUTS, H. P. 1973. A molecular theory of cell survival. 
Physics in medicine and biology, 18, 78-87. 
CHANCELLOR, J. C., SCOTT, G. B. & SUTTON, J. P. 2014. Space radiation: the number 
one risk to astronaut health beyond low earth orbit. Life, 4, 491-510. 
CHATTERJEE, A. & SCHAEFER, H. 1976. Microdosimetric structure of heavy ion 
tracks in tissue. Radiation and environmental biophysics, 13, 215-227. 
CHERRY, S., SORENSON, J. & PHELPS, M. 2003. Physics in Nuclear Medicine. 
CHIN, L., MEYERSON, M., ALDAPE, K., BIGNER, D., MIKKELSEN, T., VANDENBERG, S., 
KAHN, A., PENNY, R., FERGUSON, M. & GERHARD, D. 2008. Comprehensive 
genomic characterization defines human glioblastoma genes and core 
pathways. Nature, 455, 1061-1068. 
CHU, W. T. 2007. Overview of light-ion beam therapy. IAEA-TECDOC-1560, 5. 
COMBS, S. E., BOHL, J., ELSÄSSER, T., WEBER, K. J., SCHULZ-ERTNER, D., DEBUS, J. & 
WEYRATHER, W. K. 2009. Radiobiological evaluation and correlation with 
the local effect model (LEM) of carbon ion radiation therapy and 
temozolomide in glioblastoma cell lines. International journal of radiation 
biology, 85, 126-137. 
COMBS, S. E., BURKHOLDER, I., EDLER, L., RIEKEN, S., HABERMEHL, D., JÄKEL, O., 
HABERER, T., HASELMANN, R., UNTERBERG, A. & WICK, W. 2010a. 
Randomised phase I/II study to evaluate carbon ion radiotherapy versus  
 
  
 References 
184 
 
 
fractionated stereotactic radiotherapy in patients with recurrent or 
progressive gliomas: the CINDERELLA trial. BMC cancer, 10, 533. 
COMBS, S. E., KIESER, M., RIEKEN, S., HABERMEHL, D., JÄKEL, O., HABERER, T., 
NIKOGHOSYAN, A., HASELMANN, R., UNTERBERG, A. & WICK, W. 2010b. 
Randomized phase II study evaluating a carbon ion boost applied after 
combined radiochemotherapy with temozolomide versus a proton boost 
after radiochemotherapy with temozolomide in patients with primary 
glioblastoma: the CLEOPATRA trial. BMC cancer, 10, 478. 
CUCINOTTA, F. A., ALP, M., SULZMAN, F. M. & WANG, M. 2014. Space radiation risks 
to the central nervous system. Life Sciences in Space Research, 2, 54-69. 
DOUGLAS, B. G. & FOWLER, J. F. 1976. The Effect of Multiple Small Doses of X Rays 
on Skin Reactions in the Mouse and a Basic Interpretation. Radiation 
research, 66, 401-426. 
DURANTE, M. & LOEFFLER, J. S. 2009. Charged particles in radiation oncology. 
Nature reviews Clinical oncology, 7, 37-43. 
ELKIND, M. & SUTTON, H. 1959. X-Ray Damage and Recovery in Mammalian Cells 
in Culture. Nature, 184, 1293-1295. 
FENECH, M. 2000. The in vitro micronucleus technique. Mutation 
Research/Fundamental and Molecular Mechanisms of Mutagenesis, 455, 81-
95. 
FENECH, M. 2006. Cytokinesis-block micronucleus assay evolves into a “cytome” 
assay of chromosomal instability, mitotic dysfunction and cell death. 
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 
600, 58-66. 
FENECH, M. 2007. Cytokinesis-block micronucleus cytome assay. Nature protocols, 
2, 1084-1104. 
FENECH, M. 2010. The lymphocyte cytokinesis-block micronucleus cytome assay 
and its application in radiation biodosimetry. Health physics, 98, 234-243. 
 
  
 References 
185 
 
 
FENECH, M., CROTT, J., TURNER, J. & BROWN, S. 1999. Necrosis, apoptosis, 
cytostasis and DNA damage in human lymphocytes measured 
simultaneously within the cytokinesis-block micronucleus assay: 
description of the method and results for hydrogen peroxide. Mutagenesis, 
14, 605-612. 
FENECH, M. & CROTT, J. W. 2002. Micronuclei, nucleoplasmic bridges and nuclear 
buds induced in folic acid deficient human lymphocytes—evidence for 
breakage–fusion-bridge cycles in the cytokinesis-block micronucleus assay. 
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 
504, 131-136. 
FERTIL, B. & MALAISE, E.-P. 1981. Inherent cellular radiosensitivity as a basic 
concept for human tumor radiotherapy. International Journal of Radiation 
Oncology* Biology* Physics, 7, 621-629. 
FITZEK, M. M., THORNTON, A. F., RABINOV, J. D., LEV, M. H., PARDO, F. S., 
MUNZENRIDER, J. E., OKUNIEFF, P., BUSSIÈRE, M., BRAUN, I. & HOCHBERG, 
F. H. 1999. Accelerated fractionated proton/photon irradiation to 90 cobalt 
gray equivalent for glioblastoma multiforme: results of a phase II 
prospective trial. Journal of neurosurgery, 91, 251-260. 
FRANKEN, N. A., RODERMOND, H. M., STAP, J., HAVEMAN, J. & VAN BREE, C. 2006. 
Clonogenic assay of cells in vitro. Nature protocols, 1, 2315-2319. 
FRIEDBERG, W. & COPELAND, K. 2011. Ionizing radiation in Earth's atmosphere 
and in space near Earth. FEDERAL AVIATION ADMINISTRATION 
OKLAHOMA CITY OK CIVIL AEROSPACE MEDICAL INST. 
FRIEDMAN, H. S., KERBY, T. & CALVERT, H. 2000. Temozolomide and Treatment of 
Malignant Glioma. Clinical Cancer Research, 6, 2585-2597. 
FRIEDMAN, H. S., MCLENDON, R. E., KERBY, T., DUGAN, M., BIGNER, S. H., HENRY, A. 
J., ASHLEY, D. M., KRISCHER, J., LOVELL, S. & RASHEED, K. 1998. DNA 
mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and  
 
  
 References 
186 
 
 
response to Temodal in newly diagnosed malignant glioma. Journal of 
clinical oncology, 16, 3851-3857. 
FURNARI, F. B., FENTON, T., BACHOO, R. M., MUKASA, A., STOMMEL, J. M., STEGH, 
A., HAHN, W. C., LIGON, K. L., LOUIS, D. N. & BRENNAN, C. 2007. Malignant 
astrocytic glioma: genetics, biology, and paths to treatment. Genes & 
development, 21, 2683-2710. 
FURUSAWA, Y., FUKUTSU, K., AOKI, M., ITSUKAICHI, H., EGUCHI-KASAI, K., OHARA, 
H., YATAGAI, F., KANAI, T. & ANDO, K. 2000. Inactivation of Aerobic and 
Hypoxic Cells from Three Different Cell Lines by Accelerated 3He-, 12C-and 
20Ne-Ion Beams. Radiation research, 154, 485-496. 
GOITEIN, M. 2008. Radiation Oncology-A physicist's Eye View, New York: Springer 
Science+Business Media. 
GOITEIN, M. 2010. Trials and tribulations in charged particle radiotherapy. 
Radiotherapy and Oncology, 95, 23-31. 
GOODHEAD, D. 1985. Saturable Repair Models of Radiation Action in Mammalian 
Cells. Radiation research, 104, S58-67. 
GRAY, L. 1946. Comparative studies of the biological effects of X rays, neutrons and 
other ionizing radiations. British medical bulletin, 4, 11-18. 
GRAY, L. H., CONGER, A. D., EBERT, M., HORNSEY, S. & SCOTT, O. C. A. 1953. The 
Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a 
Factor in Radiotherapy. British journal of radiology, 26, 638-648. 
GRIMES, D. R. & PARTRIDGE, M. 2015. A mechanistic investigation of the oxygen 
fixation hypothesis and oxygen enhancement ratio. Biomedical physics & 
engineering express, 1, 045209. 
GUICHARD, M., LACHET, B. & MALAISE, E. 1977. Measurement of RBE, OER, and 
recovery of potentially lethal damage of a 645 MeV helium ion beam using 
EMT6 cells. Radiation research, 71, 413-429. 
 
 
  
 References 
187 
 
 
GUICHARD, M., WEICHSELBAUM, R., LITTLE, J. & MALAISE, E. 1984. Potentially 
lethal damage repair as a possible determinant of human tumour 
radiosensitivity. Radiotherapy and Oncology, 1, 263-269. 
GUO, G., SASAI, K., OYA, N., SHIBATA, T., SHIBUYA, K. & HIRAOKA, M. 1999. A 
significant correlation between clonogenic radiosensitivity and the 
simultaneous assessment of micronucleus and apoptotic cell frequencies. 
International journal of radiation biology, 75, 857-864. 
HADA, M. & GEORGAKILAS, A. G. 2008. Formation of clustered DNA damage after 
high-LET irradiation: a review. Journal of Radiation Research, 49, 203-210. 
HAHN, G. & LITTLE, J. 1972. Plateau-phase cultures of mammalian cells: an in vitro 
model for human cancer. Current topics in radiation research quarterly, 8, 39. 
HAHN, G. M., BAGSHAW, M. A., EVANS, R. G. & GORDON, L. F. 1973. Repair of 
potentially lethal lesions in X-irradiated, density-inhibited Chinese hamster 
cells: Metabolic effects and hypoxia. Radiation research, 55, 280-290. 
HAHN, G. M., ROCKWELL, S., KALLMAN, R. F., GORDON, L. F. & FRINDEL, E. 1974. 
Repair of potentially lethal damage in vivo in solid tumor cells after X-
irradiation. Cancer research, 34, 351-354. 
HALL, E. J. & GIACCIA, A. J. 2012. Radiobiology for the Radiologist, Lippincott 
Williams & Wilkins. 
HALL, E. J. & KRALJEVIC, U. 1976. Repair of Potentially Lethal Radiation Damage: 
Comparison of Neutron and X-Ray RBE and Implications for Radiation 
Therapy 1. Radiology, 121, 731-735. 
HALLIDAY, J., HELMY, K., PATTWELL, S. S., PITTER, K. L., LAPLANT, Q., OZAWA, T. 
& HOLLAND, E. C. 2014. In vivo radiation response of proneural glioma 
characterized by protective p53 transcriptional program and proneural-
mesenchymal shift. Proceedings of the National Academy of Sciences, 111, 
5248-5253. 
HALPERIN, E. C. 2006. Particle therapy and treatment of cancer. The lancet 
oncology, 7, 676-685. 
  
 References 
188 
 
 
HEGI, M. E., DISERENS, A. C., GORLIA, T., HAMOU, M. F., DE TRIBOLET, N., WELLER, 
M., KROS, J. M., HAINFELLNER, J. A., MASON, W. & MARIANI, L. 2005. MGMT 
gene silencing and benefit from temozolomide in glioblastoma. New 
England Journal of Medicine, 352, 997-1003. 
HELD, K. D., KAWAMURA, H., KAMINUMA, T., PAZ, A. E. S., YOSHIDA, Y., LIU, Q., 
WILLERS, H. & TAKAHASHI, A. 2016. Effects of charged particles on human 
tumor cells. Frontiers in oncology, 6, 23. 
HESS, K. R. 1999. Extent of resection as a prognostic variable in the treatment of 
gliomas. Journal of neuro-oncology, 42, 227-231. 
HOCHBERG, F. H. & PRUITT, A. 1980. Assumptions in the radiotherapy of 
glioblastoma. Neurology, 30, 907-911. 
HTTP://BECQUEREL.JINR.RU/MOVIES/MOVIES.HTML. 
HTTP://BIO.GSI.DE/RESEARCH/TRACK.HTML. Track Structure Studies [Online]. 
HTTP://CYBERBRIDGE.MCB.HARVARD.EDU/MITOSIS_3.HTML. 
HTTP://LIBRARY.THINKQUEST.ORG/C0126536/MAIN.PHP? 
HTTP://TEACHNUCLEAR.CA/ALL-THINGS-NUCLEAR/RADIATION/BIOLOGICAL-
EFFECTS-OF-RADIATION/EFFECTS-OF-IONIZING-RADIATION-ON-DNA/. 
HTTPS://CLINICALGATE.COM/BASICS-OF-RADIATION-THERAPY-2/.  [Accessed 
27 July 2017]. 
HTTPS://WWW.NDE-
ED.ORG/EDUCATIONRESOURCES/COMMUNITYCOLLEGE/RADIATIONSAFE
TY/THEORY/INTERACTION.HTM. 
HTTPS://WWW.SLIDESHARE.NET/TRISTANMATTHEWS?UTM_CAMPAIGN=PROF
ILETRACKING&UTM_MEDIUM=SSSITE&UTM_SOURCE=SSSLIDEVIEW. 
ICRU, L. E. T. 1970. Report No. 16. International Commission on Radiation Units and 
Measurements, Washington, DC. 
JÄKEL, O. 2006. Heavy ion radiotherapy. New Technologies in Radiation Oncology, 
365-377. 
 
  
 References 
189 
 
 
JEYNES, J., MERCHANT, M., BARAZZUOL, L., BARRY, M., GUEST, D., PALITSIN, V., 
GRIME, G., TULLIS, I., BARBER, P. & VOJNOVIC, B. 2013. “Broadbeam” 
irradiation of mammalian cells using a vertical microbeam facility. 
Radiation and environmental biophysics, 52, 513-521. 
JOINER, M. C., MARPLES, B., LAMBIN, P., SHORT, S. C. & TURESSON, I. 2001. Low-
dose hypersensitivity: Current status and possible mechanisms. 
International journal of radiation oncology, biology, physics, 49, 379. 
JOINER, M. C. & VAN DER KOGEL, A. 2016. Basic clinical radiobiology, CRC Press. 
KAMADA, T., TSUJII, H., BLAKELY, E. A., DEBUS, J., DE NEVE, W., DURANTE, M., 
JÄKEL, O., MAYER, R., ORECCHIA, R., PÖTTER, R., VATNITSKY, S. & CHU, W. 
T. 2015. Carbon ion radiotherapy in Japan: an assessment of 20 years of 
clinical experience. The lancet oncology, 16, e93-e100. 
KANAI, T., ENDO, M., MINOHARA, S., MIYAHARA, N., KOYAMA-ITO, H., TOMURA, H., 
MATSUFUJI, N., FUTAMI, Y., FUKUMURA, A., HIRAOKA, T., FURUSAWA, Y., 
ANDO, K., SUZUKI, M., SOGA, F. & KAWACHI, K. 1999. Biophysical 
characteristics of HIMAC clinical irradiation system for heavy-ion radiation 
therapy. International journal of radiation oncology, biology, physics, 44, 
201-210. 
KANAI, T., FURUSAWA, Y., FUKUTSU, K., ITSUKAICHI, H., EGUCHI-KASAI, K. & 
OHARA, H. 1997. Irradiation of mixed beam and design of spread-out Bragg 
peak for heavy-ion radiotherapy. Radiation research, 147, 78-85. 
KANAI, T., KOHNO, T., MINOHARA, S., SUDOU, M., TAKADA, E., SOGA, F., KAWACHI, 
K. & FUKUMURA, A. 1993. Dosimetry and Measured Differential W Values of 
Air for Heavy Ions. Radiation research, 135, 293-301. 
KAO, G. D., JIANG, Z., FERNANDES, A. M., GUPTA, A. K. & MAITY, A. 2007. Inhibition 
of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in 
glioblastoma cells following ionizing radiation. Journal of Biological 
Chemistry, 282, 21206-21212. 
 
  
 References 
190 
 
 
KATZ, R. 1996. The calculation of radial dose from heavy ions : predictions of 
biological action cross sections. Nucl Instrum Methods Phys Res Sect B-Beam 
Interact Mater Atoms, 107, 287-291. 
KATZ, R., ACKERSON, B., HOMAYOONFAR, M. & SHARMA, S. 1971. Inactivation of 
cells by heavy ion bombardment. Radiation research, 47, 402-425. 
KAWATA, T., DURANTE, M., FURUSAWA, Y., GEORGE, K., TAKAI, N., WU, H. & 
CUCINOTTA, F. 2001. Dose–response of initial G2-chromatid breaks 
induced in normal human fibroblasts by heavy ions. International journal of 
radiation biology, 77, 165-174. 
KLEIHUES, P. & OHGAKI, H. 2000. Phenotype vs genotype in the evolution of 
astrocytic brain tumors. Toxicologic pathology, 28, 164-170. 
LEA, D. E. 1955. Actions of radiations on living cells, Cambridge University Press, UK. 
LI, B., YUAN, M., KIM, I.-A., CHANG, C.-M., BERNHARD, E. J. & SHU, H.-K. G. 2004. 
Mutant epidermal growth factor receptor displays increased signaling 
through the phosphatidylinositol-3 kinase/AKT pathway and promotes 
radioresistance in cells of astrocytic origin. Oncogene, 23, 4594-4602. 
LINSTADT, D. E., CASTRO, J. R. & PHILLIPS, T. L. 1991. Neon ion radiotherapy: 
results of the phase I/II clinical trial. International Journal of Radiation 
Oncology* Biology* Physics, 20, 761-769. 
LITTLE, J. B. 1969. Repair of Sub-lethal and Potentially Lethal Radiation Damage in 
Plateau Phase Cultures of Human Cells. Nature, 224, 804-806. 
LITTLE, J. B. & HAHN, G. M. 1973. Life-cycle dependence of repair of potentially-
lethal radiation damage. International Journal of Radiation Biology and 
Related Studies in Physics, Chemistry and Medicine, 23, 401-407. 
LITTLE, J. B., HAHN, G. M., FRINDEL, E. & TUBIANA, M. 1973. Repair of Potentially 
Lethal Radiation Damage In Vitro and In Vivo 1. Radiology, 106, 689-694. 
LIU, C., KAWATA, T., ZHOU, G., FURUSAWA, Y., KOTA, R., KUMABE, A., SUTANI, S., 
FUKADA, J., MISHIMA, M. & SHIGEMATSU, N. 2013. Comparison of the 
repair of potentially lethal damage after low-and high-LET radiation  
  
 References 
191 
 
 
exposure, assessed from the kinetics and fidelity of chromosome rejoining 
in normal human fibroblasts. Journal of radiation research, 54, rrt031. 
LODGE, M., PIJLS-JOHANNESMA, M., STIRK, L., MUNRO, A. J., DE RUYSSCHER, D. & 
JEFFERSON, T. 2007. A systematic literature review of the clinical and cost-
effectiveness of hadron therapy in cancer. Radiotherapy and Oncology, 83, 
110-122. 
LOMAX, A. J. 2009. Charged particle therapy: the physics of interaction. The Cancer 
Journal, 15, 285-291. 
LONART, G., PARRIS, B., JOHNSON, A. M., MILES, S., SANFORD, L. D., SINGLETARY, S. 
J. & BRITTEN, R. A. 2012. Executive function in rats is impaired by low (20 
cGy) doses of 1 GeV/u 56Fe particles. Radiation research, 178, 289-294. 
LOUIS, D. N., OHGAKI, H., WIESTLER, O. D., CAVENEE, W. K., BURGER, P. C., JOUVET, 
A., SCHEITHAUER, B. W. & KLEIHUES, P. 2007. The 2007 WHO classification 
of tumours of the central nervous system. Acta neuropathologica, 114, 97-
109. 
LOUIS, D. N., PERRY, A., REIFENBERGER, G., VON DEIMLING, A., FIGARELLA-
BRANGER, D., CAVENEE, W. K., OHGAKI, H., WIESTLER, O. D., KLEIHUES, P. 
& ELLISON, D. W. 2016. The 2016 World Health Organization classification 
of tumors of the central nervous system: A summary. Acta neuropathologica, 
131, 803-820. 
LUNDKVIST, J., EKMAN, M., ERICSSON, S. R., JÖNSSON, B. & GLIMELIUS, B. 2005. 
Proton therapy of cancer: Potential clinical advantages and cost-
effectiveness. Acta Oncologica, 44, 850-861. 
M. KELLERER, A. & H. ROSSI, H. 1971. The theory of Dual Radiation Action. Current 
Topics in Radiation Research, 3, 85-158 
MACHIDA, M., LONART, G., XF, RGY & BRITTEN, R. A. 2010. Low (60 cGy) Doses of 
&#x2075;&#x2076;Fe HZE-Particle Radiation Lead to a Persistent 
Reduction in the Glutamatergic Readily Releasable Pool in Rat Hippocampal 
Synaptosomes. Radiation research, 174, 618-623. 
  
 References 
192 
 
 
MAHER, E. A., FURNARI, F. B., BACHOO, R. M., ROWITCH, D. H., LOUIS, D. N., 
CAVENEE, W. K. & DEPINHO, R. A. 2001. Malignant glioma: genetics and 
biology of a grave matter. Genes & development, 15, 1311-1333. 
MALAISE, E., DESCHAVANNE, P. & FERTIL, B. 1989. The relationship between 
potentially lethal damage repair and intrinsic radiosensitivity of human 
cells. International journal of radiation biology, 56, 597-604. 
MARCHESE, M. J., ZAIDER, M. & HALL, E. J. 1987. Potentially lethal damage repair in 
human cells. Radiotherapy and oncology, 9, 57-65. 
MATSUFUJI, N., FUKUMURA, A., KOMORI, M., KANAI, T. & KOHNO, T. 2003. 
Influence of fragment reaction of relativistic heavy charged particles on 
heavy-ion radiotherapy. Physics in Medicine and Biology, 48, 1605. 
MATSUFUJI, N., KANAI, T., KANEMATSU, N., MIYAMOTO, T., BABA, M., KAMADA, T., 
KATO, H., YAMADA, S., MIZOE, J.-E. & TSUJII, H. 2007. Specification of carbon 
ion dose at the National Institute of Radiological Sciences (NIRS). Journal of 
radiation research, 48, A81-A86. 
MATSUFUJI, N., KOHNO, T. & KANAI, T. 1999. Comprehensive Study on the 
Fragment Reaction of Relativistic Heavy Charged Particles for Heavy-Ion 
Radiotherapy. 放射線医学物理, 61, 230-232. 
MCELLIN, B., CAMACHO, C. V., MUKHERJEE, B., HAHM, B., TOMIMATSU, N., 
BACHOO, R. M. & BURMA, S. 2010. PTEN loss compromises homologous 
recombination repair in astrocytes: implications for glioblastoma therapy 
with temozolomide or poly (ADP-ribose) polymerase inhibitors. Cancer 
research, 70, 5457-5464. 
MIZOE, J. E., TSUJII, H., HASEGAWA, A., YANAGI, T., TAKAGI, R., KAMADA, T., TSUJI, 
H. & TAKAKURA, K. 2007. Phase I/II clinical trial of carbon ion radiotherapy 
for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and 
carbon ion radiotherapy. International journal of radiation oncology, biology, 
physics, 69, 390-396. 
 
  
 References 
193 
 
 
MIZUMOTO, M., TSUBOI, K., IGAKI, H., YAMAMOTO, T., TAKANO, S., OSHIRO, Y., 
HAYASHI, Y., HASHII, H., KANEMOTO, A. & NAKAYAMA, H. 2010. Phase I/II 
trial of hyperfractionated concomitant boost proton radiotherapy for 
supratentorial glioblastoma multiforme. International Journal of Radiation 
Oncology* Biology* Physics, 77, 98-105. 
MIZUMOTO, M., YAMAMOTO, T., TAKANO, S., ISHIKAWA, E., MATSUMURA, A., 
ISHIKAWA, H., OKUMURA, T., SAKURAI, H., MIYATAKE, S.-I. & TSUBOI, K. 
2015. Long-term survival after treatment of glioblastoma multiforme with 
hyperfractionated concomitant boost proton beam therapy. Practical 
radiation oncology, 5, e9-e16. 
MOBARAKI, A., OHNO, T., YAMADA, S., SAKURAI, H. & NAKANO, T. 2010. Cost-
effectiveness of carbon ion radiation therapy for locally recurrent rectal 
cancer. Cancer Sci, 101, 1834-1839. 
MORGAN, M. A. & LAWRENCE, T. S. 2015. Molecular Pathways: Overcoming 
Radiation Resistance by Targeting DNA Damage Response Pathways. 
Clinical Cancer Research, 21, 2898. 
NG, W.-L., HUANG, Q., LIU, X., ZIMMERMAN, M., LI, F. & LI, C.-Y. 2013. Molecular 
mechanisms involved in tumor repopulation after radiotherapy. 
Translational Cancer Research, 2, 442. 
NICKOLOFF, J. A. 2015. Photon, light ion, and heavy ion cancer radiotherapy: paths 
from physics and biology to clinical practice. Annals of Translational 
Medicine, 3, 336. 
NODA, S.-E., EL-JAWAHRI, A., PATEL, D., LAUTENSCHLAEGER, T., SIEDOW, M. & 
CHAKRAVARTI, A. Molecular advances of brain tumors in radiation 
oncology.  Seminars in radiation oncology, 2009. Elsevier, 171-178. 
O’ROURKE, D. M., KAO, G. D., SINGH, N., PARK, B.-W., MUSCHEL, R. J., WU, C.-J. & 
GREENE, M. I. 1998. Conversion of a radioresistant phenotype to a more 
sensitive one by disabling erbB receptor signaling in human cancer cells. 
Proceedings of the National Academy of Sciences, 95, 10842-10847. 
  
 References 
194 
 
 
OHGAKI, H. & KLEIHUES, P. 2007. Genetic pathways to primary and secondary 
glioblastoma. The American journal of pathology, 170, 1445. 
OHNO, T. 2013. Particle radiotherapy with carbon ion beams. EPMA Journal, 4, 9. 
ORECCHIA, R., KRENGLI, M., JERECZEK-FOSSA, B. A., FRANZETTI, S. & GERARD, J. P. 
2004. Clinical and research validity of hadrontherapy with ion beams. 
Critical reviews in oncology/hematology, 51, 81-90. 
PHILLIPS, R. & TOLMACH, L. 1966. Repair of potentially lethal damage in X-
irradiated HeLa cells. Radiation research, 29, 413-432. 
PUCK, T. T. & MARCUS, P. I. 1956. Action of X-rays on mammalian cells. The Journal 
of experimental medicine, 103, 653-666. 
RAAPHORST, G., FEELEY, M., DANJOUX, C., DASILVA, V. & GERIG, L. 1991. 
Hyperthermia enhancement of radiation response and inhibition of 
recovery from radiation damage in human glioma cells. International 
journal of hyperthermia, 7, 629-641. 
RAJU, M., FRANK, J., BAIN, E., TRUJILLO, T. & TOBEY, R. 1977. Repair of potentially 
lethal damage in Chinese hamster cells after X and α irradiation. Radiation 
research, 71, 614-621. 
RITTER, S. 1996. Comparison of chromosomal damage induced by X-rays and Ar 
ions with an LET of 1840 keV/mum in G1 V79 cells. International journal of 
radiation biology, 69, 155-166. 
ROSSI, H. H. 1959. Specification of radiation quality. Radiation research, 10, 522-
531. 
SAMPLES.JBPUB.COM/9781284032307/9781284028775_CH02_ROHLI3E_SECUR
E.PDF. Chapter 2 Atmospheric Structure and Composition [Online]. 
SAUNDERS, W., CASTRO, J., CHEN, G., COLLIER, J., ZINK, S., PITLUCK, S., PHILLIPS, T., 
CHAR, D., GUTIN, P. & GAUGER, G. 1985. Helium-ion radiation therapy at the 
Lawrence Berkeley Laboratory: Recent results of a Northern California 
Oncology Group clinical trial. Radiation research, 104, 227-234. 
 
  
 References 
195 
 
 
SCHARDT, D. 2016. Hadrontherapy. In: GARCÍA-RAMOS, J.-E., ALONSO, C. E., 
ANDRÉS, M. V. & PÉREZ-BERNAL, F. (eds.) Basic Concepts in Nuclear Physics: 
Theory, Experiments and Applications: 2015 La Rábida International 
Scientific Meeting on Nuclear Physics. Cham: Springer International 
Publishing. 
SCHERER, H. 1940. Cerebral astrocytomas and their derivatives. The American 
Journal of Cancer, 40, 159-198. 
SCHIPLER, A. & ILIAKIS, G. 2013. DNA double-strand–break complexity levels and 
their possible contributions to the probability for error-prone processing 
and repair pathway choice. Nucleic acids research, 41, 7589-7605. 
SCHOLZ, M. 2003. Effects of ion radiation on cells and tissues. Radiation effects on 
polymers for biological use, 95-155. 
SHIPLEY, W. U., STANLEY, J. A., COURTENAY, V. D. & FIELD, S. B. 1975. Repair of 
radiation damage in Lewis lung carcinoma cells following in situ treatment 
with fast neutrons and gamma-rays. Cancer research, 35, 932-938. 
SHORT, S., KELLY, J., MAYES, C., WOODCOCK, M. & JOINER, M. 2001. Low-dose 
hypersensitivity after fractionated low-dose irradiation in vitro. 
International journal of radiation biology, 77, 655-664. 
SHORT, S., MAYES, C., WOODCOCK, M. & JOINER, M. 1999a. Low-dose 
hypersensitivity in the T98G glioblastoma cell line. International journal of 
radiation biology, 75, 847-855. 
SHORT, S., MITCHELL, S., BOULTON, P., WOODCOCK, M. & JOINER, M. 1999b. The 
response of human glioma cell lines to low-dose radiation exposure. 
International journal of radiation biology, 75, 1341. 
SIMPSON, J. 1983. Elemental and isotopic composition of the galactic cosmic rays. 
Annual Review of Nuclear and Particle Science, 33, 323-382. 
SIU, A., WIND, J., IORGULESCU, J., CHAN, T., YAMADA, Y. & SHERMAN, J. 2012. 
Radiation necrosis following treatment of high grade glioma-a review of the 
literature and current understanding. Acta Neurochirurgica, 154. 
  
 References 
196 
 
 
SKARSGARD, L. 1998. Radiobiology with heavy charged particles: a historical 
review. Physica Medica, 14, 1-19. 
SLOWINSKI, J., BIERZYNSKA-MACYSZYN, G., MAZUREK, U., WIDEL, M., LATOCHA, 
M., STOMAL, M., SNIETURA, M. & MROWKA, R. 2011. Cytokinesis-block 
micronucleus assay in human glioma cells exposed to radiation. Image 
Analysis & Stereology, 23, 159-165. 
SØRENSEN, B. S., OVERGAARD, J. & BASSLER, N. 2011. In vitro RBE-LET 
dependence for multiple particle types. Acta Oncologica, 50, 757-762. 
STAAF, E., BREHWENS, K., HAGHDOOST, S., CZUB, J. & WOJCIK, A. 2012. Gamma-
H2AX foci in cells exposed to a mixed beam of X-rays and alpha particles. 
Genome Integrity, 3, 8. 
STAMBOLIC, V., MACPHERSON, D., SAS, D., LIN, Y., SNOW, B., JANG, Y., BENCHIMOL, 
S. & MAK, T. 2001. Regulation of PTEN transcription by p53. Molecular cell, 
8, 317-325. 
STEEL, G. G., MCMILLAN, T. J. & PEACOCK, J. 1989. The 5Rs of radiobiology. 
International journal of radiation biology, 56, 1045-1048. 
STUMMER, W., PICHLMEIER, U., MEINEL, T., WIESTLER, O. D., ZANELLA, F. & 
REULEN, H.-J. 2006. Fluorescence-guided surgery with 5-aminolevulinic 
acid for resection of malignant glioma: a randomised controlled multicentre 
phase III trial. The lancet oncology, 7, 392-401. 
STUPP, R., HEGI, M. E., MASON, W. P., VAN DEN BENT, M. J., TAPHOORN, M. J. B., 
JANZER, R. C., LUDWIN, S. K., ALLGEIER, A., FISHER, B. & BELANGER, K. 
2009. Effects of radiotherapy with concomitant and adjuvant temozolomide 
versus radiotherapy alone on survival in glioblastoma in a randomised 
phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology, 
10, 459-466. 
STUPP, R., MASON, W. P., VAN DEN BENT, M. J., WELLER, M., FISHER, B., 
TAPHOORN, M. J. B., BELANGER, K., BRANDES, A. A., MAROSI, C. & 
BOGDAHN, U. 2005. Radiotherapy plus concomitant and adjuvant  
  
 References 
197 
 
 
temozolomide for glioblastoma. New England Journal of Medicine, 352, 987-
996. 
SUZUKI, M., KASE, Y., KANAI, T. & ANDO, K. 2000a. Change in radiosensitivity with 
fractionated-dose irradiation of carbon-ion beams in five different human 
cell lines. International Journal of Radiation Oncology* Biology* Physics, 48, 
251-258. 
SUZUKI, M., KASE, Y., KANAI, T., YATAGAI, F. & WATANABE, M. 1997. LET 
dependence of cell death and chromatin-break induction in normal human 
cells irradiated by neon-ion beams. International journal of radiation 
biology, 72, 497-503. 
SUZUKI, M., KASE, Y., YAMAGUCHI, H., KANAI, T. & ANDO, K. 2000b. Relative 
biological effectiveness for cell-killing effect on various human cell lines 
irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion 
beams. International Journal of Radiation Oncology* Biology* Physics, 48, 
241-250. 
SUZUKI, M., TSURUOKA, C., KANAI, T., KATO, T., YATAGAI, F. & WATANABE, M. 
2006. Cellular and molecular effects for mutation induction in normal 
human cells irradiated with accelerated neon ions. Mutation 
Research/Fundamental and Molecular Mechanisms of Mutagenesis, 594, 86-
92. 
SUZUKI, M., WATANABE, M., KANAI, T., KASE, Y., YATAGAI, F., KATO, T. & 
MATSUBARA, S. 1996. LET dependence of cell death, mutation induction 
and chromatin damage in human cells irradiated with accelerated carbon 
ions. Advances in Space Research, 18, 127-136. 
THOMAS, P. & FENECH, M. 2011. Cytokinesis-block micronucleus cytome assay in 
lymphocytes. DNA Damage Detection In Situ, Ex Vivo, and In Vivo: Methods 
and Protocols, 217-234. 
 
 
  
 References 
198 
 
 
THOMAS, P., UMEGAKI, K. & FENECH, M. 2003. Nucleoplasmic bridges are a 
sensitive measure of chromosome rearrangement in the cytokinesis-block 
micronucleus assay. Mutagenesis, 18, 187-194. 
TOBIAS, C., BLAKELY, E., ALPEN, E., CASTRO, J., AINSWORTH, E., CURTIS, S., NGO, F., 
RODRIGUEZ, A., ROOTS, R. & TENFORDF, T. 1982. Molecular and cellular 
radiobiology of heavy ions. International Journal of Radiation Oncology* 
Biology* Physics, 8, 2109-2120. 
TOBIAS, C., BLAKELY, E., CHANG, P., LOMMEL, L. & ROOTS, R. 1984. Response of 
sensitive human ataxia and resistant T-1 cell lines to accelerated heavy ions. 
The British journal of cancer. Supplement, 6, 175. 
TOBIAS, C. A. 1985. The future of heavy-ion science in biology and medicine. 
Radiation research, 103, 1-33. 
TORIKOSHI, M., MINOHARA, S., KANEMATSU, N., KOMORI, M., KANAZAWA, M., 
NODA, K., MIYAHARA, N., ITOH, H., ENDO, M. & KANAI, T. 2007. Irradiation 
System for HIMAC. Journal of Radiation Research, 48, A15-A25. 
TRIKALINOS, T. A., TERASAWA, T., IP, S., RAMAN, G. & LAU, J. Particle beam 
radiation therapies for cancer. 
TSUBOI, K., TSUCHIDA, Y., NOSE, T. & ANDO, K. 1998. Cytotoxic effect of 
accelerated carbon beams on glioblastoma cell lines with p53 mutation: 
clonogenic survival and cell-cycle analysis. International journal of radiation 
biology, 74, 71. 
TSUJII, H., MIZOE, J., KAMADA, T., BABA, M., TSUJI, H., KATO, H., KATO, S., YAMADA, 
S., YASUDA, S., OHNO, T., YANAGI, T., IMAI, R., KAGEI, K., KATO, H., HARA, R., 
HASEGAWA, A., NAKAJIMA, M., SUGANE, N., TAMAKI, N., TAKAGI, R., 
KANDATSU, S., YOSHIKAWA, K., KISHIMOTO, R. & MIYAMOTO, T. 2007. 
Clinical Results of Carbon Ion Radiotherapy at NIRS. Journal of Radiation 
Research, 48, A1-A13. 
TSURUOKA, C., FURUSAWA, Y., ANZAI, K., OKAYASU, R. & SUZUKI, M. 2010. 
Rejoining kinetics of G 1-PCC breaks induced by different heavy-ion beams  
  
 References 
199 
 
 
with a similar LET value. Mutation Research/Genetic Toxicology and 
Environmental Mutagenesis, 701. 
TSURUOKA, C., SUZUKI, M., KANAI, T. & FUJITAKA, K. 2005. LET and ion species 
dependence for cell killing in normal human skin fibroblasts. Radiation 
research, 163, 494-500. 
VAN DEN BENT, M. 2005. Impact of the extent of resection on overall survival in 
newly-diagnosed glioblastoma after chemo-irradiation with temozolomide: 
Further analysis of EORTC study 26981. Eur J Cancer Suppl, 3, 134. 
VAN MEIR, E. G., HADJIPANAYIS, C. G., NORDEN, A. D., SHU, H. K., WEN, P. Y. & 
OLSON, J. J. 2010. Exciting New Advances in Neuro‐Oncology: The Avenue to 
a Cure for Malignant Glioma. CA: a cancer journal for clinicians, 60, 166-193. 
VERHAAK, R. G., HOADLEY, K. A., PURDOM, E., WANG, V., QI, Y., WILKERSON, M. D., 
MILLER, C. R., DING, L., GOLUB, T. & MESIROV, J. P. 2010. Integrated 
Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma 
Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer 
cell, 17, 98-110. 
VRAL, A., FENECH, M. & THIERENS, H. 2011. The micronucleus assay as a biological 
dosimeter of in vivo ionising radiation exposure. Mutagenesis, 26, 11-17. 
WARD, J. 1985. Biochemistry of DNA lesions. Radiation research, 104, S103-S111. 
WEICHSELBAUM, R., DAHLBERG, W., LITTLE, J., ERVIN, T., MILLER, D., HELLMAN, S. 
& RHEINWALD, J. 1984. Cellular X-ray repair parameters of early passage 
squamous cell carcinoma lines derived from patients with known responses 
to radiotherapy. British journal of Cancer, 49, 595. 
WEICHSELBAUM, R., SCHMIT, A. & LITTLE, J. 1982. Cellular repair factors 
influencing radiocurability of human malignant tumours. British journal of 
Cancer, 45, 10-16. 
WEICHSELBAUM, R. R. 1986. Radioresistant and repair proficient cells may 
determine radiocurability in human tumors. International Journal of 
Radiation Oncology* Biology* Physics, 12, 637-639. 
  
 References 
200 
 
 
WEICHSELBAUM, R. R. & BECKETT, M. 1987. The maximum recovery potential of 
human tumor cells may predict clinical outcome in radiotherapy. 
International Journal of Radiation Oncology* Biology* Physics, 13, 709-713. 
WEICHSELBAUM, R. R., DAHLBERG, W., BECKETT, M., KARRISON, T., MILLER, D., 
CLARK, J. & ERVIN, T. J. 1986. Radiation-resistant and repair-proficient 
human tumor cells may be associated with radiotherapy failure in head-and 
neck-cancer patients. Proceedings of the National Academy of Sciences, 83, 
2684-2688. 
WEICHSELBAUM, R. R., DAHLBERG, W. & LITTLE, J. B. 1985. Inherently 
radioresistant cells exist in some human tumors. Proceedings of the National 
Academy of Sciences, 82, 4732-4735. 
WEN, P. Y. & KESARI, S. 2008. Malignant Gliomas in Adults. New England Journal of 
Medicine, 359, 492-507. 
WEYRATHER, W. K., RITTER, S., SCHOLZ, M. & KRAFT, G. 1999. RBE for carbon 
track-segment irradiation in cell lines of differing repair capacity. 
International journal of radiation biology, 75, 1357-1364. 
WHEELER, K. T., NORTON, K. L., DEEN, D. F. & LEITH, J. T. 1980. In situ recovery 
from potentially lethal damage after irradiation with BEVALAC accelerated 
carbon ions. International Journal of Radiation Biology and Related Studies in 
Physics, Chemistry and Medicine, 37, 225-229. 
WICK, W., FURNARI, F. B., NAUMANN, U., CAVENEE, W. K. & WELLER, M. 1999. 
PTEN gene transfer in human malignant glioma: sensitization to irradiation 
and CD95L-induced apoptosis. Oncogene, 18, 3936-3943. 
WILSON, R. R. 1946. Radiological Use of Fast Protons. Radiology, 47, 487-491. 
WINDEYER, B. 1954. Clinical aspects of radio-resistance. Acta Radiologica, 41, 108-
119. 
WITHERS, H. R. 1975. The four R’s of radiotherapy. Adv Radiat Biol, 5, 241-271.  
 
 
  
 References 
201 
 
 
WOLFF, J. E. A., BERRAK, S., KOONTZ WEBB, S. E. & ZHANG, M. 2008. Nitrosourea 
efficacy in high-grade glioma: a survival gain analysis summarizing 504 
cohorts with 24193 patients. Journal of neuro-oncology, 88, 57-63. 
WU, H., GEORGE, K. & YANG, T. 1999. Estimate of the frequency of true incomplete 
exchanges in human lymphocytes exposed to 1 GeV/u Fe ions in vitro. 
International journal of radiation biology, 75, 593. 
YAMADA, M.-A. & PUCK, T. T. 1961. Action of radiation on mammalian cells, IV. 
Reversible mitotic lag in the S3 HeLa cell produced by low doses of X-rays. 
Proceedings of the National Academy of Sciences, 47, 1181-1191. 
YASHIRO, T., KOYAMA-SAEGUSA, K., IMAI, T., FUJISAWA, T. & MIYAMOTO, T. 2007. 
Inhibition of potential lethal damage repair and related gene expression 
after carbon-ion beam irradiation to human lung cancer grown in nude 
mice. Journal of radiation research, 48, 377-383. 
ZEITLIN, C. & LA TESSA, C. 2016. The Role of Nuclear Fragmentation in Particle 
Therapy and Space Radiation Protection. Frontiers in oncology, 6. 
ZIRKLE, R. E. & TOBIAS, C. A. 1953. Effects of ploidy and linear energy transfer on 
radiobiological survival curves. Archives of biochemistry and biophysics, 47, 
282-306. 
 
 
